

# Christopher S. Coffey

N500 CPHB

145 N. Riverside Drive

Iowa City, IA 52242

Phone: (319) 384-4197

Fax: (319) 335-6535

E-mail: [christopher-coffey@uiowa.edu](mailto:christopher-coffey@uiowa.edu)

## EDUCATION

### UNIVERSITY OF NORTH CAROLINA (Chapel Hill, North Carolina)

Ph.D. in Biostatistics, December 1999

Supporting Program: Epidemiology

Dissertation: "Internal Pilot Study Design and Analysis for Linear Models with Gaussian Errors and Fixed Predictors," K. E. Muller, chair.

### UNIVERSITY OF NORTH CAROLINA (Chapel Hill, North Carolina)

M. S. in Biostatistics, December 1996

Master's Paper: "Exact Test Size and Power of a Gaussian Error Linear Model for an Internal Pilot Study," K. E. Muller, advisor.

### UNIVERSITY OF TENNESSEE (Knoxville, Tennessee)

B. S. in Business Administration, December 1992

Major: Statistics, Summa cum Laude

## ACADEMIC APPOINTMENTS

### UNIVERSITY OF IOWA, DEPARTMENT OF BIostatISTICS (Iowa City, IA)

2010-Present Director, Clinical Trials Statistical and Data Management Center (CTSDMC)

2009-Present Professor

2009-2010 Deputy Director, Clinical Trials Statistical and Data Management Center (CTSDMC)

### UNIVERSITY OF ALABAMA AT BIRMINGHAM, DEPARTMENT OF BIostatISTICS (Birmingham, AL)

2009-2014 Adjunct Professor

2004-2009 Associate Professor

2001-2004 Assistant Professor

### UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, DEPARTMENT OF BIostatISTICS (Chapel Hill, NC)

2005-2008 Adjunct Associate Professor

### VANDERBILT UNIVERSITY MEDICAL CENTER, DIVISION OF BIostatISTICS (Nashville, TN)

1999-2001 Assistant Professor

## TEACHING EXPERIENCE

### UNIVERSITY OF IOWA

#### Cancer Center General Medical Education Clinical Research Conference Series

**Fall 2023:** Presented lectures on "Phase I & II Clinical Trials: Statistical Considerations" & "Clinical Trial Objectives & Registration"

#### Intervention and Clinical Trials (EPID:6900)

Doctoral Level – Epidemiology Course

**Fall 2023:** Presented lecture on "Adaptive Designs"

**Fall 2022:** Presented lecture on "Adaptive Designs"

**Fall 2021:** Presented lecture on "Adaptive Designs"

**Fall 2019:** Presented lecture on "Adaptive Designs"

**Fall 2017:** Presented lecture on "Adaptive Designs"

**Fall 2016:** Presented lecture on "Adaptive Designs"

**Statistical Methods for Clinical Trials (BIOS:6610)**

Master's Level – Elective Course

**Spring 2023:** Course Instructor

**Spring 2022:** Course Instructor

**Spring 2021:** Course Instructor

**Spring 2020:** Course Instructor

**Spring 2018:** Course Instructor

**Spring 2017:** Course Instructor

**Spring 2016:** Course Instructor

**Advanced Clinical Trials (BIOS:7230)**

Doctoral Level – Elective Course

**Fall 2022:** Course Instructor

**Fall 2020:** Course Instructor

**Fall 2018:** Course Instructor

**Introduction to Translational Biomedicine (TBM:5001)**

Institute for Clinical & Translational Sciences (ICTS) Course

**Fall 2020:** Presented lecture on “Phase II/III Clinical Trials

**Fall 2018:** Presented lecture on “Phase II/III Clinical Trials”

**Spring 2017:** Presented lecture on “Phase II/III Clinical Trials”

**Fall 2015:** Presented lecture on “Phase II/III Designs”

**Fall 2014:** Presented lecture on “Phase I/II Designs”

**Iowa Summer Institute of Biostatistics**

**Summer 2010-2019:** Presented lecture on “Overview of Randomized Clinical Trials”

**Advanced Seminars in Clinical Trials (BIOS:7600 – ‘Advanced Clinical Trials’)**

Doctoral Level – Elective Course

**Fall 2016:** Course Instructor

**Comparative Effectiveness and Patient Centered Outcomes Research (BE-8025)**

Course Offered as Collaborative Effort among U. Iowa & U. Cincinnati CTSA

**Fall 2016:** Presented lecture on “Conventional & Emerging Methods in the Design of Clinical Trials”

**Intervention and Clinical Trials (173:290)**

Doctoral Level – Epidemiology Course

**Fall 2015:** Presented lecture on “Adaptive Designs”

**Fall 2011:** Presented lecture on “Adaptive Designs”

**Advanced Seminars in Clinical Trials (171:290 – ‘Advanced Clinical Trials’)**

Doctoral Level – Elective Course

**Fall 2014:** Course Instructor

**Fall 2013:** Course Instructor

**Fall 2011:** Course Instructor

**Spring 2010:** Course Instructor

**Applied Survival Analysis (171:242)**

Doctoral Level – Required Service Course / Elective Course

**Spring 2013:** Course Instructor

**Applied Cohort Analysis (171:243)**

Doctoral Level – Required Service Course / Elective Course

**Spring 2013:** Course Supervisor

**Applied Survival and Cohort Data Analysis (171:242)**

Doctoral Level – Required Service Course / Elective Course

**Spring 2011:** Course Instructor

**UNIVERSITY OF ALABAMA AT BIRMINGHAM**

**Introduction to Survival Analysis (BST 665)**

MS Level – Elective Course

**Spring 2009:** Course Instructor

**Spring 2007:** Course Instructor  
**Spring 2005:** Course Instructor  
**Spring 2003:** Course Instructor  
**Summer 2001:** Co-Instructor (with Brent Shelton)

**Advanced Clinical Trials II (BST 726)**

Doctoral Level – Elective Course

**Spring 2008:** Course Instructor

**Spring 2006:** Developed and Organized Course; Presented 7 lectures

**Advanced Clinical Trials I (BST 725)**

Doctoral Level – Elective Course

**Fall 2007:** Presented 3 lectures – “DSMB Reports & Meetings”, “Interim Analysis”, & “Adaptive Designs”

**Fall 2005:** Presented four lectures on “Interim Analysis and Monitoring of Clinical Trials”

**Quantitative Methods (HMG 703)**

Doctoral Level – Required Course

**Spring 2007:** Presented lecture on “Safety Monitoring”

**Theory of Linear Models (BST 723)**

Doctoral Level – Required Course

**Fall 2005:** Course Instructor

**Fall 2003:** Course Instructor

**Summer 2002:** Course Instructor

**Applied Regression Analysis**

MS Level – Applied Service Course

**Fall 2002 – Fall 2005:** Presented two lectures on “Choosing the Best Model”

**Readings Course on ‘Internal Pilot Designs’ (BST 795)**

Doctoral Level – Elective Readings Course

**Summer 2003:** Course Instructor

**Introduction to Data Management and Computing Using the SAS System (BST 626/627)**

MS Level – Required Course

**Fall 2001 – Fall 2002:** Course Instructor

**VANDERBILT UNIVERSITY**

**1999-2001:** Statistical consultant to Radiation Oncology Fellows Journal Club

**Fall 2000: Introductory Biostatistics.**

Required introductory biostatistics course for first-year MPH students.

**Spring 2000:** Led Group Exercise on Case-Control/Cohort Studies for second year medical students at Vanderbilt University School of Medicine

**UNIVERSITY OF NORTH CAROLINA**

**1999:** Prepared and presented a lecture on "Power and Sample Size Calculations" for the course ‘Introduction to Statistical Consulting’.

**1997:** Teaching Assistant for ‘Principles of Statistical Inference’  
(also presented a lecture on statistical power to the class)

**SCHLEGEL, INC.**

**1993 - 1994:** Conducted Basic Statistics and Statistical Process Control training classes for all hourly employees and new hires at Hayward, CA and Keokuk, IA plants

**UNIVERSITY OF TENNESSEE**

**1991-1992:** Teaching Assistant for ‘Self Paced College Algebra’ course

## SHORT COURSES AND WORKSHOPS

### 23. *Essentials of Randomized Clinical Trials*

- May 2022:** Faculty Member, Workshop at Society for Clinical Trials Annual Meeting (San Diego, CA)
- May 2021:** Faculty Member, Workshop at Society for Clinical Trials Annual Meeting (Virtual Due to COVID-19)
- May 2010:** Faculty Member, Workshop at Society for Clinical Trials Annual Meeting (Baltimore, MD)

### 22. *Clinical Trials Methods in Neurology*

- July 2022:** Primary Faculty Member (Iowa City, IA)
- July 2021:** Primary Faculty Member (Virtual Due to COVID-19)
- July 2019:** Primary Faculty Member (Iowa City, IA)
- August 2018:** Primary Faculty Member (Ann Arbor, MI)
- August 2017:** Primary Faculty Member (Iowa City, IA)
- July 2015-August 2016:** Primary Faculty Member (Ann Arbor, MI)
- August 2014:** Primary Faculty Member (Iowa City, IA)
- August 2008-August 2011:** Primary Faculty Member (Vail, CO)

### 21. *Medical Monitoring*

- October 2019:** Short Course at Annual Northeast ALS Consortium Meeting (Clearwater, FL)
- October 2018:** Short Course at Annual Northeast ALS Consortium Meeting (Clearwater, FL)
- October 2017:** Short Course at Annual Northeast ALS Consortium Meeting (Clearwater, FL)

### 20. *How to Design Meaningful Clinical Trials*

- May 2019:** Faculty Member, Short Course at American Academy of Neurology Annual Meeting (Philadelphia, PA)

### 19. *Adaptive Designs – How Can We Achieve the Promise?*

- May 2018:** Pre-Conference Workshop, Society for Clinical Trials Annual Meeting (Portland, OR)

### 18. *Clinical Trials in the Drug Development Pipeline*

- April 2018:** Faculty Member, Short Course at American Academy of Neurology Annual Meeting (Los Angeles, CA)
- April 2017:** Faculty Member, Short Course at American Academy of Neurology Annual Meeting (Boston, MA)

### 17. *American Statistical Association Traveling Course – ‘Adaptive Designs: Overview, Hurdles, & Examples’*

- April 2018:** Washington Statistical Society (Washington, DC)
- November 2017:** Trenton/Princeton Chapter (Piscataway, NJ)
- September 2017:** San Diego Chapter (San Diego, CA)

### 16. *Adaptive Designs: Overview, Hurdles, Examples, & Software*

- May 2015:** Co-presenter with Daniele De Martini; Pre-Conference Workshop, Annual Meeting of the Society for Clinical Trials (Montreal, QC)

### 15. *Adaptive Designs: Overview, Hurdles, & Examples*

- April 2015:** All Day Workshop, 8<sup>th</sup> Annual ADVAMed & American Statistical Association Statistical Issues Workshop (Washington, DC)

### 14. *Clinical Research: Drug Development and Clinical Trials*

- April 2015:** Faculty Member, Short Course at American Academy of Neurology Annual Meeting (Washington, DC)

### 13. *Adaptive Designs*

- January 2014:** Two-day short course sponsored by Rho, Inc. (Chapel Hill, NC)
- September 2012:** Two-day short course sponsored by the University of Iowa CTSA (Iowa City, IA)

### 12. *Overview, Hurdles, and Future Work in Adaptive Designs*

- September 2013:** Short Course offered at FDA/Industry Workshop (Washington, DC)

### 11. *Adaptive Designs and Small Clinical Trials*

- November 2012:** Faculty Member; FDA-Sponsored Meeting the Challenges of Rare Disease Drug Review Short Course (Rockville, MD)

10. *Novel Designs for Rare Disorders, Including Adaptive Designs*  
**May 2012:** Faculty Member and Workshop Organizer; NIH-Sponsored Workshop on Designing Clinical Trials in Dystonia (Bethesda, MD)
9. *Challenges in Designing Small Clinical Trials*  
**May 2011:** Co-presenter with Janet Wittes; Pre-conference workshop held in conjunction with the Annual Meeting of the Society for Clinical Trials (Vancouver, BC)
8. *The Science of Small Clinical Trials*  
**April 2011:** Faculty Member (Silver Spring, MD)  
**February 2010:** Faculty Member (Silver Spring, MD)  
 Course, co-sponsored by the FDA Office of Orphan Products and NIH Office of Rare Diseases. (Bethesda, MD)
7. *Clinical Research Methods*  
**April 2010:** Faculty member for this short course held in conjunction with the Annual Meeting of the American Academy of Neurology (Toronto, ON)
6. *Scientific Advances in Adaptive Clinical Trial Design*  
**November 2009:** Co-organizer and presenter for two-day workshop (Bethesda, MD)
5. *Fundamentals of Randomized Clinical Trials*  
**May 2009:** Co-organizer and faculty member for pre-conference workshop at the annual meeting of the Society for Clinical Trials (Atlanta, GA)  
**May 2008:** Co-organizer and faculty member for pre-conference workshop at the annual meeting of the Society for Clinical Trials. (St. Louis, MO)
4. *Adaptive Dose-Response Studies*  
**August 2007:** Co-taught at the annual Joint Statistical Meetings (Salt Lake City, UT)
3. *Frequentist Adaptive Designs, Internal Pilots, and Stopping Rules*  
**December 2006:** Lecture as part of a Conference on Design, Analysis, and Interpretation of Randomized Clinical Trials in Obesity (Newark, NJ)
2. *Adaptive Designs and Clinical Trials*  
**May 2005:** Pre-conference workshop taught with Cyrus Mehta in conjunction with the Annual Meeting of the Society for Clinical Trials (Portland, OR)
1. *Vanderbilt-Ingram Cancer Center Biostatistics Shared Resource Three Week Workshop*  
**March 2000:** Faculty Member

## WEBINARS

8. *Designing Meaningful Early Phase Clinical Trials*  
**March 2023:** Clinical Trials Methods in Neurology Course Webinar Series (w/ Will Meurer)  
**April 2022:** Clinical Trials Methods in Neurology Course Webinar Series (w/ Will Meurer)
7. *Rare Disease Trials*  
**August 2020:** Clinical Trials Methods in Neurology Course Webinar Series (w/ Melanie Quintana)
6. *Ongoing Clinical Studies and Potential Collaborations for Neuroscience Research*  
**May 2020:** Iowa Neuroscience Institute (w/ Emine Bayman, Laurie Gutmann, Kathy Matthews)
5. *Small Sample Size Clinical Trials*  
**May 2019:** Clinical Trials Methods in Neurology Course Webinar Series  
**July 2018:** Clinical Trials Methods in Neurology Course Webinar Series  
**May 2017:** Clinical Trials Methods in Neurology Course Webinar Series
4. *Increasing the Practicality of Innovative Trial Design*  
**March 2017:** Society for Clinical Trials Webinar Series
3. *Challenges in Designing Small Clinical Trials*  
**December 2011:** Sponsored by the Association for Research in Vision and Ophthalmology
2. *Adaptive Designs for Clinical Trials: Perspectives from an NIH-Funded Workshop*  
**May 2011:** Drug Information Association (DIA) Adaptive Design Working Group Key Opinion Leaders Lecture Series

## 1. Adaptive Designs in Dose-Finding Studies

**November 2007:** Taught w/ Brenda Gaydos and Jose Pinheiro as part of a four-part web-based training series sponsored by PhRMA and the Biopharmaceutical section of the American Statistical Association.

## PUBLICATIONS AND PRESENTATIONS

### PEER REVIEWED PUBLICATIONS

195. Leroux A, Crainiceanu C, Zeger S, Taub M, Ansari B, Wager TD, Bayman E, **Coffey C**, Langefeld C, McCarthy R, Tsodikov A, Brummet C, Clauw DJ, Edwards RR, and Lindquist MA (2024). "Statistical Modeling of Acute and Chronic Pain Patient Reported Outcomes (PROs) Obtained from Ecological Momentary Assessment," *PAIN*, in press.
194. Cousins KAQ, Irwin DJ, Tropea TF, Rhodes E, Phillips JS, Chen-Plotkin AS, Brumm MC, **Coffey CS**, Kang JH, Simuni T, Foroud T, Toga AW, Tanner CM, Kiebertz K, Mollenhauer B, Galasko DR, Hutten S, Weintraub D, Siderowf A, Marek K, Kollmorgen G, Poston KL, and Shaw LM on behalf of the Parkinson's Progression Marker Initiative (2023). "Evaluation of ATN<sub>PD</sub> Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson's Disease," *Neurology*, in press.
193. Berry-Kravis E, Abbeduto L, Hagerman R, **Coffey CS**, Cudkowicz M, Erickson CA, McDuffie A, Hessel D, Ethridge L, Tassone F, Kaufmann WE, Friedmann K, Bullard L, Hoffmann A, Veenstra-VanderWeele J, Staley K, Klements D, Moshinsky M, Harkey B, Long J, Fedler J, Klingner E, Ecklund D, Costigan M, Huff T, Pearson B and the NeuroNEXT FXLEARN Investigators (2023). "Effects of AFQ056 on Language Learning in Fragile X Syndrome," *Journal of Clinical Investigation*, Published 08/31/2023 (EPub ahead of print). PMID: 37651202.
192. Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, Chowdhury S, **Coffey C**, Concha-Marambio L, Dam T, DiBiao P, Foroud T, Frasier M, Gochanour C, Jennings D, Kiebertz K, Kopil CM, Merchant K, Mollenhauer B, Montine T, Nudelman K, Pagano G, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tanner CM, Tolosa E, Weintraub D, Xiao Y, Siderowf A, Dunn B, and Marek K (2024). "Biological Definition of Neuronal Alpha-Synuclein Disease: Towards an Integrated Staging System for Research," *Lancet Neurology*, 23: 178-190.
191. Smith AG, Singleton JR, Aperghis A, **Coffey CS**, Creigh P, Cudkowicz M, Conwit R, Ecklund D, Fedler JK, Gudjonsdottir A, Hauer P, Herrmann DN, Kearney M, Kissel J, Klingner E, Quick A, Revere C, and Stino A for the NeuroNEXT NN108 TopCSPN Study Team (2023). "Safety and Efficacy of Topiramate in Individuals with Cryptogenic Sensory Peripheral Neuropathy with Metabolic Syndrome: The TopCSPN Randomized Clinical Trial," *JAMA Neurology*, 80(12): 1334-1343. PMID: 37870862.
190. Gonzalez NR, Amin-Hanjani S, Bang OY, **Coffey C**, Du R, Fierstra J, Fraser JF, Kuroda S, Tietjen GE, and Yaghi S on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, and Council on Clinical Cardiology (2023). "Adult Moyamoya Disease and Syndrome: Current Perspectives and Future Directions: A Scientific Statement From the American Heart Association/American Stroke Association," *Stroke*, 54(10): e465-e479. PMID: 37609846.
189. Brumm MC, Siderowf A, Simuni T, Burghardt E, Choi SH, Caspell-Garcia C, Chahine LM, Mollenhauer B, Foroud T, Galasko D, Merchant K, Arnedo V, Hutten SJ, O'Grady AN, Poston KL, Tanner CM, Weintraub D, Kiebertz K, Marek K, and **Coffey CS** on behalf of the Parkinson's Progression Markers Initiative (2023). "Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression," *Journal of Parkinson's Disease*, 13(6): 899-916. PMID: 37458046.
188. Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, Nguyen H, Alcalay RN, Chahine LM, Foroud T, Galasko D, Kiebertz K, Merchant K, Mollenhauer B, Poston KL, Seibyl J, Simuni T, Tanner CM, Weintraub D, Videnovic A, Choi SH, Kurth R, Caspell-Garcia C, **Coffey CS**, Frasier M, Oliveira LMA, Hutten SJ, Sherer T, Marek K, Soto C and the Parkinson's Progression Markers Initiative (2023). "Assessment of Heterogeneity and Disease Onset in the Parkinson's Progression Markers Initiative (PPMI) Cohort Using the  $\alpha$ -Synuclein Seed Amplification Assay: A Cross-Sectional Study," *Lancet Neurology*, 22(5): 407-417. PMID: 37059509.

187. Sluka KA, Wager TD, Sutherland SP, Labosky PA, Balach T, Bayman EO, Berardi G, Brummett CM, Burns J, Buvanendran A, Caffo B, Calhoun VD, Clauw D, Chang A, **Coffey CS**, Dailey DL, Ecklund D, Fiehn O, Fisch KM, Frey Law LA, Harris RE, Harte SE, Howard TD, Jacobs J, Jacobs JM, Jepsen K, Johnston N, Langefeld CD, Laurent LC, Lenzi R, Lindquist MA, Lokshin A, Kahn A, McCarthy RJ, Olivier M, Porter L, Qian WJ, Sankar CA, Satterlee J, Swensen AC, Vance CGT, Waljee J, Wandner LD, Williams DA, Wixson RL, Zhou ZJ and the A2CPS Consortium (2023). "Predicting Chronic Postsurgical Pain: Current Evidence and a Novel Program to Develop Predictive Biomarker Signatures," *Pain*, 164(9):1912-1926. PMID: 37326643.
186. Merchant K, Simuni T, Fedler J, Caspell-Garcia C, Brumm M, Nudelman K, Tengstrand E, Hsieh F, Alcalay R, **Coffey C**, Chahine L, Foroud T, Singleton A, Weintraub D, Hutten S, Sherer T, Siderowf A, Mollenhauer B, Tanner C, and Marek K (2023). "LRRK2 and GBA1 Variant Carriers Have Higher Urinary Bis(Monacylglycerol) Phosphate Concentrations in PPMI Cohorts," *NPJ Parkinson's Disease*, 9, 30(23). <https://doi.org/10.1038/s41531-023-00468-2>.
185. Weintraub D, Picillo M, Cho HR, Caspell-Garcia C, Blauwendraat C, Brown E, Chahine L, **Coffey C**, Dobkin R, Foroud T, Galasko D, Kiebertz K, Marek K, Merchant K, Mollenhauer B, Poston K, Simuni T, Siderowf A, Singleton A, Seibyl J, and Tanner C (2023). "Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study," *Movement Disorders Clinical Practice*, 10(6): 942-954. doi: 10.1002/mdc3.13751.
184. Chahine LM, Beach T, Adler C, Hepker M, Kanthasamy A, Appel S, Pritzkow S, Pinho M, Mosovsky S, Serrano G, **Coffey C**, Brumm M, Oliveira L, Eberling J, and Mollenhauer B (2023). "Central and Peripheral  $\alpha$ -Synuclein in Parkinson Disease Detected by Seed Amplification Assay," *Annals of Clinical and Translational Neurology*, 10(5): 696-705. doi:10.1002/acn3.51753.
183. Gibler RC, Peugh JL, **Coffey CS**, Chamberlin L, Ecklund DE, Klingner EA, Korbee LL, Kabbouche MA, Kacperski J, Porter LL, Reidy BL, Hershey AD, and Powers SW (2023). "Impact of Preventive Pill-Based Treatment on Migraine Days: A Secondary Outcome Study of the Childhood and Adolescent Migraine Prevention (CHAMP) Trial and a Comparison of Self-Report to Nosology-Derived Assessments," *Headache*, 63(6): 805-812. PMID: 36757131. Doi:10.1111/head.14474
182. Brumm MC, Pierz KA, Lafontant DE, Caspell-Garcia C, **Coffey CS**, Siderowf A, and Marek KL (2023). "Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older," *Neurology*, Published 02/27/2023 (EPub ahead of print). PMID: 36849448
181. Simuni T, Merchant K, Brumm MC, Cho H, Caspell-Garcia C, **Coffey CS**, Chahine LM, Alcalay RN, Nudelman K, Foroud T, Mollenhauer B, Siderowf A, Tanner C, Iwaki H, Sherer T, and Marek K on behalf of the Parkinson's Progression Marker Initiative (2022). "Longitudinal Clinical and Biomarker Characteristics of Non-Manifesting LRRK2 G2019S Carriers in the PPMI Cohort," *NPJ Parkinson's Disease*, 8(1): 140. PMID: 36273008
180. Macklin EA, **Coffey CS**, Brumm MC, and Seibyl JP (2022). "Statistical Considerations in the Design of Clinical Trials Targeting Prodromal Parkinson Disease," *Neurology*, 99(7 Suppl 1): 68-75. PMID: 35970588.
179. Saunders-Pullman R, Ortega RA, Wang C, Raymond D, Elango S, Urval KLN, Katsnelson V, Gerber R, Swan M, Shanker V, Alcalay RN, Mirelman A, Brumm MC, Meijia-Santana H, **Coffey CS**, Marek K, Ozelius LJ, Giladi N, Marder KS, and Bressman SB (2022). "Association of Olfactory Performance with Motor Decline and Age at Onset in People with Parkinson's Disease and the LRRK2 G2019S Variant," *Neurology*, 99(8): e814-e823. PMID 35995594.
178. Berardi G, Frey-Law L, Sluka KA, Bayman EO, **Coffey CS**, Ecklund D, Vance CGT, Dailey DL, Burns J, Buvanendran A, McCarthy RJ, Jacobs J, Zhou XJ, Wixson R, Balach T, Brummett CM, Clauw D, Colquhoun D, Harte SE, Harris RE, Williams DA, Chang AC, Waljee J, Fisch KM, Jepsen K, Laurent LC, Olivier M, Langefeld CD, Howard TD, Fiehn O, Jacobs JM, Dakup P, Qian WJ, Swensen AC, Lokshin A, Lindquist M, Caffo BS, Crainiceanu C, Zeger S, Kahn A, Wager T, Taub M, Ford J, Sutherland SP, and Wandner LD (2022). "Multi-Site Observational Study to Assess Biomarkers for Susceptibility or Resilience to Chronic Pain: The Acute to Chronic Pain Signatures (A2CPS) Study Protocol," *Frontiers in Medicine*, 9: 849214. PMID: 3554720

177. Signaevsky M, Marami B, Prastawa M, Tabish N, Iida MA, Zhang XF, Sawyer M, Duran I, Koenigsberg DG, Bryce CH, Chahine LM, Mollenhauer B, Mosovsky S, Riley L, Dave KD, Eberling J, **Coffey CS**, Adler CH, Serrano GE, White CL, Koll J, Fernandez G, Zeineh J, Cordon-Cardo C, Beach TG, Crary JF (2022). "Antemortem Detection of Parkinson's Disease Pathology in Peripheral Biopsies Using Artificial Intelligence," *Acta Neuropathologica Communications*, 10(1): 21. PMID: 35164870
176. Griguer CE, Oliva CR, **Coffey CS**, Cudkowicz ME, Conwit RA, Gudjonsdottir AL, Ecklund DJ, Fedler JK, Neill-Hudson TM, Nabors LB, Benghe M, Hackney JR, Chase M, Leonard TP, Patel T, Colman H, De la Fuente M, Chaudhary R, Marder K, Kreisl T, Mohlie N, Chheda MG, McNeil K, Kumthekar P, Dogan A, Drappatz J, Puduvalli V, Kowalska A, Graber J, Gerstner E, Clark S, Salacz M, and Markert J (2022). "Prospective Biomarker Study in Newly Diagnosed Glioblastoma: Cyto-C Clinical Trial," *Neurooncology Advances*, 4(1): 1-10. PMID: 35088051
175. Reidy BL, Powers SW, **Coffey CS**, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Peugh J, Kabbouche MA, Kacperski J, and Hershey AD for the CHAMP Investigators (2022). "Multimodal Assessment of Medication Adherence Among Youth with Migraine: An Ancillary Study of the CHAMP Trial," *Journal of Pediatric Psychology*, 47(4): 376-387. PMID: 34865085.
174. Reidy BL, Peugh J, Hershey AD, **Coffey CS**, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Kabbouche MA, Kacperski J, and Powers SW (2022). "Trajectory of Treatment Response in the Child and Adolescent Migraine Prevention (CHAMP) Study, A Randomized Clinical Trial," *Cephalagia*, 42(1): 44-52. PMID: 34404270.
173. Nowak RJ, **Coffey CS**, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, Wolfe GI, Burns TM, Freimer ML, Nations S, Granit V, Smith AG, Richman DP, Ciafaloni E, Al-Lozi MT, Sams LA, Quan D, Ubogu E, Pearson B, Sharma A, Yankey JW, Uribe L, Shy M, Amato AA, Conwit R, O'Connor KC, Hafner DA, Cudkowicz ME and Barohn RJ on behalf of the NN103 BeatMG Study Team (2021). "Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study," *Neurology*, 98(4): e376-e389. PMID: 34857535
172. Espay AJ, Lafontant DE, Poston KL, Caspell-Garcia C, Marsili L, Cho HR, Daniel C, Kim N, **Coffey CS**, Mahajan A, Ezzat K, and Sturchio A for the Parkinson's Progression Markers Initiative (2021). "Low Soluble Amyloid-Beta 42 is Associated with Smaller Brain Volume in Parkinson's Disease," *Parkinsonism and Related Disorders*, 92: 15-21. PMID: 34656902
171. Picillo M, LaFontant DE, Bressman S, Caspell-Garcia C, **Coffey C**, Cho HR, Burghardt EL, Dahodwala N, Sanders-Pullman R, Tanner CM, and Amara AW for the Parkinson's Progression Markers Initiative (2021). "Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson Disease," *Journal of Parkinson Disease*, 12(1): 421-436. PMID: 34744052
170. Russo MJ, Orru CD, Concha-Marambio L, Giaisi S, Groveman BR, Farris CM, Holguin B, Hughson AG, LaFontant DE, Caspell-Garcia C, **Coffey CS**, Mollon J, Hutten SJ, Merchant K, Heym RG, Soto C, Caughey B, and Kang UJ (2021). "High Diagnostic Performance of Independent Alpha-Synuclein Seed Amplification Assays for Detection of Early Parkinson's Disease," *Acta Neuropathologica Communications*, 9(1): 179. PMID: 34742348
169. Carillo N, Malicdan MC, Leoyklang P, Shrader JA, Joe G, Slota C, Perreault J, Heiss JD, Class B, Liu CY, Bradley K, Jodarski C, Ciccone C, Driscoll C, Parks R, Van Wart S, Bayman L, **Coffey CS**, Quintana M, Berry SM, Huizing M, and Gahl WA (2021). "Safety and Efficacy of N-Acetylmannosamine (ManNAc) in Patients with GNE Myopathy: An Open-Label Phase 2 Study," *Genetics in Medicine*, 23(11): 2067-2075. PMID: 34257421.
168. Kennelty K, **Coffey CS**, Ardery G, Uribe L, Yankey J, Ecklund D, James PA, Vander Weg MW, Chrischilles EA, Christensen AJ, Polgreen LA, Gryzlak B, and Carter BL on behalf of the MEDication Focused Outpatient Care for Underutilization of Secondary Prevention (MEDFOCUS) Trial Investigators (2021). "A Cluster Randomized Trial to Evaluate a Centralized Clinical Pharmacy Service in Large, Health System Primary Care Clinics," *Journal of the American College of Clinical Pharmacy*, 4: 1287-1299.
167. Fox R, Raska P, Barro C, Konig V, Bermel R, Chase M, **Coffey C**, Goodman A, Klawiter E, Naismith R, and Kuhle J (2021). "Neurofilament-Light Chain in a Phase 2 Clinical Trial of Ibudilast in Progressive Multiple Sclerosis," *Multiple Sclerosis Journal*, 27(13): 2014-2022. PMID: 33635141



166. Powers SW, **Coffey CS**, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Peugh JL, Korbee LL, Simmons K, Sullivan SM, Kabbouche MA, Kacperski J, Porter LL, Reidy BL, and Hershey AD (2021). "The Childhood and Adolescent Migraine Prevention Follow-Up Survey: Observations Three Years After the CHAMP Trial," *JAMA Network Open*, 4(7): e2114712. PMID: 34251445.
165. Kremer T, Taylor KI, Siebourg-Polster J, Gerken T, Staempfli A, Czech C, Dukart J, Galasko D, Foroud T, Chahine LM, **Coffey CS**, Simuni T, Weintraub D, Seibyl J, Poston KL, Toga AW, Tanner CM, Marek K, Hutten SJ, Dziadek S, Trenkwalder C, Pagano G, and Mollenhauer B (2021). "Longitudinal Analysis of Multiple Neurotransmitter Metabolites in CSF in Early Parkinson's Disease," *Movement Disorders*, 36(8): 1972-1978. PMID: 33942926.
164. Kang D, **Coffey CS**, Smith BJ, Yuan Y, Shi Q, and Yin J (2021). "Hierarchical Bayesian Clustering Design of Multiple Biomarker Subgroups (HCOMBS)," *Statistics in Medicine*, 40: 2893-2921. PMID: 33772843.
163. Chahine LM, Brumm MC, Caspell-Garcia C, Oertel W, Mollenhauer B, Amara A, Fernandez-Arcos A, Tolosa E, Simonet C, Hogg B, Videnovic A, Hutten SJ, Tanner C, Weintraub D, Burghardt E, **Coffey C**, Cho HR, Kieburtz K, Poston KL, Merchant K, Galasko D, Foroud T, Siderowf A, Marek K, Simuni T, and Iranzo A (2021). "Dopamine Transporter Imaging Predicts Clinically-Defined  $\alpha$ -Synucleinopathy in REM Sleep Behavior Disorder," *Annals of Clinical & Translational Neurology*, 8(1): 201-212. PMID: 33321002
162. Goodman AD, Fedler JK, Yankey J, Klingner EA, Ecklund DJ, Goebel CV, Bermel RA, Chase M, **Coffey CS**, Klawiter EC, Naismith RT, and Fox RJ on behalf of the SPRINT-MS Investigators (2021). "Response to Ibudilast Treatment According to Progressive Multiple Sclerosis Disease Phenotype," *Annals of Clinical & Translational Neurology*, 8(1): 111-118. PMID: 33460301
161. Simuni T, Fiske B, Merchant K, **Coffey CS**, Klingner E, Caspell-Garcia C, Lafontant DE, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Venuto C, Dawson TM, Baker L, Kostrzebski M, Ward, & Rafaloff for the Parkinsons Study Group NULO-PD Investigators (2021). "Nilotinib in Patients with Moderately Advanced Parkinson Disease: A Randomized Clinical Trial," *JAMA Neurology*, 78(3): 312-320. PMID: 33315105
160. Naismith RT, Bermel RA, **Coffey CS**, Goodman AD, Fedler JK, Chase M, Klawiter EC, Nakamura K, Narayanan S, Goebel C, Yankey JW, Klingner EA, and Fox RJ (2021). "Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study," *Neurology*, 96(4): e491-e500. PMID: 33268562
159. Bermel RA, Fedler J, Kaiser P, Novalis C, Schneebaum J, Klingner E, Williams D, Yankey J, Ecklund D, Chase M, Naismith R, Klawiter EC, Goodman A, **Coffey C**, and Fox RJ (2021). "Optical Coherence Tomography Outcomes from the SPRINT-MS Trial of Ibudilast in Progressive Multiple Sclerosis," *Multiple Sclerosis Journal*, 27(9): 1384-1390. PMID: 33054533
158. Brownstein MJ, Simons NG, Long DJ, Yankey J, Maibach HT, Cudkowicz M, **Coffey C**, Conwit RA, Lungu C, Anderson KE, Hersch SM, Ecklund DJ, Damiano EM, Itzkowitz DE, Lu S, Chase MK, Shefner JM, McGarry A, Thornell B, Gladden C, Costigan M, O'Sullivan P, Marshall FJ, Chesire AM, Deritis P, Adams JL, Hedera P, Lowen K, Rosas HD, Hiller AL, Quinn J, Keith K, Duker AP, Gruenwald C, Molloy A, Jacob C, Factor S, Sperin E, Bega D, Brown ZR, Seeberger LC, Sung VW, Benghe M, Kostyk SK, Daley AM, Perlman S, Suski V, Conlon P, Barrett MJ, Lowenhaupt S, Quigg M, Perlmutter JS, Wright BA, Most E, Schwartz GJ, Lamb J, Chuang RS, Singer C, Marder K, Moran JA, Singleton JR, Zorn M, Wall PV, Dubinsky RM, Gray C, and Drazinic C (2020). "Safety and Tolerability of SRX246, A Vasopressin 1A Antagonist, In Irritable Huntington's Disease Patients – A Randomized Phase 2 Clinical Trial," *Journal of Clinical Medicine*, 16(9): 3682. PMID: 33207828
157. Mollenhauer B, Dakna M, Kruse N, Liu TY, Galasko D, Foroud T, Zetterberg H, Schade S, Gera RG, Wang W, Gao F, Frasier M, Chahine LM, **Coffey CS**, Singleton AB, Simuni T, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Marek K, Siderowf A, Cedarbaum JM, Hutten SJ, Trenkwalder C, and Graham D (2020). "Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression," *Movement Disorders*, 35(11): 1999-2008. PMID: 32798333
156. Chahine LM, Beach TG, Brumm MC, Adler CH, **Coffey CS**, Mosovsky S, Caspell-Garcia C, Serrano GE, Munoz DG, White CL, Crary JF, Jennings D, Taylor P, Foroud T, Arnedo V, Kopil CM, Riley L, Dave KD, and Mollenhauer B for the Systemic Synuclein Sampling Study (2020). "In Vivo Distribution of  $\alpha$ -Synuclein in Multiple Tissues and Biofluids in Parkinson's Disease," *Neurology*, 95(9): e1267-e1284. PMID: 32747521

155. Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, **Coffey CS**, Siderowf A, Alcalay R, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Nudelman K, Tosun-Turgut D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Bressman S, and Marek K on behalf of the Parkinson's Progression Markers Initiative Investigators (2020). "Clinical and Dopamine Transporter Imaging Characteristics of Leucine-Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross Sectional Study," *Movement Disorders*, 35(5): 833-844. PMID: 32073681
154. Irwin DJ, Fedler J, **Coffey CS**, Caspell-Garcia C, Kang JH, Simuni T, Foroud T, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Weintraub D, Mollenhauer B, Galasko DR, Siderowf A, Marek K, Trojanowski JQ, and Shaw LM on behalf of the Parkinson's Progression Markers Initiative (2020). "Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease," *Annals of Neurology*, 88(3): 574-587. PMID: 32542885
153. Cudkowicz M, Chase MK, **Coffey CS**, Ecklund DJ, Thornell BJ, Lungu C, Mahoney K, Gutmann L, Shefner J, Staley KJ, Bosch M, Foster E, Long JD, Bayman EO, Torner J, Yankey J, Peters R, Huff T, Conwit RA, and the NeuroNEXT Clinical Study Sites (2020). "Seven-Year Experience from the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials," *JAMA Neurology*, 35(5): 833-844. PMID: 32202612
152. Weintraub D, Caspell-Garcia C, Simuni T, Cho HR, **Coffey CS**, Aarsland D, Alcalay RN, Barrett MJ, Chahine LM, Eberling J, Espay AJ, Hamilton J, Hawkins KA, Leverenz J, Litvan I, Richard I, Rosenthal LS, Siderowf A, and York M on behalf of the Parkinson's Progression Markers Initiative (2020). "Neuropsychiatric Symptoms and Cognitive Abilities Over the Initial Quinquennium of Parkinsons Disease," *Annals of Clinical & Translational Neurology*, 7(4): 449-461. PMID: 32285645
151. Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray C, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, **Coffey CS**, Schwarzschild MA, Sherer T, Postuma RB, Strafella AP, Singleton AB, Barker RA, Kieburtz K, Olanow CW, Lozano A, Kordower JH, Cedarbaum JM, Brundin P, Standaert DG, and Lang AE (2020). "Disease Modification and Biomarker Development in Parkinson Disease: Revision or Reconstruction?," *Neurology*, 94(11): 481-494. PMID: 32102975
150. Simuni T, Uribe L, Cho HR, Caspell-Garcia C, **Coffey CS**, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten SJ, Bressman S, and Marek K on behalf of the PPMI Investigators (2020). "Clinical and Dopamine Transporter Imaging Characteristics of Non-Manifest LRRK2 and GBA Mutation Carriers in the Parkinson's Progression Markers Initiative (PPMI): A Cross-Sectional Study," *Lancet Neurology*, 19(1): 71-80. PMID: 31678032
149. Sorkin BC, Kuszak AJ, Fukagawa NK, Hoffman FA, Jafari M, Barrett B, Brown PN, Bushman FD, Casper S, Chilton FH, **Coffey CS**, Ferruzi MG, Hopp DC, Kiely M, Lakens D, MacMillan JB, Meltzer DO, Pahor M, Paul J, Pritchett-Corning K, Quinney SK, Rehermann B, Setchell KDR, Sipes NS, Stephens JM, Taylor DL, Tiriack H, Walters WA, Xi D, Zappala G, and Pauli GF (2020). "Improving Natural Product Research Translation: From Source to Clinical Trial," *FASEB Journal*, 34(1): 41-65. PMID: 31914647
148. Chahine LM, Siderowf A, Barnes J, Seedorff N, Caspell-Garcia C, Simuni T, **Coffey CS**, Galasko D, Mollenhauer B, Arnedo V, Daegle N, Frasier M, Tanner C, Kieburtz K, Marek K and the Parkinson's Progression Markers Initiative (2019). "Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures," *Journal of Parkinson's Disease*, 9(4): 665-679. PMID: 31450510
147. Paulsen JS and **Coffey CS** (2019). "Antisense Oligonucleotides Might Change the Therapeutic Landscape for Huntington's Disease," *Lancet Neurology*, 18(10): 911-912. PMID: 31526747
146. Mollenhauer B, Caspell-Garcia CJ, **Coffey CS**, Taylor P, Singleton A, Shaw LM, Trojanowski JQ, Frasier M, Simuni T, Iranzo A, Oertel W, Siderowf A, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Marek K, and Galasko D for the PPMI Study (2019). "Longitudinal Analyses of Cerebrospinal Fluid  $\alpha$ -Synuclein in Prodromal and Early Parkinson's Disease," *Movement Disorders*, 34(9): 1354-1364.

145. Prakash N, Caspell-Garcia C, **Coffey C**, Siderowf A, Tanner CM, Kiebertz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, Herzog M, Daegele N, Arnedo V, Frasier M, Sherer T, Marek K, & Simuni T on behalf of the Parkinson's Progression Markers Initiative Steering Committee, Study Cores, Site Investigators, Coordinators, and Industry & Scientific Advisory Board (2019). "Feasibility and Safety of Lumbar Puncture in the Parkinson's Disease Research Participants: Parkinson's Progression Marker Initiative (PPMI)", *Parkinsonism & Related Disorders*, 62: 201-209.
144. Espay AJ, Foster ED, **Coffey CS**, Uribe L, Caspell-Garcia CJ, Weintraub D, and the Parkinson's Progression Markers Initiative (2019). "Lack of Independent Mood-Enhancing Effect for Dopaminergic Medications in Early Parkinson's Disease," *Journal of the Neurological Sciences*, 402: 81-85.
143. Amara AW, Chahine L, Seedorff N, Caspell-Garcia CJ, **Coffey C**, Simuni T, and the Parkinson's Progression Markers Initiative (2019). "Self-Reported Physical Activity Levels and Clinical Progression in Early Parkinson's Disease," *Parkinsonism & Related Disorders*, 61: 118-125.
142. Lyden P, Pryor KE, **Coffey CS**, Cudkowicz M, Conwit R, Jadhav A, Sawyer Jr RN, Claassen J, Adeoye O, Song S, Hannon P, Rost NS, Hinduja A, Torbey M, Lee J, Benesch C, Rippee M, Rymer M, Froehler MT, Haley EC, Johnson M, Yankey J, and Magee K (2019). "Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, In Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or Both in Moderate to Severe Acute Ischemic Stroke," *Annals of Neurology*, 85(1): 125-136. PMID: 30450637
141. Chahine LM, Beach TG, Seedorff N, Caspell-Garcia C, **Coffey CS**, Brumm M, Adler CH, Serrano GE, Linder C, Mosovsky S, Foroud T, Riss H, Ecklund D, Seibyl J, Jennings D, Arnedo V, Riley L, Dave K, and Mollenhauer B on behalf of the Systemic Synuclein Sampling Study (2018). "Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for  $\alpha$ -Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4)," *Journal of Parkinson's Disease*, 8(4): 517-527.
140. Krosschell KJ, Bosch M, Nelson L, Duong T, Lowes LP, Alfano LN, Benjamin D, Carry TB, Devine G, Kelley C, Gadekan R, Malkus EC, Pasternak A, Provance-Orr S, Roemeiser-Logan L, Nicorici A, Trussell D, Young SD, Fetterman JR, Montes J, Powers PJ, Quinones R, Quigley J, **Coffey CS**, Yankey JW, Bartlett A, Kissell JT, Kolb SJ, and the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators (2018). "Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study," *Journal of Neuromuscular Diseases*, 5(4): 509-521.
139. Marek K, Chowdhury S, Siderowf A, Lasch S, **Coffey CS**, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kiebertz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun-Turgut D, Poston K, Arnedo V, Frasier M, Sherer T, and the Parkinson's Progression Markers Initiative (2018). "The Parkinson's Progression Markers Initiative (PPMI) – Establishing a PD Biomarker Cohort," *Annals of Clinical and Translational Neurology*, 5(12): 1460-1477.
138. Fox RJ, **Coffey CS**, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koeppe M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, and Zabeti A on behalf of the NN102/SPRINT-MS Trial Investigators (2018). "Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis," *New England Journal of Medicine*, 379(9): 846-855. PMID: 3015738
137. Chahine LM, Uribe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, **Coffey CS**, Simuni T, Weintraub D, and the Parkinson's Progression Markers Initiative (2018). "Cognition Among Individuals Along a Spectrum of Increased Risk for Parkinson's Disease," *PLOS ONE*, 13(8): e0201964.

136. Beach TG, Serrano G, Kremer T, Canamero M, Dziadek S, Sade H, Derkinderen P, Corbille AG, Letournel F, Munoz DG, White CL, Schneider J, Crary JF, Sue LI, Adler CH, Glass MJ, Intorcchia AJ, Walker JE, Foroud T, **Coffey CS**, Ecklund D, Riss H, Goldmann J, Konig F, Kopil CM, Arnedo V, Riley L, Linder C, Dave KD, Jennings D, Seibyl J, Mollenhauer B, and Chahine L on behalf of the Systemic Synuclein Sampling Study (2018). "Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4)," *Journal of Neuropathology and Experimental Neurology*, 77(9): 793-802.
135. Bartlett A, Kolb SJ, Kingsley A, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, Connolly AM, Chiriboga A, McDonald C, Burnette B, Werner K, Thangarajh M, Shieh PB, Finanger E, **Coffey CS**, Yankey JW, Cudkowicz ME, McGovern MM, McNeil E, Arnold WD, and Kissel JT for the NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators (2018). "Recruitment & Retention Program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!" *Contemporary Clinical Trials Communications*, 11: 113-119.
134. Simuni T, Siderowf A, Lasch S, **Coffey CS**, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kiebertz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, and Marek K on behalf of the PPMI Investigators (2018). "Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort," *Movement Disorders*, 33(5): 771-782. PMID: 29572948
133. Anderegg MD, Gums TH, Uribe L, MacLaughlin EJ, Hoehns J, Bazaldua OV, Ives TJ, Hahn DL, **Coffey CS**, and Carter BL (2018). "Pharmacist Intervention for Blood Pressure in Patients with Diabetes and/or Chronic Kidney Disease," *Pharmacotherapy*, 38(3): 309-318.
132. Simuni T, Caspell-Garcia C, Walker M, **Coffey C**, Weintraub D, Mollenhauer B, Lasch S, Tanner C, Jennings D, Kiebertz K, Chahine L, and Marek K on behalf of the PPMI Investigators (2018). "Baseline Prevalence and Longitudinal Evolution of Non-Motor Symptoms in Early Parkinson's Disease: The PPMI Cohort," *Journal of Neurology, Neurosurgery, & Psychiatry*, 89(1): 78-88.
131. Kolb SJ, **Coffey CS**, Yankey JW, Krosschell KP, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Parsons J, Connolly A, Chiriboga CA, McDonald C, Burnette B, Werner W, Thangarajh M, Shieh P, Finanger E, Cudkowicz M, McGovern MM, McNeil DE, Finkel R, Iannaccone ST, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes A, Bartlett AHM, Kissel JT and The NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators (2017). "Natural History of Infantile-Onset Spinal Muscular Atrophy," *Annals of Neurology*, 82(6): 883-891. PMID: 29149772
130. Mollenhauer B, Caspell-Garcia CJ, **Coffey CS**, Taylor P, Shaw LM, Trojanowski JQ, Singleton A, Frasier M, Marek K, and Galasko D for the PPMI Study (2017). "Longitudinal CSF Biomarkers in Early Parkinson's Disease and Healthy Controls," *Neurology*, 89(19): 1959-1969. PMID: 29030452
129. Amara AW, Chahine LM, Caspell-Garcia C, Long JD, **Coffey C**, Hognl B, Videnovic A, Iranzo A, Mayer G, Foldvary-Schaefer N, Postuma R, Oertel W, Lasch S, Marek K, Simuni T, and the Parkinson's Progression Markers Initiative (2017). "Longitudinal Assessment of Excessive Daytime Sleepiness in Early Parkinson's Disease," *Journal of Neurology, Neurosurgery, & Psychiatry*, 88: 653-662.
128. Mollenhauer B, Batrla R, El-Agnaf O, Galasko DR, Lashuel HA, Merchant KM, Shaw LM, Selkoe DJ, Umek R, Vanderstichele H, Zetterberg H, Zhang J, Caspell-Garcia C, **Coffey C**, Hutten SJ, Frasier M, and Taylor P for the Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research (2017). "A User's Guide for  $\alpha$ -Synuclein Biomarker Studies in Biological Fluids: Peri-Analytical Considerations," *Movement Disorders*, 32(8): 1117-1130.
127. Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu I, Zhang Y, Nalls M, Singleton A, Shaw LA, Kang JH, Trojanowski JQ, Siderowf A, **Coffey C**, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, and Weintraub D on behalf of the Parkinson's Progression Markers Initiative (PPMI) (2017). "Multiple Modality Biomarker Prediction of Cognitive Impairment in Prospectively Followed De Novo Parkinson's Disease," *PLoS ONE*, 12(5): e0175674.
126. Powers SW, **Coffey CS**, and Hershey AD (2017). "Treatment of Pediatric Migraine," *The New England Journal of Medicine*, 376(14): 1388-1389.

125. Pont-Sunyer C, Tolosa E, Caspell-Garcia C, **Coffey C**, Alcalay RN, Chans P, Duda JE, Facheris M, Fernandez-Santiago R, Marek K, Lomena F, Marras C, Mondragon E, Saunders-Pullman R, and Waro B on behalf of the LRRK2 Cohort Consortium (2017). "The Prodromal Phase of LRRK2 Associated Parkinson Disease: Clinical and Imaging Studies," *Movement Disorders*, 32(5): 726-738.
124. Visanji NP, Mollenhauer B, Beach TG, Adler CH, **Coffey CS**, Kopil CM, Dave KD, Foroud T, Chahine L, and Jennings D on behalf of the Systemic Synuclein Sampling Study (S4) Investigators (2017). "The Systemic Synuclein Sampling Study: Toward a Biomarker for Parkinson's Disease," *Biomarkers in Medicine*, 11(4): 359-368.
123. Powers SW, Hershey AD, and **Coffey CS** on behalf of the CHAMP Study Group (2017). "The Childhood and Adolescent Migraine Prevention (CHAMP) Study: 'What Do We Do Now?'," *Headache*, 57(2): 180-183.
122. Powers SW, **Coffey CS**, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, & Hershey AD for the CHAMP Investigators (2017). "Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine," *The New England Journal of Medicine*, 376(2): 115-124. PMID: 27788026
121. Laage T, Loewy J, Menon S, Miller E, Pulkstenis E, Kan-Dobrosky N, & **Coffey C** (2016). "Ethical Considerations in Novel Adaptive Design Clinical Trials," *Therapeutic Innovation & Regulatory Science*, 51(2): 190-199.
120. Lyden P, Weymer S, **Coffey C**, Cudkowicz M, Berg S, O'Brien S, Fisher M, Haley EC, Khatri P, Saver J, Levine S, Levy H, Rymer M, Wechsler L, Jadhav A, McNeil E, Waddy S, and Pryor K (2016). "Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection," *Stroke*, 47(12): 2979-2985.
119. Anderegg MD, Gums TH, Uribe L, **Coffey CS**, James PA, & Carter BL (2016). "Physician-Pharmacist Collaborative Management: Narrowing the Socioeconomic Blood Pressure Gap," *Hypertension*, 68(5): 1314-1320.
118. Fox RJ, **Coffey CS**, Cudkowicz ME, Gleason T, Goodman, A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Bermel R, Ecklund D, Koepp M, Long J, Natarajan S, Ramachandran S, Skaramagas T, Thornell B, Yankey J, Agius M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Miravalle A, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, Weinstock-Gutman B, Yadav V, & Zabeta A (2016). "Design, Rationale, and Baseline Characteristics of the Randomized Double-Blind Phase II Clinical Trial of Ibudilast in Progressive Multiple Sclerosis," *Contemporary Clinical Trials*, 50:166-177.
117. Simuni T, Long JD, Caspell-Garcia C, **Coffey CS**, Lasch S, Tanner CM, Jennings D, Kieburtz KD, & Marek K on behalf of the PPMI Investigators (2016). "Predictors of Time to Initiation of Symptomatic Therapy in Early Parkinson's Disease," *Annals of Clinical and Translational Neurology*, 3(7):482-494.
116. Simuni T, Caspell-Garcia C, **Coffey C**, Lasch S, Tanner C, & Marek K on behalf of the PPMI Investigators (2016). "How Stable are Parkinson's Disease Subtypes in De Novo Patients: Analysis of the PPMI Cohort," *Parkinsonism & Related Disorders*, 28:62-67.
115. McClure LA, Szychowski JM, Benavente O, Hart RG, & **Coffey CS** (2016). "A Post Hoc Evaluation of a Sample Size Re-Estimation in the Secondary Prevention of Small Subcortical Strokes Study," *Clinical Trials*, 13(5):537-544.
114. Marras C, Alcalay RN, Caspell-Garcia C, **Coffey C**, Chan P, Duda JE, Facheris MF, Fernandez-Santiago R, Ruiz-Martinez J, Mestre T, Saunders-Pullman R, Pont-Sunyer C, Tolosa E, & Waro B on behalf of the LRRK2 Cohort Consortium (2016). "Motor and Nonmotor Heterogeneity of LRRK2-Related and Idiopathic Parkinson's Disease," *Movement Disorders*, 31(8):1192-1202.
113. Powers SW, Hershey AD, **Coffey CS**, Chamberlin LA, Ecklund DJ, Sullivan SM, Klingner EA, Yankey JW, Kashikar-Zuck S, Korbee LL, Costigan ML, Riss HH, & Porter LL (2016). "The Childhood and Adolescent Migraine Prevention (CHAMP) Study: A Report on Baseline Characteristics of Participants," *Headache*, 56(5): 859-870.

112. Wanner A, Groft SC, Teagarden JR, Krischer J, Davis BR, **Coffey CS**, Hickam DH, Teckman J, Nelson DR, McCaleb ML, Loomba R, Strange C, Sandhaus RA, Brantly M, Edelman JM, and Farrugia A (2015). "Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases," *Chronic Obstructive Pulmonary Diseases*, 2(2): 177-190.
111. Polgreen LA, Han J, Carter BL, Ardery GP, **Coffey CS**, Chrischilles EA, & James PA (2015). "Cost-Effectiveness of a Physician-Pharmacist Collaboration Intervention to Improve Blood Pressure Control," *Hypertension*, 66(6): 1145-1151.
110. Kang JH, Mollenhauer B, **Coffey CS**, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligorska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Keiburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, & Shaw LM on behalf of the Parkinson's Progression Markers Initiative (2016). "CSF Biomarkers Associated with Disease Heterogeneity in Early Parkinson's Disease: The Parkinson's Progression Marker's Initiative Study," *Acta Neuropathologica*, 131(6): 935-949.
109. Smith SM, Carris NW, Dietrich E, Gums JG, Uribe L, **Coffey C**, Gums TH, & Carter BL (2016). "Physician-Pharmacist Collaboration versus Usual Care for Treatment-Resistant Hypertension," *Journal of the American Society for Hypertension*, 10(4): 307-317.
108. Kolb SJ, **Coffey CS**, Yankey JW, Krossschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sankoku A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworkski PG, Prior TW, Burghes AHM, Bartlett A, Kissell JT & the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators (2016). "Baseline Results of the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study," *Annals of Clinical and Translational Neurology*, 3(2): 132-145.
107. Schuff N, Wu IW, Foster ED, **Coffey CS**, Gitelman DR, Mendick S, Seibyl J, Simuni T, Zhang Y, Jankovic J, Hunter C, Tanner CM, Rees L, Factor S, Berg D, Wurster I, Gauss K, Sprenger F, Seppi K, Poewe W, Mollenhauer B, Knake S, Mari Z, McCoy A, Rowe D, Ranola M, and Marek K (2015). "Diffusion Imaging of Nigral Alterations in Early Parkinson's Disease with Dopaminergic Deficits," *Movement Disorders*, 30(14): 1885-1892.
106. Powers WJ, Derdeyn CP, Biller J, **Coffey CS**, Hoh BL, Jauch EC, Johnston KC, Johnston SC, Khalessi AA, Kidwell CS, Meschia JF, Ovbiagele B, and Yavagal DR on Behalf of the American Heart Association Stroke Council (2015). "2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients with Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association," *Stroke*, 46(10): 3020-3035. PMID: 26123479
105. Carter BL, **Coffey CS**, Chrischilles EA, Ardery G, Ecklund D, Gryzlak B, Vander Weg MW, James PA, Christensen AJ, Parker CP, Gums T, Finkelstein RJ, Uribe L, and Polgreen LA on behalf of the MEDication Focused Outpatient Care for Underutilization of Secondary Prevention (MEDFOCUS) Trial Investigators (2015). "A Cluster-Randomized Trial of a Centralized Clinical Pharmacy Cardiovascular Risk Service to Improve Guideline Adherence," *Pharmacotherapy*, 35(7): 653-662.
104. Simuni T, Caspell-Garcia C, **Coffey C**, Chahine LM, Lasch S, Oertel WH, Mayer G, Hogl B, Postuma R, Videnovic A, Amara AW, and Marek K for the PPMI Sleep Working Group on Behalf of the PPMI Investigators (2015). "Correlates of Excessive Daytime Sleepiness in De Novo Parkinson's Disease: A Case Control Study," *Movement Disorders*, 30(10): 1371-1381.
103. Gums TH, Uribe L, Vander Weg MW, James P, **Coffey C**, and Carter BL (2015). "Pharmacist Intervention for Blood Pressure Control: Medication Intensification and Adherence," *Journal of the American Society for Hypertension*, 9(7): 569-578.
102. Zhang Y, Wu IW, Buckley S, **Coffey CS**, Foster E, Mendick S, Seibyl J, and Schuff N (2015). "Diffusion Tensor Imaging of the Nigrostriatal Fibers in Parkinson's Disease," *Movement Disorders*, 30(9): 1229-1236.

101. Carter BL, **Coffey CS**, Ardery G, Uribe L, Ecklund D, James P, Egan B, Vander Weg M, Chrischilles E, and Vaughn T (2015). "A Cluster-Randomized Trial of a Physician/Pharmacist Collaborative Model to Improve Blood Pressure Control," *Circulation: Cardiovascular Quality & Outcomes*, 8(3): 235-243.
100. Weintraub D, Simuni T, Caspell-Garcia C, **Coffey C**, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins, KA, and the Parkinson's Progression Markers Initiative (2015). "Cognitive Performance and Neuropsychiatric Symptoms in Early, Untreated Parkinson Disease," *Movement Disorders*, 30(7): 919-927.
99. **Coffey CS** (2015). "You May Have Worked on More Adaptive Designs than You Think," *Stroke*, 46(2): e26-28.
98. Lau H, White CL, **Coffey C**, Kase CS, Babikian VL et al. (2015). "Clinical Trial Participation and Health Behavior Modification: Secondary Prevention of Small Subcortical Strokes (SPS3)," *J Neurol Disord Stroke*, 3(1): 1094.
97. Kairalla JA, **Coffey CS**, Thomann MA, Shorr RI, and Muller KE (2015). "Adaptive Designs for Comparative Effectiveness Research Trials," *Clinical Research and Regulatory Affairs*, 32(1): 36-44.
96. Sharma M, Pearce LA, Benavente OR, Anderson DC, Connolly SJ, Palacio S, **Coffey CS**, and Hart RG (2014). "Predictors of Mortality in Patients with Lacunar Stroke in the Secondary Prevention of Small Subcortical Strokes Trial," *Stroke*, 45(10): 2989-2994.
95. Gums TH, Carter BL, Milavetz G, Buys L, Rosenkrans K, Uribe L, Coffey C, MacLaughlin EJ, Young RB, Ables AZ, Patel-Shori N, and Wisniewski A (2014). "Physician-Pharmacist Collaborative Management of Asthma in Primary Care," *Pharmacotherapy*, 34(10): 1033-1042.
94. Yeatts SD, Martin RH, **Coffey CS**, Lyden PD, Foster LD, Woolson RF, Broderick JP, and Palesch YY (2014). "The Challenges of Decision Making Regarding Futility in a Randomized Trial: The IMS-III Experience," *Stroke*, 45(5): 1408-1414.
93. Morgan C, Huyck S, Jenkins M, Chen L, Bedding A, **Coffey C**, Gaydos B, and Wathen J (2014). "Adaptive Design: Results of 2012 Survey on Perception and Use," *Therapeutic Innovation & Regulatory Science*, 48(4): 473-481.
92. Elkind MS, Luna JM, McClure LA, Zhang Y, **Coffey CS**, Roldan A, Del Brutto O, Pretell EJ, Pettigrew LC, Meyer BC, Tapia J, White C, and Benavente OR on behalf of the LIMITS Investigators (2014). "C-Reactive Protein as a Prognostic Marker After Lacunar Stroke: Levels of Inflammatory Markers in the Treatment of Stroke Study," *Stroke*, 45(3): 707-716.
91. Galpern WR, **Coffey CS**, Albanese A, Cheung K, Comella CL, Ecklund DJ, Fahn S, Jankovic J, Kieburtz K, Lang AE, McDermott MP, Shefner JM, Teller JK, Thompson JLP, Yeatts SD, and Jinnah HA (2014). "Designing Clinical Trials for Dystonia," *Neurotherapeutics*, 11(1): 117-127.
90. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, **Coffey CS**, Waligorska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM and the Parkinson's Progression Marker Initiative Investigators (2013). "Association of Cerebrospinal Fluid A $\beta$ <sub>1-42</sub>, t-tau, p-tau<sub>181</sub>, and  $\alpha$ -synuclein Levels with Clinical Features of Early Drug Naïve Parkinson's Disease Patients," *Archives of Neurology*, 70(10): 1277-1287.
89. Leira EC, **Coffey CS**, Jorge RE, Morton SM, Froehler MT, Davis PH, and Adams HP (2013). "The NIHSS Supplementary Motor Scale: A Valid Tool for Multidisciplinary Recovery Trials," *Cerebrovasc Dis*, 36(1): 69-73.
88. The SPS3 Investigators (2013). "Effects of Blood Pressure Targets in Patients with Recent Lacunar Stroke," *Lancet*, 382(9891): 507-515. (Writing Group: Benavente OR, **Coffey CS**, Conwit R, Hart RG, McClure LA, Pearce LA, Pergola PE, and Szychowski JM)
87. DeMik DE VanderWeg WM, Lundt ES, **Coffey CS**, Ardery G, and Carter BL (2013). "Using Theory to Predict Implementation of a Physician-Pharmacist Collaborative Intervention within a Practice-Based Research Network," *Research in Social and Administrative Pharmacy*, 9(6): 719-730.
86. Leira EC, Jorge RE, **Coffey CS**, Morton SM, Froehler MT, Davis PH, and Adams HP (2013). "The NIHSS Supplementary Motor Scale: A Valid Tool for Multidisciplinary Recovery Trials," *Cerebrovasc Dis*, 36: 69-73.

85. White CL, Szychowski JM, Roldan A, Benavente MF, Pretell EJ, Del Brutto OH, Kase CS, Arauz A, Meyer BC, Meissner I, Demaerschalk BM, McClure LA, **Coffey CS**, Pearce LA, Conwit R, Irby LH, Peri K, Pergola PE, Hart RG, and Benavente OR for the SPS3 Investigators. "Clinical Features and Racial/Ethnic Differences among the 3020 Participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) Trial," *Journal of Stroke and Cerebrovascular Diseases*, 22(6): 764-774.
84. Carter BL, **Coffey CS**, Uribe L, James PA, Egan BM, Ardery G, Chrischilles EA, Ecklund D, VanderWeg M, and Vaughn T on behalf of the Collaboration Among Pharmacists and Physicians to Improve Outcomes Now (CAPTION) Trial Investigators (2013). "Similar Blood Pressure Values Across Racial and Economic Groups: Baseline Data from a Group Randomized Trial," *The Journal of Clinical Hypertension*, 15(6): 404-412.
83. Hershey AD, Powers SW, **Coffey CS**, Ecklund D, Chamberlin LA, and Korbee LL on behalf of the CHAMP Study Group (2013). "Childhood and Adolescent Migraine Prevention (CHAMP) Study: A Double-Blinded, Placebo-Controlled, Comparative Effectiveness Study of Amitriptyline, Topiramate, and Placebo in the Prevention of Childhood and Adolescent Migraine," *Headache*, 53(5): 799-816.
82. McClure LA, **Coffey CS**, and Howard GH (2013). "Monitoring Futility in a Two-by-Two Factorial Design: The SPS3 Experience," *Clinical Trials*, 10(2): 250-256.
81. **Coffey CS**, Levin B, Clark C, Timmerman C, Wittes J, Gilbert P, and Harris S (2012). "Overview, Hurdles, and Future Work in Adaptive Designs: Perspectives from a National Institutes of Health-Funded Workshop," *Clinical Trials*, 9(6): 671-680.
80. McClure LA, Szychowski JM, Benavente O, and **Coffey CS** (2012). "Sample Size Re-Estimation in an Ongoing NIH-Sponsored Clinical Trial: The Secondary Prevention of Small Subcortical Strokes Experience," *Contemporary Clinical Trials*, 33: 1088-1093.
79. Kairalla JA, **Coffey CS**, Thomann MA, and Muller KE (2012). "Adaptive Trial Designs: A Review of Barriers and Opportunities," *Trials*. Aug 23; 13:145.
78. The SPS3 Investigators (2012). "Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke," *New England Journal of Medicine*, 367(9): 817-825. (Writing Group: Benavente OR, Hart RG, McClure LA, Szychowski JM, **Coffey CS**, and Pearce LA). PMID: 22931315
77. Graves JW, White CL, Szychowski JM, Pergola PE, Benavente OR, **Coffey CS**, Hornung LN, and Hart RG for the SPS3 Investigators (2012). "Predictors of Lowering Systolic Blood Pressure to Assigned Targets at Twelve Months in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study," *Journal of Hypertension*, 30: 1233-1240.
76. Clifton GL, **Coffey CS**, Fourwinds S, Zygun D, Valadka A, Smith KR, Frisby ML, Bucholz RD, Wilde EA, Levin HS, and Okonkwo DO (2012). "Early Induction of Hypothermia for Evacuated Hematomas: A Post Hoc Analysis of Two Clinical Trials," *Journal of Neurosurgery*, 117(4): 714-720.
75. The Parkinson's Progression Markers Initiative Investigators (2011). "The Parkinson's Progression Markers Initiative," *Progress in Neurobiology*, 95(4): 629-635.
74. **Coffey CS**, Asselbergs FW, Hebert PR, Hillege HL, Li Q, Moore JH, and van Gilst WH (2011). "The Association of the Metabolic Syndrome with PAI-1 and t-PA Levels," *Cardiology Research and Practice*, Volume 2011, Article ID 541467.
73. Clifton GL, Valadka A, Zygun D, **Coffey CS**, Drever P, Fourwinds S, Janis LS, Wilde E, Taylor P, Harshman K, Conley A, Puccio A, Levin HS, McCauley SR, Bucholz RD, Smith KR, Schmidt JH, Scott JN, Yonas H, and Okonkwo D (2011). "Very Early Hypothermia Induction in Patients with Severe Brain Injury (National Acute Brain Injury Study: Hypothermia II): A Randomized Trial," *Lancet Neurology*, 10(2): 131-139.
72. Benavente OR, White CL, Pearce L, Pergola P, Roldan A, Benavente M, **Coffey C**, McClure LA, Szychowski JM, Conwit R, Heberling PA, Howard G, Bazan C, Vidal-Pergola G, Talbert R, and Hart RG for the SPS3 Investigators (2011). "The Secondary Prevention of Small Subcortical Strokes (SPS3) Study," *International Journal of Stroke*, 6(2): 164-175.
71. Gurka MJ, **Coffey CS**, and Gurka KK (2010). "Internal Pilots for Observational Studies," *Biometrical Journal*, 52(5): 590-603.



70. Bentley JP, Asselbergs FW, **Coffey CS**, Hebert PR, Moore JH, Hillege HL, and van Gilst WH (2010). "Cardiovascular Risk Associated with Interactions among Polymorphisms in Genes from the Renin-Angiotensin, Bradykinin, and Fibrinolytic Systems," *PLoS One*, 5(9): e12757.
69. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, **Coffey CS**, Frost A, Barst RJ, Badesch DB, Elliot G, Liou TG, and McGoon MD (2010). "Predicting Survival in Pulmonary Arterial Hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)," *Circulation*, 122(2): 164-172.
68. Kairalla JA, Muller KE, and **Coffey CS** (2010). "Combining an Internal Pilot with an Interim Analysis for Single Degree of Freedom Tests," *Communications in Statistics – Theory & Methods*, 39(20): 3717-3738.
67. Elkind MSV, Luna JM, **Coffey CS**, McClure LA, Liu KM, Spitalnik S, Paik MC, Roldan A, White C, Hart R, and Benavente O (2010). "The Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) Study: Inflammatory Biomarkers as Risk Predictors after Lacunar Stroke," *International Journal of Stroke*, 5(2): 117-125.
66. Benza RL, **Coffey CS**, Pekarek DM, Barchue JP, Tallaj JA, Passineau MJ, and Grenett HE (2009). "TGF- $\beta$  Polymorphisms and Cardiac Allograft Rejection," *Journal of Heart and Lung Transplantation*, 28(10): 1057-1062.
65. Hines RB, Shanmugam C, Waterbor JW, McGwin G, Funkhouser E, **Coffey CS**, Posey J, and Manne U (2009). "Effect of Comorbidity and Body Mass Index on Colon Cancer Survival of African American and Caucasian Patients," *Cancer*, 115(24): 5798-5806.
64. Hines R, Chatla C, Bumpers H, Waterbor J, McGwin G, Funkhouser E, **Coffey C**, Posey J, and Manne U (2009). "Predictive Capacity of Three Comorbidity Indices in Estimating Mortality Following Surgery for Colon Cancer," *Journal of Clinical Oncology*, 27(26): 4339-4345.
63. Bretz F, Branson M, Burmann CF, Chuang-Stein C, and **Coffey CS**. "Adaptivity in Drug Discovery and Development," *Drug Development Research*, 70: 169-190.
62. Brown DL and **Coffey CS** (2009). "A Shift to Shift Analysis?" *Neurology*, 72(15): 1292-1293.
61. Elobeid M, Padilla M, McVie T, Thomas O, Brock D, Musser B, Lu K, **Coffey C**, Desmond R, St-Onge M, Gadde K, Heymsfield S, and Allison D (2009). "Missing Data in Randomized Clinical Trials for Weight Loss: Scope of the Problem, State of the Field, and Performance of Statistical Methods," *PLoS One*, 4(8): e6624.
60. Yi N, Ding S, Keith SW, **Coffey CS**, and Allison DB (2008). "Bayesian Analysis of the Effect of Intentional Weight Loss on Mortality Rate," *International Journal of Body Composition Research*, 6: 185-192.
59. Kairalla JA, **Coffey CS**, and Muller KE (2008). "GLUMIP 2.0: SAS/IML Software for Planning Internal Pilots," *Journal of Statistical Software*, 28(7): 1-32.
58. Hebert PR, **Coffey CS**, Byrne DW, Scott TA, Fagard RH, Rottman JN, Murray KT, and Oates JA (2008). "Treatment of Elderly Hypertensive Patients with Epithelial Sodium Channel Inhibitors Combined with a Thiazied Diurectic Reduces Coronary Mortality and Sudden Cardiac Death," *Journal of the American Society of Hypertension*, 2: 355-365.
57. Newsome BB, McClellan WM, Allison JJ, Eggers PW, Chen SC, Collins AJ, Kiefe CI, **Coffey CS**, and Warnock DG (2008). "Racial Differences in the Competing Risks of Mortality and End-Stage Renal Disease after Acute Myocardial Infarction," *American Journal of Kidney Diseases*, 52: 251-261.
56. Gadbury GL, Supapakorn T, **Coffey CS**, Keith SW, and Allison DB (2008). "Application of Potential Outcomes to an Intentional Weight Loss Latent Variable Problem," *Statistics and Its Interface*, 1: 87-97.
55. **Coffey CS** and Kairalla JA (2008). "Adaptive Designs: Progress and Challenges," *Drugs in R&D*, 9(4): 229-242.
54. Asselbergs FW, Williams SM, Hebert PR, **Coffey CS**, Hillege HL, Sneider H, Navis G, Vaughan DE, van Gilst WH, and Moore JH (2007). "The Effects of Polymorphisms in Genes from the Renin-Angiotensin, Bradykinin, and Fibrinolytic Systems on Plasma t-PA and PAI-1 Levels Are Dependent on Environmental Context," *Human Genetics*, 122: 275-281.

53. Gurka MJ, **Coffey CS**, and Muller KE (2007). "Internal Pilots for a Class of Linear Mixed Models with Gaussian and Compound Symmetric Data," *Statistics in Medicine*, **26**: 4083-4099.
52. **Coffey CS**, Kairalla JA, and Muller KE (2007). "Practical Methods for Bounding Type I Error Rate with an Internal Pilot Design," *Communications in Statistics – Theory and Methods*, **36**: 2143-2157.
51. Musani SK, Shriner D, Liu N, Feng R, **Coffey CS**, Yi N, Tiwari HK, and Allison DB (2007). "Detection of Gene x Gene Interactions in Genome-Wide Association Studies of Human Population Data," *Human Heredity*, **63**: 67-84.
50. Benza RL, Cavender MA, Barchue JA, Tallaj JA, Bourge RC, Kirklin JK, and **Coffey CS** (2007). "Alterations in the Fibrinolytic Cascade Post Transplant: Evidence of a Bimodal Expression Pattern," *Journal of Heart and Lung Transplantation*, **26**: 494-497.
49. Pergola PE, White CL, Graves JW, **Coffey CS**, Tonarelli SB, Hart RG, and Benavente OR for the SPS3 Investigators (2007). "Reliability and Validity of Blood Pressure Measurement in the Secondary Prevention of Small Sub-cortical Strokes (SPS3) Study," *Blood Pressure Monitoring*, **12**: 1-8.
48. Asselbergs FW, Williams SM, Hebert PR, **Coffey CS**, Hillege HL, Navis G, Vaughan DE, van Gilst WH, and Moore JH (2007). "Epistatic Effects of Polymorphisms in Genes from the Renin-Angiotensin, Bradykinin, and Fibrinolytic Systems on Plasma t-PA and PAI-1 Levels," *Genomics*, **89**: 362-369.
47. Asselbergs FW, Williams SM, Hebert PR, **Coffey CS**, Hillege HL, Navis G, Vaughan DE, van Gilst WH, and Moore JH (2007). "Gender-Specific Correlations of PAI-1 and t-PA Levels with Cardiovascular Disease-Related Traits," *Journal of Thrombosis and Haemostasis*, **5**: 313-320.
46. Howard GH, McClure LA, Krakauer JW, and **Coffey CS** (2007). "Stroke and the Statistics of the Aspirin/Clopidogrel Secondary Prevention Trials," *Current Opinions in Neurology*, **20**: 71-77.
45. Ritchie MD, Motsinger AA, Bush WS, **Coffey CS**, and Moore JH (2007). "Genetic Programming Neural Networks: A Powerful Bioinformatics Tool for Human Genetics," *Applied Soft Computing Journal*, **7**: 471-479.
44. Newsome BB, McClellan WM, **Coffey CS**, Allison JJ, Kiefe CI, and Warnock DG (2006). "Survival Advantage of African American with Kidney Disease after Acute Myocardial Infarction," *Clinical Journal of the American Society of Nephrology*, **1**: 993-1000.
43. Asselbergs FW, Williams SM, Hebert PR, **Coffey CS**, Hillege HL, Navis G, Vaughan DE, van Gilst WH, and Moore JH (2006). "The Gender-Specific Role of Polymorphisms from the Fibrinolytic, Renin-Angiotensin, and Bradykinin Systems in Determining Plasma t-PA and PAI-1 Levels," *Thrombosis and Haemostasis*, **96**: 471-477.
42. Del Brutto OH, Roos KL, **Coffey CS**, and Garcia HH (2006). "Albendazole and Praziquantel Therapy for Neurocysticercosis: A Meta-Analysis of Randomized Trials," *Annals of Internal Medicine*, **145**: 43-51.
41. Qian HZ, Vermund SH, Kaslow RA, **Coffey CS**, Chamot E, Yang Z, Qiao X, Zhang Y, Shi X, Jiang Y, Shao Y, and Wang N (2006). "Coinfection with HIV and Hepatitis C Virus in Former Plasma/Blood Donors: Challenge for Patient Care in Rural China," *AIDS*, **20**: 1429-1435.
40. Benza RL, Rayburn BK, Tallaj JA, **Coffey CS**, Pinderski LJ, Pamoukian SV, and Bourge RC (2006). "Efficacy of Bosentan in a Small Cohort of Adult Patients with Pulmonary Arterial Hypertension Related to Congenital Heart Disease," *Chest*, **129(4)**: 1009-1015.
39. Howard GH, **Coffey CS**, and Cutter GR (2005). "Is Bayesian Analysis Ready for Use in Phase III Randomized Clinical Trials 'Beware the Sound of the Sirens'," *Stroke*, **36**: 1622-1623.
38. Hemminger BM, Molina PL, Egan TM, Detterbeck FC, Muller KE, **Coffey CS**, and Lee JKT. (2005) "Assessment of Realtime 3D Visualization for Cardiothoracic Diagnostic Evaluation and Surgery Planning," *Journal of Digital Imaging*, **18(2)**: 145-153.
37. Alexander D, Jhala N, Chatla C, Funkhouser E, **Coffey CS**, Grizzle WE, and Manne U. (2005) "High Grade Tumor Differentiation is an Indicator of Poor Prognosis in African Americans with Colonic Adenocarcinomas," *Cancer*, **103(10)**: 2163-2170.
36. **Coffey CS**, Gadbury GL, Fontaine KR, Wang C, Weindruch R, and Allison DB. (2005) "The Effects of Intentional Weight Loss as a Latent Variable Problem," *Statistics in Medicine*, **24(6)**: 941-954.

35. **Coffey CS**, Steiner D, Baker BA, and Allison DB. (2004) "A Randomized Double-Blind Placebo Controlled Clinical Trial of a Product Containing Ephedrine, Caffeine, and Other Ingredients from Herbal Sources for Treatment of Overweight and Obesity in the Absence of Lifestyle Treatment," *International Journal of Obesity*, **28(11)**: 1411-1419. PMID: 15356670
34. Ko DT, Hebert PR, **Coffey CS**, Curtis JP, Foody JM, Sedrakyan A, and Krumholz HM. (2004) "Adverse Effects of Beta Blocker Therapy for Heart Failure Patients: A Quantitative Overview of Randomized Trials," *Archives of Internal Medicine*, **164(13)**: 1389-1394.
33. **Coffey CS**, Hebert PR, Ritchie MD, Krumholz HM, Gaziano JM, Ridker PM, Brown NJ, Vaughan DE, and Moore JH. (2004) "An Application of Conditional Logistic Regression and Multifactor Dimensionality Reduction for Detecting Gene-Gene Interactions on Risk of Myocardial Infarction: The Importance of Model Validation," *BMC Bioinformatics*, **5**: 49.
32. Yang D, Howard G, **Coffey CS**, and Roseman J. (2004) "The Confounding of Race and Geography: How Much of the Excess Mortality among African Americans is Explained by Geography," *Neuroepidemiology*, **23**: 118-122.
31. Wang C, Weindruch R, Fernandez JR, **Coffey CS**, Patel P, and Allison DB. (2004) "Caloric Restriction and Body Weight Independently Affect Longevity in Wistar Rats," *International Journal of Obesity*, **28**: 357-362.
30. **Coffey CS**, Hebert PR, Krumholz HM, Morgan TM, Williams SM, and Moore JH. (2004) "Reporting of Model Validation Procedures in Human Studies of Genetic Interactions," *Nutrition*, **20**: 69-73.
29. Neuzil KM, **Coffey CS**, Mitchel EF, and Griffin MR. (2003) "Cardiopulmonary Hospitalizations During Influenza Season in Adults and Adolescents with Advanced HIV Infection," *Journal of Acquired Immune Deficiency Syndromes*, **34**: 304-307.
28. Gadbury GL, **Coffey CS**, and Allison DB. (2003) "Modern Statistical Methods for Handling Missing Repeated Measurements in Obesity Trial Data: Beyond LOCF," *Obesity Reviews*, **4**: 175-184.
27. **Coffey CS** and Muller KE. (2003) "Properties of Internal Pilots with the Univariate Approach to Repeated Measures," *Statistics in Medicine*, **22**: 2469-2485.
26. Morgan TM, **Coffey CS**, and Krumholz HM. (2003) "Overestimation of Gene-Associated Risks Due to Small Sample Size in Cardiovascular Genetic Case-Control Studies," *Clinical Genetics*, **64**: 7-17.
25. Aqel RA, Zoghbi GJ, Baldwin SA, Abo Auda WS, Calhoun DA, **Coffey CS**, Perry GJ, and Iskandrian AE. (2003) "Prevalence of Renal Artery Stenosis in High-Risk Veterans Referred to Cardiac Catheterization," *Journal of Hypertension*, **21**: 1157-1162.
24. Ellis SE, **Coffey CS**, Mitchel EF, Dittus RS, and Griffin MR. (2003) "Influenza and Respiratory Syncytial Virus-Associated Morbidity and Mortality in the Nursing Home Population," *Journal of the American Geriatrics Society*, **51(6)**: 761-767.
23. Goldstein DR, **Coffey CS**, Benza RL, Nanda NC, and Bourge RC. (2003) "Relative Perioperative Bradycardia Does Not Lead to Adverse Outcomes After Cardiac Transplantation," *American Journal of Transplantation*, **3(4)**: 484-491.
22. Grossklaus DJ, Smith JA, Shappell SB, **Coffey CS**, Chang SS, and Cookson MS. (2002) "The Free/Total Prostate-Specific Antigen Ratio (% fPSA) is the Best Predictor of Tumor Involvement in the Radical Prostatectomy Specimen Among Men with Elevated PSA," *Urologic Oncology*, **7(5)**: 195-198.
21. Jack GS, Cookson MS, **Coffey CS**, Vader V, Roberts RL, Chang SS, Smith JA Jr, and Shappell SB. (2002) "Pathological Parameters of Radical Prostatectomy for Clinical Stages T1c versus T2 Prostate Adenocarcinoma: Decreased Pathological Stage and Increased Detection of Transition Zone Tumors," *Journal of Urology*, **168(2)**: 519-524.
20. Ko DT, Hebert PR, **Coffey CS**, Sedrakyan A, Curtis JP, and Krumholz HM. (2002) "Beta Blocker Therapy and Symptoms of Depression, Fatigue, and Sexual Dysfunction," *Journal of the American Medical Association*, **288(3)**: 351-357.
19. Perz JF, Craig AS, **Coffey CS**, Jorgensen DM, Mitchel E, Hall S, Schaffner W, and Griffin MR. (2002) "Reduction of Antibiotic Use Among Children After a Community-Wide Campaign," *Journal of the American Medical Association*, **287(23)**: 3103-3109.

18. Dutta SC, Chang SC, **Coffey CS**, Smith JA Jr, Jack G, and Cookson MS. (2002) "Health Related Quality of Life Assessment after Radical Cystectomy: Comparison of Ileal Conduit with Continent Orthotopic Neobladder," *Journal of Urology*, **168(1)**: 164-167.
17. Griffin MR, **Coffey CS**, Neuzil KM, Mitchel EF, Wright PF, and Edwards KM. (2002) "Winter Viruses: Influenza and Respiratory Syncytial Virus-Related Morbidity in Chronic Lung Disease," *Archives of Internal Medicine*, **162(11)**: 1229-1236.
16. Allison DB and **Coffey CS**. (2002) "Two-Stage Testing in Microarray Analysis: What is Gained?" *Journal of Gerontology: Biological Sciences*, **57**: B189-B192.
15. Grossklaus DJ, **Coffey CS**, Shappell SB, Jack GS, Chang SS, and Cookson MS. (2002) "Percent of Cancer in the Biopsy Set Correlates with Pathologic Findings after Prostatectomy," *Journal of Urology*, **167(5)**, 2032-2036.
14. Grossklaus DJ, **Coffey CS**, Shappell SB, Jack GS, and Cookson MS. (2001) "Prediction of Tumor Volume and Pathologic Stage in Radical Prostatectomy Specimens is not Enhanced by Increasing the Number of Prostate Needle Biopsy Cores," *BJU International*, **88**, 722-726.
13. Hemminger BM, Zong S, Muller KE, **Coffey CS**, DeLuca MC, Johnston RE, and Pisano ED. (2001) "Improving the Detection of Simulated Masses in Mammograms Through Two Different Image Processing Techniques," *Academic Radiology*, **8**, 845-855.
12. Shappell SB, Manning S, Boeglin WE, Guan YF, Roberts RL, Davis L, Olson SJ, Jack GS, **Coffey CS**, Wheeler TM, Breyer MD, and Brash AR. (2001) "Alterations in Lipoxygenase and Cyclooxygenase-2 Catalytic Activity and mRNA Expression in Prostate Carcinoma," *Neoplasia*, **3**, 287-303.
11. Dutta SC, Smith JA, Shappell SB, **Coffey CS**, Chang SS, and Cookson MS. (2001) "Clinical Understaging of High Risk Nonmuscle Invasive Urothelial Carcinoma Treated with Radical Cystectomy," *Journal of Urology*, **166**, 490-493.
10. **Coffey CS** and Muller KE. (2001) "Controlling Test Size While Gaining the Benefits on an Internal Pilot Design," *Biometrics*, **57**, 625-631.
9. Cardin S, Jackson PA, Edgerton DS, Neal DW, **Coffey CS**, and Cherrington AD. (2001) "Effect of Vagal Cooling on the Counterregulatory Response to Hypoglycemia Induced by a Low Dose of Insulin in the Conscious Dog," *Diabetes*, **50**, 558-564.
8. Jackson PA, Cardin S, **Coffey CS**, Neal DW, Allen EJ, Penaloza AR, Snead WL, and Cherrington AD (2000). "Effect of Hepatic Denervation on the Counterregulatory Response to Insulin-Induced Hypoglycemia in the Dog," *American Journal of Physiology – Endocrinology and Metabolism*, **279**, E1249-E1257.
7. **Coffey CS** and Muller KE. (2000) "Some Distributions and Their Implications for an Internal Pilot Study with a Univariate Linear Model," *Communications in Statistics-Theory and Methods*, **29(12)**, 2677-2691.
6. Jack GS, Brash AR, Olson SJ, Manning S, **Coffey CS**, Smith J, and Shappell SB. (2000). "Reduced 15-lipoxygenase-2 Immunostaining in Prostate Adenocarcinoma: Correlation with Grade and Expression in High Grade Prostatic Intraepithelial Neoplasia," *Human Pathology*, **31(9)**, 1146-1154.
5. **Coffey CS** and Muller KE. (2000) "Properties of Doubly-Truncated Gamma Variables," *Communications in Statistics-Theory and Methods*, **29(4)**, 851-857.
4. Hemminger BM, Dillon A, Johnston RE, Muller KE, Pisano E, Deluca M, and **Coffey C** (1999). "Effect of Display Luminance on the Feature Detection Rates of Masses in Mammograms," *Medical Physics*, **26(11)**, 2266-2272.
3. **Coffey CS** and Muller KE. (1999) "Exact Test Size and Power of a Gaussian Error Linear Model for an Internal Pilot Study," *Statistics in Medicine*, **18**, 1199-1214.
2. Bullitt E, Liu A, Aylward S, **Coffey C**, Stone J, Mukherji SK, Muller K, and Pizer SM. (1999) "Registration of 3D Cerebral Vessels with 2D Digital Angiograms: Clinical Evaluation," *Academic Radiology*, **6**, 539-546.
1. Boxwala AA, Chaney EL, Fritsch DS, Raghavan S, **Coffey CS**, Major SA, and Muller KE. (1999) "Comparison of Computer Workstation with Light Box for Detecting Setup Errors from Portal Images," *International Journal of Radiation Oncology, Biology, Physics*, **44**, 711-716.

## INVITED BOOK CHAPTERS

2. **Coffey CS**. "Adaptive Design across Stages of Development." *Clinical Trials in Neurology*. Eds: Ravina B, Cummings MP, McDermott MP, and Poole M. Cambridge University Press, 2012, 91-100.
1. **Coffey CS** and Cofield SS. "Parametric Linear Models." *DNA Microarrays and Related Genomic Techniques: Design, Analysis, and Interpretation of Experiments*. Eds: Allison DB, Page GP, Beasley TM, and Edwards JW. Boca Raton: Chapman & Hall/CRC, 2005, 223-243.

## OTHER PUBLICATIONS

7. Hoffman EP on behalf of **Workshop Participants** and the TREAT-NMD Alliance (2017). "Facilitating Orphan Drug Development: Proceedings of the TREAT-NMD International Conference, December 2015, Washington, DC, USA," *Neuromuscular Disorders*, 27(7): 693-701.
6. **Coffey CS** (2010). "Power Analysis," In *Encyclopedia of Research Design*, NJ Salkind (ed.), Publisher: Sage, Thousand Oaks, CA.
5. Kairalla JA, **Coffey CS**, and Muller KE (2010). "Achieving the Benefits of Both an Internal Pilot and Interim Analysis in Small Samples," *2010 Proceedings of the Joint Statistical Meetings*, ENAR Section, 5239-5252.
4. Ritchie MD, **Coffey CS**, and Moore JH. (2005) "Genetic Programming Neural Networks as a Bioinformatics Tool for Human Genetics," *Lecture Notes in Computer Science: Genetic and Evolutionary Computation – GECCO 2004 Conference Proceedings*, **3102**: 438-448.
3. **Coffey CS** and Muller KE. (2003) "Practical Methods for Bounding Test Size with an Internal Pilot Design," *2003 Proceedings of the Joint Statistical Meetings*, Biopharmaceutical Section [CD-ROM].
2. **Coffey CS** and Muller KE. (2001) "GLUMIP 1.0: Free SAS IML Software for Internal Pilots," *2001 Proceedings of the Joint Statistical Meetings*, Biometrics Section [CD-ROM].
1. Bullitt E, Aylward S, Liu A, Stone J, Mukherji S, **Coffey C**, Gerig G, and Pizer SM. (1999) "3D Graph Description of the Intracerebral Vasculature from Segmented MRA and Tests of Accuracy by Comparison with X-Ray Angiograms," *Lecture Notes in Computer Science*, **1613**, 308-321.

## INVITED PRESENTATIONS

75. *Statistical Design Considerations*  
**January 2024**: BIG10 Neurosurgery Consortium Meeting (Los Angeles, CA)
74. *Achieving the Promise of Innovative Clinical Designs in an Academic Setting*  
**October 2022**: Icahn School of Medicine at Mt. Sinai (Virtual)  
**June 2020**: University of Alabama at Birmingham (Birmingham, AL – Virtual Due to COVID-19)  
**January 2019**: Duke University (Durham, NC)  
**August 2018**: University of Minnesota (Minneapolis, MN)
73. *Study Design & Statistical Issues*  
**October 2022**: Planning for Prevention of Parkinson's: A Trial Design Forum (Boston, MA)
72. *Trial Design & Statistics*  
**September 2022**: International Linked Clinical Trials (iLCT) Meeting (Grand Rapids, MI)
71. *Running Up That Hill: Navigating the Upside Down World of Coordinating Clinical Trials*  
**August 2022**: University of Iowa College of Public Health Spotlight Series (Iowa City, IA)
70. *Clinical Trials Regulatory Overview*  
**July 2022**: Keynote Address, 2022 Clinical Trials Methodology Course (Iowa City, IA)
69. *We Built This Network: How NeuroNEXT Increases Innovative Design in Neurology*  
**April 2022**: University of Rochester Michael P. McDermott Endowed Lectureship in Experimental Therapeutics (Virtual Due to COVID-19)
68. *Planning for Success: Clinical Trial Design*  
**November 2021**: Panelist, Alpha Synuclein Summit: Clinical Development of Alpha-Synuclein Therapeutics (Virtual Due to COVID-19)
67. *Data Coordinating Centers: Telling the Story of Research*  
**August 2021**: Panelist, Joint Statistical Meetings (Virtual Due to COVID-19)

66. *Is Sample Size Re-Estimation Controversial? – Well, Yes & No*  
**May 2021:** Society for Clinical Trials Annual Meeting (Virtual Due to COVID-19)
65. *Designing Meaningful Early Phase Clinical Trials*  
**April 2021:** American Academy of Neurology Annual Meeting (Virtual Due to COVID-19)
64. *How to Measure Prevention? Selecting an Intervention – Study Design/Statistical Foundation*  
**April 2021:** Planning for Prevention of Parkinson's: A Trial Design Symposium and Workshop (Virtual Due to COVID-19)
63. *An Overview of Adaptive Designs*  
**February 2020:** University of Iowa Institutional Review Board (Iowa City, IA)
62. *Increasing the Chances of Finding Effective Treatments*  
**November 2019:** NIH Workshop – Improving the Identification of Disease Modification PD Targets and Their Testing in Early Phase Clinical Trials (Bethesda, MD)
61. *The Clinical Trials Statistical & Data Management Center (CTSDMC) – History & Current Neurological Activities*  
**July 2019:** University of Iowa Department of Neurology Grant Rounds (Iowa City, IA)
60. *An Overview of Data Sharing*  
**May 2019:** Society for Clinical Trials Annual Meeting (New Orleans, LA); Part of an Invited Session on “Preparing and Submitting Data to Open and Limited-Access Repositories” (Organizer: Janel Fedler, University of Iowa)
59. *An Overview of NeuroNEXT*  
**May 2019:** Society for Clinical Trials Annual Meeting (New Orleans, LA); Part of an Invited Session on “Switching Boats Mid-Stream: Maintaining Continuity in a Large Clinical Trials Network in the Face of Change” (Organizer: Julie Qidwai, University of Iowa)
58. *Novel Trial Designs of ‘Disease Modifying Therapy’ in Oncology (e.g., I-SPY2) and Other Diseases*  
**April 2019:** The Krembil Knowledge Gaps in Parkinson's Disease Symposium (Toronto, Canada)
57. *Innovative Statistical Design and Analysis in ALS*  
**November 2018:** Massachusetts ALS Partnership Symposium (Boston, MA)  
**October 2018:** 17<sup>th</sup> Annual Northeast ALS Consortium Annual Meeting (Clearwater, FL)
56. *Design Considerations When Planning Clinical Trials*  
**September 2018:** “Enhancing Natural Products Clinical Trials” Workshop (Bethesda, MD)
55. *We Built This Network: How NeuroNEXT Increases Innovative Design in Academic Trials*  
**August 2018:** University of Iowa College of Public Health Distinguished Faculty Lecture (Iowa City, IA)
54. *What We Measure and How: Outcomes Panel*  
**July 2018:** ALS Community Workshop – Therapy Development & Regulatory Discussion; Panel Discussion w/ Drs. Jeremy Shefner (Barrow Neurological Institute), Steve Hersch (Voyager Therapeutics), and Madeline Kennedy (Person w/ ALS; Washington, DC)
53. *Adaptive Timing of Interim Analysis: DSMB Perspective*  
**May 2018:** Society for Clinical Trials Annual Meeting (Portland, OR)
52. *University of Iowa Clinical Trials Statistical & Data Management Center – Overview of Ongoing Parkinson's Disease Research Efforts*  
**April 2018:** University of Iowa, Parkinson's Foundation Center of Excellence Evaluation Site Visit (Iowa City, IA)
51. *University of Iowa Clinical Trials Statistical & Data Management Center – Overview of Ongoing Collaborations with the Michael J. Fox Foundation*  
**April 2018:** Eastern Iowa Parkinson's Symposium (Cedar Rapids, IA)
50. *Innovative Statistical Design and Analysis in PD*  
**February 2018:** The International Society for CNS Clinical Trials & Methodology Annual Meeting (Washington, DC)
49. *Utilizing NIH Networks for Clinical Trials: Lessons from the Trenches*  
**July 2017:** Cleveland Clinic (Cleveland, OH – Co-Presenter w/ Merit Cudkowicz, MGH; Robin Conwit, NINDS; Codrin Lungu, NINDS)

48. *Implementing Adaptive Designs: Balancing the Practical with the Statistical*  
**May 2017:** Discussant, Society for Clinical Trials Annual Meeting (Liverpool, UK)
47. *Statistical Aspects of the Childhood & Adolescent Migraine Prevention (CHAMP) Study*  
**April 2017:** UAB Department of Biostatistics (Birmingham, AL)
46. *Increasing the Practicality of Innovative Trial Designs*  
**April 2017:** DIA Adaptive Design Scientific Working Group Key Opinion Leaders Webinar Series  
**March 2017:** The Society for Clinical Trials Webinar Series  
**March 2017:** Iowa Department of Biostatistics Seminar Series (Iowa City, IA)  
**December 2016:** National Institute of Neurological Disorders & Stroke (Bethesda, MD)  
**April 2016:** University of Florida Department of Biostatistics (Gainesville, FL)  
**October 2015:** UAB Department of Biostatistics (Birmingham, AL)  
**April 2015:** Keynote Address at 8<sup>th</sup> Annual ADVAMed & American Statistical Association Statistics Workshop (Washington, DC)
45. *Challenges and Experience in Designing Small Clinical Trials*  
**August 2016:** Invited Session at Joint Statistical Meetings (Chicago, IL)
45. *NeuroNEXT Overview & Accomplishments*  
**July 2016:** The Ohio State University School of Medicine (Columbus, OH)
44. *Adaptive & Bayesian Trial Design*  
**February 2016:** ICTS Sponsored Workshop on Patient-Centered Outcomes and Comparative Effectiveness Research (Cincinnati, OH)
43. *The State of the Clinical Trials Statistical and Data Management Center*  
**February 2016:** Iowa Department of Biostatistics Seminar Series (Iowa City, IA)
42. *Innovative Trial Designs for Rare Disease*  
**December 2015:** TREAT-NMD International Conference (Washington, DC)
41. *Common Data Elements: The User's Perspective*  
**May 2015:** Invited Session at Annual Society for Clinical Trials Meeting (Washington, DC)
40. *Overview of the Clinical Trials Statistical and Data Management Center & NeuroNEXT*  
**April 2015:** Iowa Department of Epidemiology Seminar Series (Iowa City, IA)
39. *Re-Estimating Sample Size Midtrial: The SPS3 Experience*  
**April 2015:** 8<sup>th</sup> Annual ADVAMed & American Statistical Association Workshop (Washington, DC)
38. *Small Phase II Trials*  
**March 2015:** ALS Association Patient Webinar Series
37. *Overview, Hurdles, and Future Work in Adaptive Designs*  
**August 2014:** American Statistical Association Webinar Series
36. *Adaptive Trial Designs*  
**February 2014:** Alpha-One Foundation Sponsored Workshop on 'Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases' (Bethesda, MD)
35. *Challenges in Designing Clinical Trials for Rare Diseases*  
**September 2013:** FDA/Industry Workshop (Washington, DC)
34. *Overview of Adaptive Designs, and Extensions beyond Clinical Trials*  
**July 2013:** East Tennessee State University College of Public Health (Johnson City, TN)
33. *Revolutionizing Clinical Trials by Creating Infrastructure for Phase 2 Trials in Neurological Disorders*  
**May 2013:** Invited Session at Annual Society for Clinical Trials Meeting (Panel with Cudkowicz M, Kearney M, Ecklund D, McNeil E; Boston, MA)
32. *An Overview of Adaptive Designs*  
**March 2013:** College of Nursing Seminar Series, University of Iowa (Iowa City, IA)
31. *Overview, Hurdles, and Future Work in Adaptive Designs*  
**February 2013:** Department of Statistics, University of Iowa (Iowa City, IA)  
**May 2011:** Mackey Cancer Center, University of Kentucky (Lexington, KY)
30. *Overview of Randomized Clinical Trials*  
**September 2012:** Department of Obstetrics/Gynecology Seminar, University of Iowa (Iowa City, IA)

29. *Quantitative Pitfalls in Comparative Effectiveness Research and How to Avoid Them*  
**February 2012:** Department of Internal Medicine Grand Rounds, University of Florida  
 (with KE Muller & RI Shorr; Gainesville, FL)
28. *Building a Clinical Studies Database*  
**December 2011:** NINDS Sponsored Parkinson's Disease Biomarkers Resource Data Management  
 Workshop (Bethesda, MD)
27. *Use of Adaptive Designs in Clinical Effectiveness Trials*  
**November 2011:** University of Iowa CTSA Lecture Series (Iowa City, IA)
26. *Adaptive Designs and Small Clinical Trials*  
**October 2011:** FDA/Industry Workshop (Washington, DC)  
**October 2011:** US Conference on Rare Diseases and Orphan Products (Washington, DC)  
**March 2011:** US FDA Center for Biologics Evaluation and Research (Rockville, MD)  
**March 2011:** US FDA Center for Drug Evaluation and Research Office of Biostatistics (Silver Spring,  
 MD)
25. *Adaptive Design for Clinical Trials: Perspectives from an NIH-Funded Workshop*  
**May 2011:** Drug Information Association (DIA) Adaptive Design Working Group KOL Lecture Series  
 (webinar)
24. *Hurdles and Future Work in Adaptive Designs*  
**April 2011:** University of Pennsylvania Clinical Trials Symposium (Philadelphia, PA)
23. *Biostatistics*  
**October 2010:** Fourth Annual Iowa Mathematical Field of Dreams Conference (Iowa City, IA)
22. *Adaptive Designs*  
**November 2009:** Huntington Disease Study Group (Baltimore, MD)
21. *The Emerging Role of the Data and Safety Monitoring Board: Implications of Adaptive Clinical Trial  
 Designs*  
**Oct 2009:** University of Rochester (Rochester, NY)  
**June 2009:** Annual Meeting of the Southern Research Council on Statistics (Jekyll Island, GA)
20. *Avoiding the Pitfalls of a Meta-Analysis*  
**April 2009:** Third Annual Methods in Epidemiology and Outcomes Research Symposia, University of  
 Alabama at Birmingham (Birmingham, AL)
19. *Internal Pilot Designs: They're Not Just for Clinical Trials Anymore*  
**December 2008:** Department of Biostatistics, The University of Iowa (Iowa City, IA)
18. *Internal Pilot Designs: An Overview and Recent Extensions*  
**November 2008:** Department of Public Health Sciences, University of Virginia (Charlottesville, VA)  
**October 2008:** College of Public Health, The Ohio State University (Columbus, OH)
17. *Internal Pilot Designs for Cluster Samples*  
**August 2008:** Joint Statistical Meetings (Denver, CO)
16. *Advantages and Disadvantages When Implementing an Adaptive Design in an NIH-Funded Study*  
**August 2007:** Joint Statistical Meetings (Salt Lake City, UT)
15. *Treatment Effect in Sample Size Determination: Clinical vs. Statistical Significance*  
**May 2007:** Annual Meeting of the Society for Clinical Trials (Montreal, Quebec, Canada)
14. *Activities of the Statistical Center for the Secondary Prevention of Small Subcortical Strokes (SPS3)  
 Trial*  
**May 2007:** Clinical Trials and Data Management Center, Department of Biostatistics, University of Iowa  
 (Iowa City, IA)
13. *Clarifying the Controversy Surrounding Adaptive Designs for Sample Size Re-Estimation*  
**May 2007:** Department of Biostatistics, University of Iowa (Iowa City, IA)  
**March 2007:** Department of Epidemiology and Health Policy Research, University of Florida  
 (Gainesville, FL)
12. *An Introductory Overview Lecture on Adaptive Designs/Internal Pilots*  
**August 2006:** Annual Joint Statistical Meetings (Seattle, WA)



11. *Adaptive and Internal Pilot Designs*  
**December 2006:** Department of Neurology, Columbia University Medical Center (New York, NY)  
**June 2006:** Department of Epidemiology and Health Policy Research, University of Florida (Gainesville, FL)  
**April 2006:** Department of Public Health, East Tennessee State University (Johnson City, TN)
10. *Internal Pilot Designs for Medical Imaging Studies*  
**March 2006:** Department of Biostatistics, University of North Carolina at Chapel Hill (Chapel Hill, NC)
9. *An Overview of Adaptive Designs with Emphasis on Internal Pilots*  
**March 2006:** Health Services Administration Doctoral Seminar, University of Alabama at Birmingham (Birmingham, AL)  
**November 2005:** Medical Statistics Section Seminar, University of Alabama at Birmingham Comprehensive Cancer Center (Birmingham, AL)  
**October 2005:** Center for Nursing Research Seminar, University of Alabama at Birmingham (Birmingham, AL)  
**June 2004:** National Institute of Neurological Disorders and Stroke, Clinical Trials Program (Bethesda, MD)
8. *Using Internal Pilot Designs with Repeated Measures*  
**August 2005:** Annual Joint Statistical Meetings (Minneapolis, MN)
7. *Sample Size Adjustments Using Internal Pilot Designs for Repeated Measures ANOVA*  
**April 2005:** Department of Biostatistics, University of North Carolina at Chapel Hill (Chapel Hill, NC)
6. *Internal Pilots and Power Adjustments for Controlled Clinical Trials*  
**January 2005:** Center for Aging/VA GRECC, University of Alabama at Birmingham (Birmingham, AL)
5. *Promises and Pitfalls of Modifying the Sample Size during a Study: Adaptive and Internal Pilot Designs*  
**November 2004:** Department of Biostatistics, University of North Carolina at Chapel Hill (Chapel Hill, NC)
4. *Exact and Approximate Methods for Internal Pilots: Beyond Two Group Comparisons*  
**April 2003:** Annual Meeting of the Eastern North American Region (ENAR) of the Biometrics Society (Tampa, FL)
3. *GLUMIP 1.0: Free SAS IML Software for Planning Internal Pilots.*  
**August 2001:** Annual Joint Statistical Meetings (Atlanta, GA)
2. *Is There an Interaction between the ACE I/D and PAI-1 4G/5G Gene Polymorphisms on Risk of Myocardial Infarction?*  
(Joint presentation with Patricia Hebert, Yale, and Jason Moore, Vanderbilt)  
**August 2001:** Joint with P Hebert (Yale) and J Moore (Vanderbilt), Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine (New Haven, CT)
1. *Internal Pilot Study Design and Analysis for Gaussian Error Linear Models with Fixed Predictors.*  
**April 2000:** Department of Biostatistics, University of Alabama at Birmingham (Birmingham, AL)  
**October 1999:** Middle Tennessee Chapter, American Statistical Association, (Nashville, TN)  
**September 1999:** Gertrude M. Cox Building Dedication and Statistical Symposium, Research Triangle Institute (Research Triangle Park, NC)  
**August 1999:** Annual Meeting of General Clinical Research Center Statisticians (Baltimore, MD)

#### CONTRIBUTED PRESENTATIONS

13. *Adaptive Design for Clinical Trials: Perspectives from an NIH-Sponsored Workshop*  
**May 2011:** Annual Meeting of the Society for Clinical Trials (Vancouver, BC)
12. *Power in Time to Event Trials: Bigger Isn't Always Better*  
**September 2006:** 4<sup>th</sup> Annual SPS3 Investigator's Meeting (San Antonio, TX)
11. *Premature Termination of Clinical Trials*  
**September 2005:** 3<sup>rd</sup> Annual SPS3 Investigator's Meeting (Scottsdale, AZ)
10. *Internal Pilot Designs with Compound Symmetric and Gaussian Repeated Measures*  
**August 2004:** Annual Joint Statistical Meeting (Toronto, Ontario)

9. *Controlling Bias in Internal Pilots with the Univariate Approach to Repeated Measures*  
**March 2004:** Annual Meeting of the Eastern North American Region (ENAR) of the Biometrics Society (Pittsburgh, PA)
8. *Practical Methods for Bounding Test Size with an Internal Pilot Design*  
**August 2003:** Annual Joint Statistical Meeting (San Francisco, CA)
7. *Reporting of Internal Prediction Errors in Case-Control Studies of Genetic Interactions* (Joint presentation with Patricia Hebert, Yale)  
**May 2003:** Annual Meeting of the Society for Clinical Epidemiology and Health Care Research (Vancouver, BC)  
 Abstract Published: *Journal of Clinical Epidemiology*, **56(9)**:922-3.
6. *A Comparison of Two Methods for Detecting Interactions among Genetic Polymorphisms in Matched Case-Control Studies*  
**March 2002:** Annual Meeting of the Eastern North American Region (ENAR) of the Biometrics Society (Crystal City, VA)
5. *Internal Pilot for the Univariate Approach to Repeated Measures*  
**March 2001:** Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society (Charlotte, NC)
4. *Controlling Test Size While Gaining the Benefits of an Internal Pilot Design.*  
**March 2000:** Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society (Chicago, IL)
3. *The Impact on Power of Controlling Test Size for an Internal Pilot Study.*  
**August 1999:** Annual Joint Statistical Meeting (Baltimore, MD)
2. *Approximations and Bounds on Test Size for an Internal Pilot Study.*  
**March 1999:** Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society (Atlanta, GA)
1. *Exact Test Size and Power of a Gaussian Error Linear Model for an Internal Pilot Study.*  
**March 1997:** Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society (Memphis, TN)

#### CONTRIBUTED POSTER PRESENTATIONS

7. *The Parkinson's Progression Markers Initiative: A Prospective Biomarkers Study.*  
**May 2011:** Annual Meeting of the Society for Clinical Trials (Vancouver, BC)
6. *Development of an Advanced Clinical Trials Course in a Biostatistics Doctoral Program.*  
**May 2009:** Annual Meeting of the Society for Clinical Trials (Atlanta, GA)
5. *The Metabolic Syndrome and its Association with PAI-1 and t-PA Antigen Levels in a Population-Based Study.*  
**April 2005:** Annual Conference on Cardiovascular Disease Epidemiology and Prevention (Washington DC)
4. *The Effects of Intentional Weight Loss as a Latent Variable Problem.* **November 2003:** North American Association for the Study of Obesity Annual Scientific Meeting (Ft. Lauderdale, FL)
3. *The Importance of Model Validation in Determining the Clinical Utility of Genetic Interactions on Disease Risk.* **October 2002:** Annual Meeting of the American Society for Human Genetics (Baltimore, MD)
2. *Safety of an Herbal Formulation Including Ephedra Alkaloids Dosed Intermittently or Continuously for Weight Control.* **April 2002:** Annual Meeting of the Federation of American Societies for Experimental Biology (New Orleans, LA)
1. *A Comparison of Two Methods for Detecting Interactions among Genetic Polymorphisms in Matched Case-Control Studies.* **October 2001:** Annual Meeting of the American Society for Human Genetics (San Diego, CA)

## ABSTRACTS (CO-AUTHORED PRESENTATIONS/POSTERS)

191. *Path to Prevention (P2P) Therapeutics Platform Trial in Stage 2B Neuronal Alpha-Synuclein Disease: Study and Timeline*  
Simuni T, **Coffey C**, Siderowf A, Tanner C, Chowdhury S, Kopil C, Sherer T, Brumm M, Kiebertz K, Fabrizio K, Saville B, Allen-Savietta C, Wendelberger B, Crawford A, and Marek K on behalf of the PPMI Investigators  
**March 2024:** Poster Presentation, To be presented at International Conference on Alzheimer's and Parkinson's Diseases & Related Disorders (AD/PD: Lisbon, Portugal)
190. *Path to Prevention (P2P) Therapeutics Platform Trial in Biomarker Defined Prodromal Parkinson's Disease: Study Design*  
Simuni T, **Coffey C**, Siderowf A, Tanner C, Chowdhury S, Kopil C, Sherer T, Brumm M, Kiebertz K, Fabrizio K, Saville B, Allen-Savietta C, Wendelberger B, Crawford A, and Marek K on behalf of the PPMI Investigators  
**October 2023:** Poster Presentation, Michael J. Fox Foundation Therapeutics Conference (New York, NY)
189. *Estimating Power Under Differences in Placebo Response in a Platform Trial*  
McCabe ME, **Coffey CS**, and Bayman EO  
**October 2023:** Poster Presentation, College of Public Health Research Day (Iowa City, IA)
188. *The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis*  
Wong KH, Day GS, Torner J, Cudkowicz M, **Coffey C**, Cho S, Ohayon J, Klawiter E, Singleton JR, Mitchell D, Cahalan S, Fedler J, Ecklund DJ, Klements D, Costigan M, Pearson B, Steinhart E, Desir C, Titulaer MJ, and Clardy SL  
**October 2023:** Poster Presentation, World Congress of Neurology (Montreal, Canada)  
**October 2023:** Poster Presentation, European Committee for Treatment & Research in Multiple Sclerosis (ECTRIMS) Meeting (Milan, Italy)
187. *ATN<sub>PD</sub> Framework Using Biofluid Markers Predicts Cognitive Decline in Early Parkinson's Disease*  
Cousins KAQ, Irwin DJ, Tropea TF, Rhodes E, Phillips JS, Chen-Plotkin AS, Brumm MC, **Coffey CS**, Kang JH, Simuni T, Foroud T, Toga AW, Tanner CM, Kiebertz K, Mollenhauer B, Galasko DR, Hutten S, Weintraub D, Siderowf A, Marek K, Poston KL, and Shaw LM on behalf of the Parkinson's Progression Marker Initiative  
**September 2023:** Poster Presentation, American Neurological Association Annual Meeting (Philadelphia, PA)
186. *Widespread Synuclein Pathology in Hyposmics Precedes Dopamine Transporter Deficit in PARS*  
Marek K, Russell D, Concha L, Choi C, Jennings D, Brumm M, **Coffey C**, Brown E, Stern M, Seibyl J, Soto C, and Siderowf A for the PARS Investigators  
**August 2023:** Virtual Poster Presentation, International Congress of Parkinson's Disease & Movement Disorders (Copenhagen, Denmark)
185. *Digital Mobility Sub-Study in the Parkinson's Progression Marker Initiative (PPMI) Study*  
Mirelman A, Simuni T, Tanner C, Flagg E, Lorenzo A, Dimos J, **Coffey C**, Siderowf A, Marek K, and The Parkinson's Progression Markers Initiative  
**August 2023:** Poster Presentation, International Congress of Parkinson's Disease & Movement Disorders (Copenhagen, Denmark)
184. *Comparison of Original and Revised Versions of the University of Pennsylvania Smell Identification Test*  
Brumm MC, Pierz K, Aamodt W, Gochanour C, Kurth R, **Coffey CS**, Foroud T, Brown E, Doty R, Simuni T, Tanner CM, Marek K, Siderowf A  
**August 2023:** Virtual Poster Presentation, International Congress of Parkinson's Disease & Movement Disorders (Copenhagen, Denmark)

183. *Parkinson's Progression Markers Initiative (PPMI): Defining PD Biology to Accelerate PD Therapeutics*  
 McMahon B, Siderowf A, Simuni T, Tanner C, Mollenhauer B, **Coffey C**, Galasko D, Poston K, Chahine L, Dobkin R, Foroud T, Kiebertz K, Weintraub D, Merchant K, Frasier M, Sherer T, Chowdhury S, Brown E, Alcalay R, Videnovic A, Fabrizio K, Flagg E, & Marek K  
**August 2023:** Poster Presentation, International Congress of Parkinson's Disease & Movement Disorders (Copenhagen, Denmark)
182. *Path to Prevention (P2P) Therapeutics Platform Trial in Biomarker Defined Prodromal Parkinson's Disease: Study Design*  
 Simuni T, **Coffey C**, Siderowf A, Tanner C, Chowdhury S, Kopil C, Sherer T, Brumm M, Kiebertz K, Fabrizio K, Saville B, Allen-Savietta C, Wendelberger B, Crawford A, and Marek K on behalf of the PPMI Investigators  
**August 2023:** Poster Presentation, International Congress of Parkinson's Disease & Movement Disorders (Copenhagen, Denmark)
181. *10 Year Longitudinal Change in Clinical and Biological Characteristics of Sporadic Parkinson Disease PPMI Cohort*  
 Gonzalez-Latapi P, Simuni T, Siderowf A, Fedler J, Brumm M, Gochanour C, **Coffey C**, and Marek K on behalf of the PPMI Investigators  
**August 2023:** Poster Presentation, International Congress of Parkinson's Disease & Movement Disorders (Copenhagen, Denmark)
180. *Longitudinal Clinical and Biomarker Characteristics of Non-Manifest GBA1 N40S Carriers: The PPMI Cohort*  
 Gonzalez-Latapi P, Harvell D, Simuni T, Merchant K, Brumm MC, Alcalay RN, Cho H, Caspell-Garcia C, Gochanour C, **Coffey C**, and Marek K on behalf of the PPMI Investigators  
**August 2023:** Poster Presentation, International Congress of Parkinson's Disease & Movement Disorders (Copenhagen, Denmark)
179. *Long-Term Dementia Prevalence in Parkinson Disease: Glass Half-Full?*  
 Gallagher J, Gochanour C, Caspell-Garcia C, Dobkkin R, Aarsland D, Alcalay R, Barrett M, Chahine LM, Chen-Plotkin A, **Coffey C**, Dahodwala N, Eberling J, Espay A, Leverenz JB, Litvan I, Mamikonyan E, Morley JF, Richard I, Rosenthal L, Siderowf A, Simuni T, York M, Willis A, Xie SX, & Weintraub D  
**July 2023:** Poster Presentation, World Parkinson's Congress (Barcelona, Spain)
178. *Evaluation of Current Practices in the Reporting of Results from Platform Trials*  
 McCabe ME, **Coffey CS**, and Bayman EO  
**May 2023:** Poster Presentation, Society for Clinical Trials Annual Meeting (Baltimore, MD)
177. *Acute to Chronic Pain Signatures (A2CPS) Thoracic Enrollment*  
 Bayman EO, Nadel L, **Coffey C**, Sluka K, Dailey D, McCarthy, and Brummett C  
**April 2023:** Poster Presentation at United States Association for the Study of Pain Annual Meeting (Durham, NC)
176. *Longitudinal Clinical and Biomarkers Characteristics of Non-Manifest GBA1 N40S Carriers: The PPMI Cohort*  
 Gonzalez-Latapi P, Simuni T, Merchant K, Brumm M, Alcalay RN, Cho H, Caspell-Garcia C, Gochanour C, **Coffey C**, and Marek K on behalf of the PPMI Investigators  
**March 2023:** Poster Presentation, ADPD 2023 – International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders (Gothenberg, Sweden)
175. *An Overview of Statistical Approaches and Operational Challenges Related to Non-Concurrent Controls in Platform Trials*  
 McCabe ME, **Coffey CS**, and Bayman EO  
**February 2023:** Poster Presentation, American Statistical Association Conference on Statistical Practice (San Francisco, CA)

174. *The ExTINGUISH Trial: A Multi-Site Phase-2B Randomized Placebo-Controlled Trial to Study the Safety and Efficacy of Inebilizumab in Anti-NMDA Receptor Encephalitis*  
 Day GS, Titulaer MJ, Wong KH, Torner J, Cudkowicz M, **Coffey C**, Lungu C, Klawiter E, Singleton JR, Mitchell D, Fedler J, Ecklund DJ, Klements D, Costigan M, and Clardy SL  
**October 2022:** American Neurological Association Annual Meeting (Chicago, IL)  
**April 2022:** Poster Presentation, American Academy of Neurology Annual Meeting (Seattle, WA)
173. *Acute to Chronic Pain Signatures Program (A2CPS): An Update on Study Enrollment and Data Completion*  
 Berardi G, Frey-Law L, Vance CGT, Bayman EO, **Coffey CS**, Dailey DL, Ecklund D, Sluka KA, Burns J, Buvanendran A, Jacobs J, McCarthy RJ, Wixson R, Zhou WJ, Brummett CM, Clauw D, Harris RE, Harte S, Crainiceanu C, Ford J, Kahn A, Lindquist M, Sutherland S, Taub M, Wager T, Wandner LD and The Acute to Chronic Pain Signatures Consortium  
**September 2022:** Poster Presentation, IASP 2022 World Congress of Pain (Toronto, Canada)
172. *Acute to Chronic Pain Signature Program Powered for Discovery and Prediction Modeling*  
 Bayman EO, Langefeld CD, Lindquist M, **Coffey C** Leroux A, Crainiceanu C, McCarthy R, Tsodikov A, Zeger SL, Berardi G, Brummett C, Burns J, Clauw D, Johnston N, Porter L, Sluka K, and Wager TD  
**September 2022:** Poster Presentation, IASP 2022 World Congress of Pain (Toronto, Canada)
171. *Longitudinal Clinical and Biological Characteristics of LRRK2 Non-Manifest Carriers: PPMI Cohort*  
 Simuni T, Merchant K, Brumm MC, Cho H, Caspell-Garcia C, **Coffey C**, Chahine LM, Alcalay RN, Nudelman K, Foroud T, Mollenhauer B, Siderowf A, Tanner C, Iwaki H, Sherer T, and Marek K on behalf of the PPMI Investigators  
**September 2022:** Poster Presentation, International Congress of Parkinson's Disease and Movement Disorders (Madrid, Spain)
170. *Parkinson's Progression Markers Initiative (PPMI) Online Identifies People with Features of Prodromal Parkinson's Disease Through Online Questionnaires*  
 Brown E, Chahine L, Alonso D, **Coffey CS**, Dobkin R, Korell M, Lorenzo A, Marras C, Poewe W, Sherer T, Siderowf A, Simuni T, Tolosa E, Twiggs JV, Weintraub D, Chowdhury S, Marek K, and Tanner CM  
**September 2022:** Poster Presentation, International Congress of Parkinson's Disease and Movement Disorders (Madrid, Spain)
169. *Parkinson's Progression Markers Initiative (PPMI) Online Expands Biomarker Research in Parkinson's Disease (PD)*  
 Brown E, Alonso D, Chahine L, **Coffey CS**, Dobkin R, Korell M, Lorenzo A, Marras C, Poewe W, Sherer T, Siderowf A, Simuni T, Tolosa E, Twiggs JV, Weintraub D, Chowdhury S, Marek K, and Tanner CM  
**September 2022:** Poster Presentation, International Congress of Parkinson's Disease and Movement Disorders (Madrid, Spain)
168. *Bis(Monoacylglycerol) Phosphate Levels are Elevated at Baseline in Carriers of Pathogenic Variants in LRRK2 and GBA1 and Do Not Predict Progression of PD in PPMI Cohorts*  
 Merchant KM, Simuni T, Fedler J, Caspell-Garcia C, Brumm M, Nudelman K, Tengstrandt E, Hsieh F, Alcalay RN, **Coffey C**, Chahine L, Foroud T, Singleton A, Sherer T, Siderowf A, Tanner C and Marek K on behalf of the PPMI Investigators  
**September 2022:** Poster Presentation, International Congress of Parkinson's Disease and Movement Disorders (Madrid, Spain)
167. *FX LEARN Trial: Effects of AFQ0566 on Language Learning in Fragile X Syndrome*  
 Berry-Kravis E, McDuffie A, Hessel D, Ethridge L, Erickson C, Kaufmann W, Friedmann K, Bullard L, Hagerman R, Cudkowicz M, Staley K, Klements D, Moshinsky M, Harkey B, **Coffey C**, Long J, Fedler J, Klingner E, Ecklund D, Costigan M, Huff T, Pearson B, Abbeduto L, and the NeuroNEXT FXLEARN Investigators  
**July 2022:** Presented at National Fragile X Foundation Meeting (San Diego, CA)

166. *Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN): A NeuroNEXT Trial*  
Smith AG, Singleton JR, Chase M, **Coffey CS**, Conwit R, Cudkowicz M, Ecklund D, Fedler J, Gudjonsdottir A, Greene T, Hauer P, Klingner L, Revere C, and the NN108 Study Team  
**May 2022:** Presented at Peripheral Nerve Society Annual Meeting (Miami, FL)
165. *Clinical Trials Methodology Course: What Is It? Who Is It For?*  
Meurer W, **Coffey C**, Gutmann L, and Conwit R  
**April 2022:** Presented at American Academy of Neurology Annual Meeting (Seattle, WA)
164. *Parkinson's Progression Markers Initiative (PPMI) Online Expands Biomarker Research in Parkinson's Disease (PD)*  
Brown E, Alonso D, Chahine L, **Coffey C**, Dobkin R, Korell M, Lorenzo A, Marras C, Poewe W, Sherer T, Siderowf A, Simuni T, Tolosa E, Weintraub D, Chowdhury S, Marek K, and Tanner C  
**April 2022:** Presented at the American Academy of Neurology Annual Meeting (Seattle, WA)
163. *High Diagnostic Performance of Independent Alpha-Synuclein Seed Amplification Assays for Detection of Early Parkinson's Disease*  
Russo MJ, Orru CD, Concha-Marambio L, Giaisi S, Groveman BR, Farris CM, Holguin B, Hughson AG, LaFontant DE, Caspell-Garcia C, **Coffey CS**, Mollon J, Hutten SJ, Merchant K, and Heym RG  
**April 2022:** Poster Presentation at Synuclein 2022 Meeting (Belgium, Germany)
162. *A Milestone-Based Approach to Monitoring Disease Progression in Parkinson's Disease*  
Brumm MC, Siderowf A, Simuni T, Burghardt E, Caspell-Garcia C, Toga AW, Galasko D, Mollenhauer B, Chahine LM, Foroud T, Arnedo V, Frasier M, Reimer A, Tanner C, Poston K, Weintraub D, Hutten SJ, Kiebertz K, Marek K, and **Coffey CS**  
**September 2021:** Guided Poster Tour, Movement Disorder Society Virtual Congress
161. *Parkinson Progression Marker Initiative – New Science/New Cohorts*  
Marek K, Siderowf A, Simuni T, **Coffey C**, Foroud T, Flagg E, Chowdhury S, Mollenhauer B, Galasko D, Merchant K, Kiebertz K, Brown E, Poston K, Chahine L, Tanner C, and the Parkinson's Progression Markers Initiative  
**September 2021:** Guided Poster Tour, Movement Disorder Society Virtual Congress
160. *Conceptual Design and Protocol for the Acute to Chronic Pain Signatures Program (A2CPS)*  
Sluka KA, Frey Law L, **Coffey C**, Bayman E, Ecklund D, Vance CGT, Dailey DL, Wager T, Lindquist MA, Kahn A, Burns JW, McCarthy RJ, Jacobs JJ, Buvanendran A, Zhou X, Brummett C, Clauw D, Chang W, Waljee J, Harris R, Williams D, Harte S, Olivier M, Langefeld CD, Howard T, Jepsen K, Laurent L, Fisch KM, Jacobs J, Qian W, Loshkin A, Sankar C, Lenzi R, Wandner L, Saterlee J, Labosky P, and Porter L  
**December 2020:** Poster Presentation, Inaugural Meeting of the US Association for the Study of Pain
159. *NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson's Disease: Final Study Results*  
The Parkinsons Study Group / NILO-PD Investigators (Simuni T – PI)  
**September 2020:** American Academy of Neurology Emerging Science Virtual Live Presentation  
**May 2020:** Poster Presentation, American Academy of Neurology Virtual Annual Meeting
158. *Sample Size Estimates for Optical Coherence Tomography Outcome Measures Based on Trends Observed in the SPRINT-MS Trial*  
Fedler JK, Bermel RA, **Coffey CS**, Klingner E, Yankey J, Fox RJ  
**August 2020:** Society for Clinical Trials Virtual Meeting
157. *Rates of Pharmacological Treatment of Neuropsychiatric Symptoms in Early Parkinson's Disease*  
Kulick-Soper CV, Caspell-Garcia C, **Coffey C**, Picillo M, Weintraub D, Dahodwala N, and the Parkinson Progression Markers Initiative  
**August 2020:** Guided Poster Tour, Movement Disorder Society Virtual Congress

156. *Longitudinal Clinical and DAT Imaging Characteristics of Non-Manifest LRRK2 Carriers: The PPMI Cohort*  
 Simuni T, Siderowf A, Brumm M, Caspell-Garcia C, **Coffey C**, Chahine LM, Merchant K, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun-Turgut D, Poston K, Poewe W, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Reimer A, Hutten S, Marek K and the Parkinson's Progression Markers Initiative  
**August 2020:** Guided Poster Tour, Movement Disorder Society Virtual Congress
155. *Physiologically-Based Pharmacokinetic Modeling of Nilotinib to Determine Serum, Cerebrospinal Fluid, and Brain Exposures*  
 Venuto C, Simuni T, Fiske B, **Coffey C**, Matthews H, Wyse R, Brundin P, Simon D, Schwarzschild M, Weiner D, Adams J, Trusso L, Kostrzebski M, Ward T, Rafaloff G, and Merchant K  
**August 2020:** Guided Poster Tour, Movement Disorder Society Virtual Congress
154. *Feasibility of Studying Microbiome in Frozen Saliva and Formalin-Fixed Colon in PD Using Systemic Synuclein Sampling Study (S4) Samples*  
 Mosovsky S, Methe B, Beach TG, Adler CH, **Coffey CS**, Foroud T, Eberling J, Mollenhauer B, & Chahine L for the Systemic Synuclein Sampling Study  
**August 2020:** Guided Poster Tour, Movement Disorder Society Virtual Congress
153. *NILO-PD: A Phase 2A Study of Nilotinib in Patients with Moderately Advanced Parkinson's Disease: Exploratory Efficacy Outcomes*  
 Simuni T, **Coffey CS**, Klingner E, Caspell-Garcia C, Lafontant DE, Merchant K, Fiske B, Matthews H, Wyse R, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Trusso L, Baker L, Kostrzebski M, Venuto C, Rafaloff G, and Ward T on behalf of the NILO-PD Investigators  
**August 2020:** Guided Poster Tour, Movement Disorder Society Virtual Congress
152. *Childhood and Adolescent Migraine Prevention [CHAMP] Trial: The 3-Yea Follow-Up Survey Results*  
 Powers SW, Chamberlin L, Peugh J, Reidy BL, Klingner EA, Yankey J, Porter LL, Kabbouche M, Kacperski J, Ecklund D, **Coffey CS**, and Hershey AD.  
**June 2020:** Virtual Platform Presentation, American Headache Society Virtual Annual Meeting
151. *Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advanced Parkinson's Disease*  
 Merchant K, Simuni T, Fiske B, **Coffey CS**, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Trusso L, Baker L, Kostrzebski M, Ward T, Rafaloff G, and Venuto C on behalf of the NILO-PD PSG Investigators  
**April 2020:** Poster Presentation, Advances in Alzheimer's and Parkinson's Therapies; An AAT-AD/PD Virtual Focus Meeting
150. *Modeling Outcomes in the PPMI Cohort: Implications for Clinical Trial Design*  
 Brumm MC, **Coffey CS**, Siderowf A, Simuni T, Galasko D, Mollenhauer B, Chahine LM, Arnedo V, Daegele N, Frasier M, Tanner C, Poston K, Weintraub D, Hutten S, Kieburtz K, Marek K, and the Parkinson's Progression Markers Initiative  
**April 2020:** Poster Presentation, Advances in Alzheimer's and Parkinson's Therapies; An AAT-AD/PD Virtual Focus Meeting
149. *NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson's Disease – Final Study Results*  
 Simuni T, Fiske B, Merchant K, **Coffey CS**, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild MA, Weiner D, Adams J, Venuto C, Trusso L, Baker L, Kostrzebski M, Ward T, & Rafaloff G on behalf of the NILO-PD PSG Investigators  
**February 2020:** Poster Presentation, Pan American Parkinson's Disease and Movement Disorders Congress (Miami, FL)
148. *Analyses of Pharmacokinetics, CSF Exposures and CSF Dopamine and its Metabolite Levels in NILO-PD, A Phase 2A Study of Nilotinib in Moderate to Advanced Parkinson's Disease*  
 Merchant KM, Simuni T, Fiske B, **Coffey C**, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild MA, Weiner D, Adams J, Trusso L, Baker L, Kostrzebski M, Ward T, Rafaloff G, and Venuto C on behalf of the NILO-PD Steering Committee  
**October 2019:** Poster Presentation, Society for Neuroscience Annual Meeting (Chicago, IL)

147. *Rituximab Response in Patients with Moderate to Severe Myasthenia Gravis (MG): A Subgroup Analysis of the BeatMG Study*  
 Nowak RJ, **Coffey C**, Goldstein JM, Yankey JW, Uribe L, Dimachkie MM, Benatar M, Wolfe GI, Burns T, Pearson B, O'Connor KC, Conwit R, Kissel JT, Hafler DA, Cudkowicz ME, and Barohn RJ on behalf of the NeuroNEXT NN103 BeatMG Study Team  
**October 2019:** Platform Presentation, American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting (Austin, TX)
146. *Evaluation of Continual Reassessment Method with Lagged Group: A Study Design for Early Phase Dose-Finding Clinical Trials*  
 Welhaven A, **Coffey C**, and Foster E.  
**October 2019:** Oral Presentation, Women in Statistics and Data Science Conference (Bellevue, WA)
145. *PPMI 2.0 – Transforming PPMI – New Cohorts, New Science – Focus on Prodromal PD*  
 Marek K, Siderowf A, Simuni T, **Coffey C**, Foroud T, Arnedo V, Flagg E, Chowdhury S, Kieburtz K, Chahine L, Tanner C, and the Parkinson's Progression Markers Initiative  
**September 2019:** Poster Presentation, Movement Disorders Society Meeting (Nice, France)
144. *Clinical and DAT Imaging Characteristics of Participants with Scans without Evidence of Dopaminergic Deficit (SWEDDs): PPMI Cohort 2 Year Follow-Up*  
 Marek K, Simuni T, Siderowf A, Lafontant DE, Caspell-Garcia C, **Coffey C**, Mollenhauer B, Tanner C, Kieburtz K, Chahine L, & Seibyl J on behalf of the PPMI Investigators  
**September 2019:** Poster Presentation, Movement Disorders Society Meeting (Nice, France)
143. *Identifying Incident Cases of Neurodegenerative Parkinsonism in a Large Observational At-Risk Cohort: The PPMI Study*  
 Chahine L, Kieburtz K, Brumm M, Caspell-Garcia C, **Coffey C**, Siderowf A, Weintraub D, Tanner C, Foroud T, Galasko D, Mollenhauer B, Simuni T, Marek K, and the Parkinson's Progression Markers Initiative  
**September 2019:** Poster Presentation, Movement Disorders Society Meeting (Nice, France)
142. *Neuropsychiatric Symptoms Over the Initial Lustrum of Parkinson Disease: Common, Increasing, Comorbid & Varied*  
 Weintraub D, Caspell-Garcia C, Simuni T, Cho R, **Coffey C**, Aarsland D, Alcalay R, Barrett M, Chahine LM, Eberling J, Espay A, Hamilton J, Hawkins K, Leverenz J, Litvan I, Richard I, Rosenthal L, Siderowf A, York M, and the Parkinson's Progression Markers Initiative  
**September 2019:** Poster Presentation, Movement Disorders Society Meeting (Nice, France)
141. *NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson's Disease – Study Design and Status Update*  
 Simuni T, Fiske B, Merchant K, **Coffey CS**, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Venuto C, Trusso L, Baker L, Kostrzebski M, Ward T, and Rafaloff G on behalf of the NILO-PD PSG Investigators  
**September 2019:** Poster Presentation, Movement Disorders Society Meeting (Nice, France)
140. *Highlights From a Workshop on Enhancing Natural Product Clinical Trials*  
 Pauli G, Kuszak A, Bloss G, Fukagawa N, Jafari M, Walters M, Barrett B, Bushman F, Casper S, Chilton F, **Coffey C**, Feruzzi M, Hopp C, Kiely M, Lakens D, MacMillan J, Meltzer D, Paul J, Pritchett-Corning K, Quinney S, Ross S, Seifried H, Setchell K, Sipes N, Stephens J, Taylor D, Tiriach H, Xi D, Hoffman FA, and Sorkin B  
**July 2019:** Poster Presentation, American Society of Pharmacognosy Meeting (Madison, WI)
139. *Evaluation of Continual Reassessment Method with Lagged Cohort*  
 Wellhaven AE, **Coffey CS**, and Foster EF.  
**May 2019:** Oral Presentation, Society for Clinical Trials Annual Meeting (New Orleans, LA)
138. *Response to Treatment According to Progressive Disease Type: Analysis from a Phase II Progressive MS Trial of Ibudilast*  
 Goodman A, Barnes J, Yankey J, Zahn E, Natarajan S, Bermel R, **Coffey CS**, Klawiter EC, Matsuda K, Naismith RT, & Fox RJ on behalf of the SPRINT-MS Investigators  
**May 2019:** Platform Presentation, American Academy of Neurology Annual Meeting (Philadelphia, PA)



137. *Effect of Ibudilast on Macular Measures in Progressive MS: OCT Analysis from a Phase II Trial*  
 Bermel RA, Barnes J, Yankey J, Zahn E, Natarajan S, **Coffey CS**, Goodman A, Klawiter EC, Matsuda K, Naismith RT, and Fox RJ on behalf of the SPRINT-MS Investigators  
**May 2019:** Poster Presentation, American Academy of Neurology Annual Meeting (Philadelphia, PA)
136. *Effect of Ibudilast on Serum Neurofilament in Progressive MS: Analysis from a Phase II Trial*  
 Fox RJ, Kuhle J, Karafa M, Konig V, Natarajan S, Bermel RA, **Coffey CS**, Goodman A, Klawiter EC, Matsuda K, and Naismith RT on behalf of the SPRINT-MS Investigators  
**May 2019:** Poster Presentation, American Academy of Neurology Annual Meeting (Philadelphia, PA)
135. *NILO-PD: A Phase 2 Study of Nilotinib in Patients with Advanced and Early Parkinson's Disease: Study Design and Status Update*  
 Simuni T, Fiske B, Merchant K, **Coffey CS**, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Venuto C, Trusso L, Baker L, Kostrzebski M, Ward T, and Rafaloff G on behalf of the NILO-PD PSG Investigators  
**May 2019:** Poster Presentation, American Academy of Neurology Annual Meeting (Philadelphia, PA)
134. *NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson's Disease: Study Design and Status Update*  
 Simuni T, Fiske B, Merchant K, **Coffey C**, Matthews H, Wyse R, Brundin P, Simon DK, Schwarzschild M, Weiner D, Venuto C, Trusso L, Baker L, Kostrzebski M, Ward T, and Rafaloff G on behalf of the NILO-PD Steering Committee  
**March 2019:** Poster Presentation, Alzheimer's & Parkinson's Disease Congress (Portugal, Spain)
133. *Irritability in Huntington's Disease: A Phase 2 Exploratory Clinical Trial with a Novel Vasopressin 1a Antagonist SRX246*  
 Simon N, Hersch S, Anderson K, Long J, Ecklund D, Costigan M, Thornell B, Gladden C, Coffey C, Cudkowicz M, & Brownstein M  
**December 2018:** Poster Presentation, American College of Neuropsychopharmacology Annual Meeting (Hollywood, FL)
132. *Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4)*  
 Chahine LM, Beach T, **Coffey C**, Caspell-Garcia C, Adler C, Serrano G, Mosovsky S, Foroud T, Linder C, Riss H, Ecklund D, Seibyl J, Mallya A, Arnedo V, Riley L, Dave K, Jennings D, & Mollenhauer B  
**October 2018:** Poster Presentation, Annual Movement Disorders Society Meeting (Hong Kong)
131. *The National Institute of Neurological Disorders and Stroke Clinical Trials Methodology Course: Outcomes of Trainees After 3 Years*  
 Seedorff N, Black J, Conwit R, Lewis R, **Coffey C**, Gutmann L, & Meurer W  
**May 2018:** Poster Presentation, Society for Clinical Trials Annual Meeting (Portland, OR)
130. *A Phase II Trial of Ibudilast in Progressive Multiple Sclerosis*  
 Fox RJ, **Coffey CS**, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koeppe M, Natarajan S, Thornell B, Yankey J, Bermel RA, Huang X, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Debbins JP, Zhou X, Alvarez E, Apperson M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, & Zabeti A on behalf of the NN102/SPRINT-MS Investigators  
**April 2018:** Clinical Trials Plenary Session, American Academy of Neurology Annual Meeting (Los Angeles, CA)
129. *B Cell Targeted Treatment in Myasthenia Gravis (BeatMG) – A Phase 2 Trial of Rituximab in MG: Topline Results*  
 Nowak RJ, **Coffey C**, Goldstein JM, Dimachkie MM, Benatar M, Huq SN, Pearson B, Herbelin L, O'Connor KC, Conwit R, Kissel JT, Hafler DA, Cudkowicz ME, & Barohn RJ on behalf of the NeurNEXT NN013 BeatMG Study Team  
**April 2018:** Poster Presentation, American Academy of Neurology Annual Meeting (Los Angeles, CA)

128. *Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Update on Success and Five-Year Renewal Application*  
Qidwai J, Kearney Chase M, Ecklund D, Bosch M, Thornell B, **Coffey C**, & Cudkowicz M.  
**March 2018:** Poster Presentation, American Society for Experimental Neurotherapeutics (ASENT) Meeting (Washington, DC)
127. *SPRINT-MS/NN012 Phase II Trial of Ibudilast in Progressive MS: Top-Line Results*  
Naismith R, **Coffey CS**, Cudkowicz ME, Gleason T, Goodman AD, Klawiter EC, Matsuda K, McGovern MM, Conwit R, Ashokkumar A, Ecklund DJ, Klingner E, Koeppe M, Natarajan S, Thornell B, Yankey JW, Bermel R, Huang X, Lowe M, Nakamura K, Narayanan S, Sakaie K, Debbins J, Zhou X, Alvarez E, Apperson ML, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda DD, Perumal JS, Racke MK, Repovic P, Riley CS, Severson CA, Shinnar S, Suski V, Weinstock-Gutman B, Yadav V, Zabeti A, & Fox RJ.  
**February 2018:** Poster Presentation, American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting (San Diego, CA)
126. *Final Results of the RHAPSODY Trial*  
Lyden P, Coffey CS, Cudkowicz M, Conwit RA, & Pryor KE on behalf of the RHAPSODY Investigators  
**January 2018:** Plenary Presentation at the International Stroke Conference (Los Angeles, CA)
125. *Safety and Tolerability of SRX246 in Irritable/Aggressive Subjects with Huntington's Disease (STAIR): A Phase II Exploratory Clinical Trial*  
Raulerson S, Berg S, Costigan M, Hersch SM, Anderson KE, Long J, **Coffey CS**, Yankey J, Cudkowicz M, Conwit R, Lungu C, Brownstein MJ, & Simon NG  
**November 2017:** Poster Presentation, Huntington's Study Group Annual Meeting (Denver, CO)
124. *Measurement of Huntington's Irritability and Aggression in the Azevan Pharmaceuticals-NeuroNEXT STAIR Study*  
Anderson K, Hersch S, Long J, Cudkowicz M, **Coffey C**, Yankey J, Costigan M, Raulerson S, Berg S, Conwit R, Lungu C, Brownstein M, & Simon L.  
**November 2017:** Poster Presentation, Huntington's Study Group Annual Meeting (Denver, CO)
123. *SPRINT-MS/NN012 Phase II Trial of Ibudilast in Progressive MS: Top-Line Results*  
Fox RJ, **Coffey CS**, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Ecklund D, Koeppe M, Long J, Natarajan S, Skaramagas T, Thornell B, Yankey J, Bermel R, Huang X, Lin J, Lowe M, Nakamura K, Narayanan S, Sakaie KE, Debbins JP, Zhou X, Alvarez E, Apperson M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, Weinstock-Gutman B, Yadav V, & Zabeti A on behalf of the NN102/SPRINT-MS Study Investigators.  
**October 2017:** Plenary Presentation at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting (Paris, France)
122. *Biological Analyses of PPMI Samples*  
Mollenhauer B, Caspell-Garcia CJ, **Coffey CS**, Taylor P, Shaw LM, Trojanowski JQ, Singleton A, Naito A, Reimer A, Frasier M, Marek K, and Galasko D for the Parkinson Progression Marker Initiative  
**October 2017:** PD Therapeutics Conference (New York, NY)
121. *Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4)*  
Linder C, Mollenhauer B, **Coffey C**, Beach T, Foroud T, Adler C, Riss H, Ecklund D, Caspell-Garcia C, Dave K, Deshpande S, Lasch S, Arnedo V, Riley L, Kopil C, Jennings D, & Chahine L  
**June 2017:** Poster Presentation, Annual Movement Disorders Society Meeting (Vancouver, BC)
120. *Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Pre-Award Process and Experiences*  
Foster E, Mahoney K, Ecklund D, Kearney Chase M, Bosch M, Thornell B, **Coffey C** & Cudkowicz M  
**May 2017:** Poster Presentation, Society for Clinical Trials Annual Meeting (Liverpool, UK)

119. *Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4)*  
Linder C, Mollenhauer B, **Coffey C**, Beach TG, Foroud T, Adler CH, Riss H, Ecklund D, Caspell-Garcia C, Dave KD, Deshpande S, Lasch S, Arnedo V, Riley L, Jennings D, & Chahine L  
**April 2017:** Poster Presentation, American Academy of Neurology Annual Meeting (Boston, MA)
118. *The Systemic Synuclein Sampling Study*  
Mollenhauer B, **Coffey C**, Beach TG, Foroud T, Adler CH, Ecklund D, Dave KD, Deshpande S, Lasch S, Arnedo V, Riley L, Jennings D, & Chahine L.  
**March 2017:** Poster Presentation, Alzheimer's & Parkinson's Disease Congress (Vienna, Austria)
117. *Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Increasing Efficiency in Clinical Trials*  
Kearney Chase M, Ecklund D, Bosch M, Thornell B, **Coffey C**, & Cudkowicz M.  
**October 2016:** Poster, American Neurological Association Annual Meeting (Baltimore, MD)
116. *Longitudinal Evolution of Possible REM Sleep Behavior Disorder in Early Parkinson's Disease*  
Oertel W, Simuni T, Caspell-Garcia C, Long J, **Coffey CS**, Iranzo A, Mayer G, Chahine L, Lasch S, & Marek K on behalf of the PPMI Sleep Working Group  
**June 2016:** International Movement Disorders Congress (Berlin, Germany)
115. *The Systemic Synuclein Sampling Study (S4)*  
Jennings D, **Coffey C**, Beach T, Foroud T, Adler CH, Mollenhauer B, Seibyl J, Ecklund D, Lasch S, Arnedo V, & Kopil C  
**June 2016:** International Movement Disorders Congress (Berlin, Germany)
114. *Longitudinal Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease and Healthy Controls*  
Mollenhauer B, Caspell-Garcia CJ, **Coffey CS**, Taylor P, Shaw LM, Trojanowski JQ, Singleton A, Frasier M, Marek K, & Galasko DR  
**June 2016:** International Movement Disorders Congress (Berlin, Germany)
113. *Baseline Prevalence and Longitudinal Evolution of Non-Motor Symptoms in Early Parkinson's Disease – PPMI Cohort*  
Simuni T, Weintraub D, Caspell-Garcia C, Walker M, **Coffey CS**, Lasch S, Tanner C, Jennings D, Kiebertz K, & Marek K on behalf of the PPMI Investigators  
**June 2016:** International Movement Disorders Congress (Berlin, Germany)
112. *Longitudinal Evolution of Excessive Daytime Sleepiness in Early Parkinson's Disease*  
Simuni T, Caspell-Garcia C, Long J, **Coffey CS**, Oertel W, Lasch S, & Marek K on behalf of the PPMI Sleep Working Group  
**June 2016:** International Movement Disorders Congress (Berlin, Germany)
111. *Clinical and Biological Predictors of Time to Initiation of Symptomatic Therapy in Early Parkinson's Disease*  
Simuni T, Long J, Caspell-Garcia C, **Coffey CS**, Lasch S, Tanner C, Jennings D, Kiebertz K, & Marek K on behalf of the PPMI Investigators  
**June 2016:** International Movement Disorders Congress (Berlin Germany)
110. *Physician-Pharmacist Collaboration: Overcoming Socioeconomic Barriers*  
Gums TH, Anderegg MD, Uribe L, **Coffey C**, and Carter BL.  
**May 2016:** Annual Meeting of the American Society for Hypertension (New York, NY)
109. *Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection*  
Lyden P, Weymer S, **Coffey C**, Cudkowicz M, Fisher M, Haley EC, Khatri P, Saver J, Levine S, Levy H, Pryor K, Rymer M, and Wechsler L.  
**February 2016:** International Stroke Conference (Los Angeles, CA)
108. *A Phase 2 Trial of Rituximab in Myasthenia Gravis: Study Update*  
Nowak RJ, **Coffey C**, Goldstein JM, Dimachkie M, Benatar M, O'Connor KC, Kissel J, Hafler DA, Barohn R, and Cudkowicz for the NeuroNEXT NN103 Study Team.  
**September 2015:** Annual Meeting of the American Neurological Association (Chicago, IL)

107. *Can We Reliably Establish Parkinson's Disease Subtypes in De Novo Patients: Follow Up Results from the PPMI Study*  
 Simuni T, Caspell-Garcia C, **Coffey C**, Lasch S, Jennings D, Tanner C, Kieburz K, and Marek K.  
**June 2015:** 19th Int. Congress of Parkinson's Disease and Movement Disorders (San Diego, CA)
106. *Initial Results from the NeuroNEXT SMA Infant Biomarker Study*  
 Kolb SJ, **Coffey CS**, Yankey JW, Arnold D, Rutkove SB, Bartlett A, Renusch S, Wang S, Snyder PJ, Prior TW, and Kissel JT for the NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators.  
**June 2015:** Cure SMA Annual Researcher Meeting (Kansas City, MO)
105. *Including Uncertainty in the Target Probability of Dose Limiting Toxicity in Phase I/II Studies with a Dose Finding Component*  
 Foster E, Thomann MA, and **Coffey CS**.  
**May 2015:** Society for Clinical Trials Annual Meeting (Washington, DC)
104. *The NINDS Clinical Trials Methodology Course: Approach and Lessons from Year 1*  
 Meurer WJ, Mawocha S, Conwit R, Lewis R, **Coffey C**, and Gutmann L.  
**May 2015:** Society for Clinical Trials Annual Meeting (Washington, DC)
103. *The Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) Protocol Working Group Design Phase Experiences*  
 Foster E, **Coffey CS**, Cudkowicz ME, Ecklund DJ, Bosch MJ, Thornell BJ, Kearney M, Littizzio E, Ashokkumar A, and Mahoney K  
**May 2015:** Society for Clinical Trials Annual Meeting (Washington, DC)
102. *NN102/SPRINT-MS Phase II Trial of Ibudilast in Progressive MS: Baseline Characteristics*  
 Fox R, **Coffey C**, Cudkowicz M, Gleason T, Goodman A, Klawiter E, Matsuda K, McGovern M, McNeil E, Naismith R, and Yankey J.  
**April 2015:** Annual Meeting of the American Academy of Neurology (Washington, DC)
101. *Initial Results from the NeuroNEXT SMA Infant Biomarker Study*  
 Kolb SJ, **Coffey CS**, Arnold WD, Rutkove SB, Bartlett A, and Kissel JT from the NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators  
**April 2015:** Annual Meeting of the American Academy of Neurology (Washington, DC)
100. *Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Increasing Efficiency in Clinical Trial Management*  
 Kearney M, Ecklund D, Bosch M, Thornell B, McNeil E, Cordell J, **Coffey C**, and Cudkowicz M  
**April 2015:** Annual Meeting of the American Academy of Neurology (Washington, DC)
99. *Multicenter Evaluation of Parkinson's Disease Progression using 123-I-Ioflupane SPECT: Update from the Parkinson's Progression Marker Initiative Trial*  
 Seibyl J, Jennings D, **Coffey C**, and Marek K  
**June 2014:** 18<sup>th</sup> Int. Congress of Parkinson's Disease and Movement Disorders (Stockholm, Sweden)
98. *Excessive Day Time Sleepiness Is Not Part of Parkinson's Disease Disability in De Novo Patients: Results from the PPMI Study*  
 Simuni T, Caspell C, **Coffey C**, Chahine LC, Lasch S, Oertel W, and Marek K for the PPMI Investigators.  
**June 2014:** 18<sup>th</sup> Int. Congress of Parkinson's Disease and Movement Disorders (Stockholm, Sweden)
97. *Degeneration of Corticostriatal Fibers in Parkinson's Disease and Their Differential Relations to Cognitive and Motor Deficits*  
 Zhang Y, Wu K, Buckley S, Mendick S, Seibyl J, Foster E, **Coffey C**, Marek K, and Schuff N for the Parkinson's Progression Markers Initiative (PPMI).  
**June 2014:** 18<sup>th</sup> Int. Congress of Parkinson's Disease and Movement Disorders (Stockholm, Sweden)
96. *Cognitive Performance and Psychiatric Symptoms in De Novo, Untreated Parkinson's Disease: Results from the PPMI Study*  
 Weintraub D, Simuni T, **Coffey C**, Caspell-Garcia C, Foster E, Barone P, Leverenz J, Burn D, Eberling J, Chahine L, Litvan T, Troyer M, Siderowf A, Aarsland D, and Hawkins K for the PPMI Cognitive Behavioral Working Group  
**June 2014:** 18<sup>th</sup> Int. Congress of Parkinson's Disease and Movement Disorders (Stockholm, Sweden)

95. *Can We Reliably Establish Parkinson's Disease Subtypes in De Novo Patients: Results from the PPMI Study*  
Simuni T, **Coffey C**, Uribe L, Lasch S, Jennings D, Tanner C, and Marek K for the PPMI Investigators  
**June 2014:** 18<sup>th</sup> Int. Congress of Parkinson's Disease and Movement Disorders (Stockholm, Sweden)
94. *Coordinating Center Support Required for an Academic Central IRB: The NeuroNEXT Network Experience*  
Kearney M, Flynn K, Huq S, Ashokkumar A, Simpson E, McCourt M, Ecklund D, Bosch M, **Coffey C**, and Cudkowicz M.  
**May 2014:** Society for Clinical Trials Annual Meeting (Philadelphia, PA)
93. *The NeuroNEXT Experience of Patient Engagement in Protocol Development*  
Kearney M, Thornell B, Mahoney K, Ecklund D, **Coffey C**, and Cudkowicz M  
**May 2014:** Society for Clinical Trials Annual Meeting (Philadelphia, PA)
92. *Assessment of Site Feasibility: The NeuroNEXT Network Experience*  
Kearney M, McCourt M, Huq S, Strodel R, Thornell B, Ecklund D, Bosch M, **Coffey C**, & Cudkowicz M.  
**May 2014:** Society for Clinical Trials Annual Meeting (Philadelphia, PA)
91. *Simulation Study to Assess an A Priori Decision Algorithm for a Randomized Three-Armed Clinical Trial*  
Zahn E and **Coffey C**  
**May 2014:** Society for Clinical Trials Annual Meeting (Philadelphia, PA)
90. *Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Increasing Efficiency in Clinical Trial Management*  
Kearney M, Ecklund D, Bosch M, Thornell B, McNeil E, Koroshetz W, Kaufmann P, **Coffey C**, Cudkowicz M  
**April 2014:** Annual Meeting of the American Academy of Neurology (Philadelphia, PA)
89. *Risk of Stroke and Vascular Events and Response to Antiplatelet Therapy in Young Adults with Recent Lacunar Strokes: The SPS3 Study*  
Pikula A, **Coffey CS**, Lau HW, White CL, Kase CS, and Benavente O  
**February 2014:** International Stroke Congress (San Diego, CA)
88. *Benefits of Clinical Trial Participation for Risk Factor Control: Experience from the SPS3 Study*  
Lau H, White C, **Coffey C**, Romero J, Pikula A, Babikian V, and Benavente O  
**February 2014:** International Stroke Congress (San Diego, CA)
87. *Rapid Rollout of a Pediatric Migraine Prevention Study Conducted in Academic Research Centers*  
Korbee L, Powers S, Hershey A, Chamberlin L, Allen J, LeCates S, White S, Kroner J, Sullivan S, **Coffey C**, and Ecklund D.  
**November 2014:** International Headache Congress (Scottsdale, AZ)
86. *123-I Ioflupane SPECT Measures of Parkinson Disease Progression in the Parkinson Progression Marker Initiative (PPMI) Trial*  
Seibyl JP, Jennings D, Grachev, I, **Coffey C**, & Marek K on behalf of the PPIM Investigators  
**June 2013:** Annual Meeting of the Movement Disorders Society (Sydney, Australia)
85. *Relationship Between Serum Urate and Clinical Features in Early Parkinson's Disease: PPMI Baseline Data*  
Constantinescu R, Jennings D, Foster ED, Auinger P, **Coffey CS**, & Marek K for the Parkinson's Progression Markers Initiative  
**June 2013:** Annual Meeting of the Movement Disorders Society (Sydney, Australia)
84. *Cognitive Performance and Psychiatric Symptoms in De Novo, Untreated Parkinson's Disease: Results from the PPMI Study*  
Weintraub D, Jennings D, Foster ED, Auinger P, **Coffey CS**, & Marek K for the Parkinson's Progression Markers Initiative  
**June 2013:** Annual Meeting of the Movement Disorders Society (Sydney, Australia)
83. *Rapid Rollout of a Pediatric Migraine Prevention Study Conducted in Academic Research Centers*  
Korbee L, Powers S, Hershey A, Chamberlin L, Allen J, LeCates S, White S, Kroner J, Sullivan S, **Coffey C**, and Ecklund D  
**June 2013:** International Headache Congress (Boston, MA)

82. *Internal Pilot Design for Cluster Randomized Trials with Unequal Cluster Sizes*  
Ranjan A, McClure LA, and **Coffey CS**  
**May 2013:** Society for Clinical Trials Annual Meeting (Boston, MA)
81. *Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Concept to Implementation*  
Kearney M, Ecklund D, Simpson E, Bosch M, Sweet B, Jackson K, Mahoney K, McCourt M, Thornell B, Titus S, Soodoo N, O'Brien J, Gloer K, Costigan M, Logsdon-Sackett N, Huff T, Shefner J, Staley K, Guttman L, Clarke W, Torner J, Long J, Chaloner K, Bayman E, McNeil E, Kaufmann P, Koroshetz W, Cudkowicz M, and **Coffey CS**  
**March 2013:** American Academy of Neurology Annual Meeting (San Diego, CA)
80. *The Coalition Against Major Diseases: Dopamine Transporter Imaging as an Enrichment Biomarker to Enable Parkinson's Disease Clinical Trials*  
Gordon M, Stephenson D, **Coffey C**, Cole PE, Comery TA, Grachev I, Grosset D, Harbron C, Kuoppamaki M, Lindstedt K, Meibach R, Marek K, Matthews D, Romero K, Russell D, Seibyl J, Sherer T, Stark Y, Subramaniam R, and Walton M for the Coalition Against Major Diseases (CAMD)  
**March 2013:** American Academy of Neurology Annual Meeting (San Diego, CA)
79. *Factors Affecting Time to Achieve Blood Pressure Targets in the Secondary Prevention of Small Subcortical Strokes (SPS3) Trial*  
Szychowski JM, McClure LA, White CL, Pergola PE, Benavente O, and **Coffey CS**  
**February 2013:** International Stroke Conference (Honolulu, HI)
78. *Increasing the Sample Size in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study: What Did We Gain?*  
McClure LA, Szychowski JM, Benavente O, Hart RG, and **Coffey CS**  
**February 2013:** International Stroke Conference (Honolulu, HI)
77. *The NIHSS Supplementary Motor Scale: A Valid Tool for Multidisciplinary Recovery Trials*  
Leira EC, **Coffey CS**, Jorge RE, Morton SM, Froehler MT, Davis PH, and Adams HP  
**February 2013:** International Stroke Conference (Honolulu, HI)
76. *Factors Affecting Time to Achieve Blood Pressure Targets in the Secondary Prevention of Small Subcortical Strokes (SPS3) Trial*  
Szychowski JM, McClure LA, White CL, Pergola PE, Benavente OR, and **Coffey CS**  
**February 2013:** International Stroke Conference (Honolulu, HI)
75. *Adaptive Designs for Comparative Effectiveness Trials*  
Kairalla JA, **Coffey CS**, Thomann MA, and Muller KE  
**August 2012:** Joint Statistical Meetings (San Diego, CA)
74. *CSF Biomarkers in Early Parkinson's Disease: Predictors of Risk for Disease Progression*  
Kang JH, Chen-Plotkin A, Irwin D, Siderowf A, Caspell C, **Coffey C**, Taylor P, Frasier M, Marek K, Trojanowski J, Shaw LM, and the Parkinson's Progression Marker Initiative  
**July 2012:** Alzheimer's Association International Conference (Vancouver, BC)
73. *Diurnal and Intersubject Variability of Cerebrospinal Fluid Biomarkers in Parkinson's Disease and Healthy Volunteers*  
Frasier MA, Marek K, Taylor P, Caspell C, **Coffey C**, Ereshefsky L, Yen M, and Sherer T  
**June 2012:** Annual Meeting of the Movement Disorders Society (Dublin, Ireland)
72. *Association Between CSF Biomarkers and Clinical Phenotype of Early Parkinson's Disease*  
Kang JH, Caspell C, **Coffey C**, Taylor P, Frasier M, Marek K, Trojanowski JQ, Shaw LM, and the Parkinson's Progression Marker's Initiative  
**June 2012:** Annual Meeting of the Movement Disorders Society (Dublin, Ireland)
71. *Adaptive Designs for Clinical Comparative Effectiveness Research: Are We Ready?*  
Kairalla JA, Thomann MA, **Coffey CS**, Shorr RI, and Muller KE.  
**May 2012:** Society for Clinical Trials Annual Meeting (Miami, FL).
70. *NeuroNEXT: Developing Infrastructure for Phase 2 Clinical Trials in Neurological Disorders.*  
Ecklund D, Kearney M, **Coffey CS**, Cudkowicz M, and McNeil E  
**May 2012:** Society for Clinical Trials Annual Meeting (Miami, FL).

69. *A Class of Two-Stage Internal Pilot with Interim Analysis Designs for Two Group Comparative Effectiveness Trials.*  
Kairalla JA, Thomann MA, **Coffey CS**, and Muller KE.  
**March 2012:** Annual Meeting of the Eastern North American Region (ENAR) of the Biometric Society (Washington, DC).
68. *Diurnal Fluctuations of Parkinson's Disease Biomarkers in Healthy Volunteers*  
Frasier M, Marek K, Schlossmacher M, Yen M, Taylor P, Caspell C, and **Coffey C**  
**June 2011:** International Congress of Parkinson's Disease and Movement Disorders (Toronto, ON)
67. *Some Strategies for Report Generation by Biostatisticians in Clinical Trials.*  
Yankey J, **Coffey CS**, and Clarke WR.  
**May 2011:** Society for Clinical Trials Annual Meeting (Vancouver, BC)
66. *Predictors of Blood Pressure Control at 6 and 12 Months in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study*  
Hornung LN, Szychowski J, White CL, Graves JW, Pergola PE, McClure LA, **Coffey CS**, Hart RG, and Benavente OR.  
**May 2011:** Society for Clinical Trials Annual Meeting (Vancouver, BC).
65. *Benefits of Clinical Trial Participation for Risk Factor Control: Experience from the SPS3 Study*  
Lau H, White C, **Coffey C**, Romero J, Pikula A, Babikian V, Kase C, and Benavente O  
**February 2011:** International Stroke Conference (New Orleans, LA)
64. *The Use of an Unplanned Adaptive Design in an NIH-Sponsored Stroke Prevention Trial*  
McClure LA, Szychowski JM, Benavente O, Hart RG, Conwit R, and **Coffey CS**  
**February 2011:** International Stroke Conference (Los Angeles, CA)
63. *Achieving the Benefits of Both an Internal Pilot and Interim Analysis in Small Samples*  
Kairalla JA, Muller KE, and **Coffey CS**  
**August 2010:** Joint Statistical Meetings (Vancouver, BC).
62. *The Parkinson's Progression Marker's Initiative: A Prospective Biomarkers Study*  
Frasier M, Chowdury S, Sherer T, Eberling J, Meunier C, Ravina B, Siderowf A, Scherzer C, Jennings D, Tanner C, Kieburtz K, **Coffey C**, Poewe W, Mollenhauer B, Seibyl J, Toga A, Ansbach A, De Blasio P, Piovella M, Trojanowski J, Shaw L, Singleton A, and Marek K  
**June 2010:** Annual Movement Disorders Society Meeting (Buenos Aires, Argentina).
61. *Survey on the Use of Adaptive Designs in the Journal of the American Medical Association (2007-2008)*  
Mbowe O, Birkner T, and **Coffey CS**.  
**May 2010:** Society for Clinical Trials Annual Meeting (Baltimore, MD)
60. *The Effect of an Unplanned Sample Size Re-Estimation on the Type I Error Rate*  
McClure LA, Szychowski JM, Benavente O, and **Coffey CS**  
**May 2010:** Society for Clinical Trials Annual Meeting (Baltimore, MD)
59. *Achieving the Benefits of an Internal Pilot with Interim Analysis While Controlling Type I Errors for Gaussian Linear Models*  
Kairalla JA, Muller KE, and **Coffey CS**  
**August 2009:** Joint Statistical Meetings (Washington, DC).
58. *Ambulatory Blood Pressure as Related to White Matter Hyperintensity*  
Howard KP and **Coffey CS**  
**May 2009:** Society for Clinical Trials Annual Meeting (Atlanta, GA)
57. *Monitoring Futility in Two-by-Two Factorial Studies*  
McClure LA, Howard G, and **Coffey CS**  
**May 2009:** Society for Clinical Trials Annual Meeting (Atlanta, GA).
56. *Factors Affecting Time to In-Target Blood Pressure Status in a Multicenter International Trial.*  
Szychowski J, McClure L, White C, Pergola P, Graves J, Hart R, Benavente O, and **Coffey CS**  
**May 2009:** Society of Clinical Trials Annual Meeting (Atlanta, GA).

55. *Predicting Survival in Pulmonary Arterial Hypertension Using the REVEAL Database*  
Benza RL, Foreman AJ, Prucka WR, Gomberg-Maitland M, Frantz RP, Miller DP, **Coffey CS**, Elliott CG, and McGoan MD.  
**May 2009:** Annual Meeting of the American Thoracic Society (San Diego, CA).
54. *Are Lacunar Strokes Different in Hispanic Patients? The SPS3 Study.*  
Benavente O, Del Brutto O, Arauz A, Ruiz-Sandoval JL, Roldan A, Szychowski J, Peri K, **Coffey CS**, White C, and Hart RG. **February 2009:** American Stroke Association Annual Meeting (San Diego, CA).
53. *Cytokine SNP's and Their Relationship to the Development of Peripartum Cardiomyopathy.*  
Pekarek D, Barchue J, Grenett H, Biggio J, Robin N, **Coffey CS**, and Benza R.  
**January 2009:** Annual Meeting of the Society for Maternal and Fetal Medicine (San Diego, CA).
52. *Estimating Predictive Error for Left- and Right-Censored Survival Data with Time-Varying Covariates.*  
Prucka WR and **Coffey CS**  
**August 2008:** Joint Statistical Meetings (Denver, CO).
51. *GLUMIP 2.0: SAS/IML Software for Planning Internal Pilots.*  
Kairalla JA, **Coffey CS**, and Muller KE. **August 2008:** Joint Statistical Meetings (Denver, CO).
50. *Potential Outcomes Applied to an Intentional Weight Loss Application.*  
Supapkorn T, Gadbury GL, **Coffey CS**, Keith SW, and Allison DB.  
**August 2008:** Joint Statistical Meetings (Denver, CO).
49. *ET-1 Polymorphism and Functional Capacity Interactions in PAH Patients Treated with Endothelin Antagonists.*  
Benza R, Prucka W, Frost A, Gomberg M, Lawrence E, Barchue J, **Coffey CS**, and Grenett H.  
**May 2008:** American Thoracic Society Annual Meeting (Toronto, Canada)
48. *eNOS Polymorphism and 6MWD Interactions in PAH Patients on Endothelin Antagonists.*  
Benza R, Prucka W, Torbicki A, Pulido R, Langleben D, Barchue J, **Coffey CS**, and Grenett H.  
**May 2008:** American Thoracic Society Annual Meeting (Toronto, Canada)
47. *Atypical Lacunar Syndromes: Same Disease as Classical Lacunar Infarcts? The Secondary Prevention of Small Subcortical Strokes (SPS3) Study.*  
Benavente OR, Arboix A, Bazan C, Rubio F, **Coffey CS**, McClure L, Nair N, Roldan A, White C, and Hart R.  
**May 2008:** European Stroke Meeting (Nice, France)
46. *HsCRP and SAA among Patients with Lacunar Stroke: Preliminary Findings from the Levels of Inflammatory Markers in Treatment of Ischemic Stroke (LIMITS) Study.*  
Luna J, McClure LA, Szychowski JM, **Coffey CS**, Benavente O, White C, Roldan A, Liu K, Wang H, Fink DJ, and Elkind MSV.  
**April 2008:** American Academy of Neurology Meeting (Chicago, IL)
45. *A Two-Stage Procedure for Factorial Designs Utilizing a Formal Futility Rule.*  
Nair NK and **Coffey CS**  
**March 2008:** Annual Meeting of the Eastern North American Region (ENAR) of the Biometrics Society (Alexandria, VA)
44. *GLMIP 1.0: SAS/IML Software for Planning Repeated Measures Internal Pilots.*  
Muller KE, **Coffey CS**, Kairalla JA, and Johnson JL.  
**March 2008:** Annual Meeting of the Eastern North American Region (ENAR) of the Biometrics Society (Alexandria, VA)
43. *Adjusting for Covariates in the Analysis of Microarray and Other High Dimensional Biological Data.*  
Chen L, Beasley MB, **Coffey CS**, and Page GP.  
**March 2008:** Annual Meeting of the Eastern North American Region (ENAR) of the Biometrics Society (Alexandria, VA)
42. *Internal Pilot Designs for Observational Studies.*  
Gurka MJ and **Coffey CS**  
**March 2008:** Annual Meeting of the Eastern North American Region (ENAR) of the International Biometric Society (Alexandria, VA)



41. *Internal Pilot with Interim Analysis for Single Degree of Freedom Hypothesis Tests*  
Kairalla JA, Muller KE, and **Coffey CS**  
**March 2008:** Annual Meeting of the Eastern North American Region (ENAR) of the International Biometric Society (Alexandria, VA)
40. *Single vs. Multiple Lacunar Infarcts: Are They Caused by Different Diseases? The SPS3 Study.*  
Benavente O, Bazan C, Nair N, McClure L, **Coffey C**, Pretel J, Krupinski Y, Vaishnav A, Hart R, and Roldan A.  
**February 2008:** American Stroke Association Annual Meeting (New Orleans, LA)
39. *An Internal Pilot Study with Interim Analysis for Gaussian Linear Models*  
Kairalla J, Muller KE, and **Coffey CS**  
**August 2007:** Annual Joint Statistical Meetings (Salt Lake City, UT)
38. *Small Sample Properties of Information-Based Monitoring*  
Sawrie D and **Coffey CS**.  
**August 2007:** Annual Joint Statistical Meetings (Salt Lake City, UT)
37. *Bayesian Analysis of the Effect of Intentional Weight Loss on Mortality Rate*  
Yi N, Ding S, Keith SW, **Coffey CS**, and Allison DB.  
**August 2007:** Annual Joint Statistical Meetings (Salt Lake City, UT)
36. *Wavelet-Based Modeling of Clinical Outcomes Using Diffusion Tensor Image Data*  
Prucka W, **Coffey CS**, Cutter G, and Reich DS.  
**August 2007:** Annual Joint Statistical Meetings (Salt Lake City, UT)
35. *Internal Pilot Designs and Mixed Models*  
Gurka M, **Coffey CS**, and Muller KE.  
**August 2007:** Annual Joint Statistical Meetings (Salt Lake City, UT)
34. *Monitoring Serious Adverse Events via a Web-Based System*  
Guyton F, Allcorn C, Stern B, McCarthy S, and **Coffey CS**.  
**May 2007:** Society for Clinical Trials Annual Meeting (Montreal, Quebec, Canada)
33. *TGF-Beta Polymorphisms, Gender, Age, and Their Effect on Acute Cardiac Rejection.*  
Pekarek D, **Coffey CS**, Barchue J, Grennett H, Tallaj J, Rayburn B, Kirklin J, and Benza RL.  
**April 2007:** Annual Meeting of the International Society for Heart and Lung Transplantation (San Francisco, CA)
32. *Relationship between u-PA and TGF-Beta Genotypes and Allograft Coronary Disease.*  
Pekarek D, **Coffey CS**, Barchue J, Grennett H, Tallaj J, Rayburn B, and Benza RL.  
**April 2007:** Annual Meeting of the International Society for Heart and Lung Transplantation (San Francisco, CA)
31. *A Wavelet Based Method for Determining Persistent DNA Copy Number Variation Across Multiple Subjects.*  
Prucka WR and **Coffey CS**  
**March 2007:** Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society (Atlanta, GA)
30. *Internal Pilot Design with Interim Analysis.*  
Kairalla JA, Muller KE, **Coffey CS**.  
**March 2007:** Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society (Atlanta, GA)
29. *Preemptive Power and the Consulting Statistician.*  
Sawrie DF and **Coffey CS**  
**March 2007:** Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society (Atlanta, GA)
28. *DWI Overestimates the Ultimate Size of Lacunar Infarcts.*  
Benavente O, Bazan C, Tonarelli S, Pergola G, McClure L, **Coffey C**, and Hart RG.  
**February 2007:** American Stroke Association Annual Meeting (San Francisco, CA)

27. *Orthostatic Hypotension (OH) at Six and Twelve Months in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study.*  
Graves JW, Wochos DN, and **Coffey CS** for the SPS3 Study Group.  
**October 2006:** Annual Meeting of the International Society of Hypertension (Fukuoka, Japan)
26. *Predictors of Achievement of Assigned Blood Pressure Target at Six Months and One Year in the SPS3 Study.*  
Graves JW, Pergola PE, Benavente OR, Hart RG, **Coffey CS**, & White CL for the SPS3 Study Group.  
**October 2006:** Annual Meeting of the International Society of Hypertension (Fukuoka, Japan)
25. *Secondary Prevention of Small Subcortical Strokes with BP Lowering and Antiplatelet Therapies: A 2x2 Factorial Trial (SPS3).*  
Grimm R, Pergola P, Hart R, Anderson D, Benavente O, White C, Graves J, **Coffey C**, and Brauer D.  
**October 2006:** Annual Meeting of the International Society of Hypertension (Fukuoka, Japan)
24. *GLUMIP 2.0: Free SAS/IML Software for Planning Internal Pilots.*  
Kairalla JA, **Coffey CS**, Muller KE.  
**August 2006:** Annual Joint Statistical Meeting (Seattle, WA)
23. *Monitoring Futility in 2x2 Factorial Studies.*  
McClure LA, **Coffey CS**, and Howard GH.  
**August 2006:** Annual Joint Statistical Meeting (Seattle, WA)
22. *Predictive Value of Adipokines for Development of Cardiovascular Events in a Population-Based Cohort.*  
Wolffenbuttel BHR, van Beek AP, Hebert PR, **Coffey CS**, and de Jong PE.  
**June 2006:** Annual Meeting of the American Diabetes Association (Washington, DC)
21. *Treatment of Hypertension with Epithelial Sodium Channel Inhibitors Combined with Hydrochlorothiazide Reduces Sudden Coronary Death and Total Coronary Mortality.*  
Hebert PR, Murry KT, Rottman JN, **Coffey CS**, Byrne DW, McCormack VA, Fagard RH, Meade TW, and Oates JA.  
**November 2005:** Annual Meeting of the American Heart Association (Dallas, TX)
20. *African-Americans with Kidney Disease Have Better Survival Than Whites After Acute Myocardial Infarction.*  
Newsome BB, McClellan WM, Allison JJ, Kiefe CI, **Coffey CS**, and Warnock DG.  
**November 2005:** Annual Meeting of American Society of Nephrology (Philadelphia, PA)
19. *African-Americans Have a Greater Risk of End-Stage Renal Disease Following Hospitalization for Acute Myocardial Infarction.*  
Newsome BB, Warnock DG, Allison JJ, Eggers P, Kiefe CI, Collins A, Chen S, **Coffey CS**, and McClellan WM.  
**November 2005:** Annual Meeting of American Society of Nephrology (Philadelphia, PA)
18. *Quality of Blood Pressure Measurement in the SPS3 (Secondary Prevention of Small Subcortical Strokes) Study.*  
Graves JW and **Coffey CS** for the SPS3 Study Group.  
**May 2005:** Annual Meeting of American Society of Hypertension (San Francisco, CA)
17. *GLUMIP 2.0: Free SAS/IML Software for Planning Internal Pilots.*  
Kairalla JA, **Coffey CS**, Muller KE.  
**March 2005:** Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society (Austin, TX)
16. *Repeated Measures for Gaussian Multivariate Linear Models: A Tutorial.*  
Simpson SL, **Coffey CS**, Muller KE.  
**March 2005:** Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society (Austin, TX)
15. *Avoiding Test Size Bias Due to Internal Pilots with Gaussian Repeated Measures.*  
Clement ME, **Coffey CS**, Muller KE.  
**March 2005:** Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society (Austin, TX)

14. *Toward Unbiased Estimation of the Effects of Risk Factors in the Presence of Latent Confounders Estimated with Error by Simulation-Extrapolation in Cox Proportional Hazard Model: The Example of Intentional Weight Loss and Mortality Rate.*  
Wang C, **Coffey CS**, Allison DB.  
**November 2004:** North American Association for the Study of Obesity Annual Scientific Meeting (Las Vegas, NV).
13. *Restructuring of Biostatistics at UAB.*  
Howard G, Beasley TM, **Coffey CS**, George V  
**August 2004:** Annual Joint Statistical Meetings (Toronto, ON).
12. *Genetic Programming Neural Network Has Improved Power in Comparison to Logistic Regression for Detecting Gene-Gene Interactions in Studies of Human Disease.*  
Ritchie MD, **Coffey CS**, Moore JH.  
**June 2004:** Annual Genetic and Evolutionary Computation Conference (Seattle, WA);  
Nominated for the Best Paper Award.
11. *Pharmacogenomics in Pulmonary Arterial Hypertension (PAH): The Relationship between an ET-1 Gene Polymorphism (PM) and Efficacy of Bosentan.*  
Benza RL, Mohanty GS, Grenett HE, **Coffey CS**, Rayburn BK, Tallaj JA, Law MA, Pinderski LJ, Pambokian SV, Bourge RC.  
**May 2004:** International Conference of the American Thoracic Society (Orlando, FL)
10. *Genotypes and Acute Chronic Rejection in Cardiac Transplant Recipients.*  
Benza RL, Barchue JP, Grennett HE, **Coffey CS**, Tallaj JA, Rayburn BK, Pinderski LJ, Pambokian SV, McGiffin DC, Kirklin JK, Bourge RC.  
**April 2004:** Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (San Francisco, CA)
9. *PAI-1 and Allograft Vasculopathy: Insights from a Murine Model of Transplantation.*  
Benza RL, Mohanty GS, **Coffey CS**, Anderson PG, Lyle K, George JF.  
**April 2004:** Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (San Francisco, CA)
8. *Caloric Restriction and Body Weight Independently Affect Longevity in Wistar Rats.*  
Wang C, Weindruch R, Fernandez JR, **Coffey CS**, Patel P, Allison DB.  
**November 2003:** North American Association for the Study of Obesity Annual Scientific Meeting (Ft. Lauderdale, FL).
7. *Fibrinolytic Proteins and Genotypes: Implications for Allograft Coronary Disease.*  
Benza RL, **Coffey CS**, Barchue JP, Cavender MA, Rayburn BK, Bourge RC, Tallaj JA, Kirklin JK, Pinderski LJ.  
**November 2003:** American Heart Association Annual Meeting (Orlando, FL).
6. *A Comparison of Data Mining and Logistic Regression Approaches for Detecting Gene-Gene Interactions.*  
Ritchie MD, **Coffey CS**, Moore JH.  
**November 2003:** Intl Genetic Epidemiology Society Meeting (Redondo Beach, CA)
5. *Adverse Effects of Beta Blocker Therapy for Heart Failure Patients: A Quantitative Overview.*  
Ko DT, Hebert PR, **Coffey CS**, Foody JM, Curtis JP, Sedrakyan A, Krumholz HM  
**November 2002:** American Heart Association Annual Meeting (Chicago, IL).
4. *Population Based Study of Methotrexate Use and Risk of Lymphoma in Patients with Rheumatoid Arthritis.*  
Watterson MK, Arrowsmith ER, **Coffey CS**, Cookson MS, Mitchel E, Stein CM  
**October 2002:** American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting (New Orleans, LA).
3. *Is There an Interaction between the ACE I/D and the PAI-1 4G/5G Gene Polymorphisms on Risk of Myocardial Infarction.*  
Hebert PR, **Coffey CS**, Ajani UA, Morgan TM, Brown NJ, Vaughan DE, Ridker PM.  
**November 2001:** American Heart Association Annual Meeting (Anaheim, CA).

2. *Amiodarone Delays Cellular Rejection in Bradycardic Transplant Patients.*  
Goldstein DR, Benza RL, Rayburn BK, Foley BA, **Coffey CS**, Thomas KL, Bourge. RC.  
**November 2001:** American Heart Association Annual Meeting (Anaheim, CA).
1. *Pathological Parameters in Radical Prostatectomies of Clinical Stage T1c versus T2 Prostate Carcinoma.*  
Jack GS, Vader V, **Coffey CS**, Cookson MS, Smith JA, Shappell SB  
**June 2001:** American Urological Association National Meeting (Anaheim, CA).

## GRANT ACTIVITY

### ACTIVE

#### ***Network of Excellence in Neuroscience Clinical Trials (NEXT) – DCC [NIH U01 NS077352]*** **09/30/2011-08/31/2028 [Role: PI]**

A central goal of the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) is to facilitate, from initial conception through final analysis, high-quality early phase clinical trials and biomarker studies with clear go/no-go decisions in adult and pediatric neurological disorders. The Data Coordinating Center (DCC) at the University of Iowa will continue to support study design, data collection, data management, data sharing, project management, clinical site monitoring, quality management, safety monitoring, and all statistical aspects of trials conducted within the network. The DCC will continue to build on our robust, standardized, and accessible infrastructure in a manner that is explicitly designed to accommodate dynamically changing requirements that naturally occur in clinical trials, and will continue to help NeuroNEXT succeed in providing more rapid evaluation of promising treatments in the neurosciences.

#### ***Clinical Coordinating Center for the Acute to Chronic Pain Signature Program [NIH U24 NS112873]*** **08/15/2019-07/31/2024 [Role: Co-PI (w/ K. Sluka & L Frey Law)]**

The Acute to Chronic Pain Signatures (A2CPS) Program aims to develop a large consortium to identify biomarkers and their collective biosignatures (a combination of several individual biomarkers) that predict susceptibility or resilience to the development of chronic pain after an acute pain event. Two pain populations will be followed for 6 months, with baseline and 3-month collection of multiple psychosocial, imaging, “omics”, quantitative sensory testing (QST), physical function, and pain variables. The success of the A2CPS program is dependent on effective management and coordination of activities across the consortium. The Clinical Coordinating Center will apply thorough and well-organized principles to facilitate, support, and enhance the scientific rigor and effectiveness of key stakeholders for the identification of critical biomarkers for the acute to chronic pain transition.

#### ***The Parkinson's Progression Markers Initiative Statistical Core*** **The Michael J. Fox Foundation for Parkinson's Research** **06/24/2010-06/30/2024 [Role: PI]**

The Parkinson's Progression Markers Initiative is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic, and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

#### ***Iowa Summer Institute for Research Education in Biostatistics [NIH R25 HL147231]*** **03/01/2022-02/28/2027 [Role: Co-Investigator; PI: G. Zamba(U. Iowa)]**

The ultimate vision of the Summer Institute for Research Education in Biostatistics is to increase the number of undergraduates who enter graduate programs in biostatistics, and to maintain a solid underrepresented minority pipeline into biostatistics graduate programs. This project supports the University of Iowa, Department of Biostatistics in recruiting a diverse group of trainees each year with focus on minority, underrepresented, and disadvantaged students who may not have otherwise been exposed to the field of biostatistics.

### ACTIVE NEURONEXT SUBCONTRACTS (NO FUNDED EFFORT – CTSDMC SUPPORT ONLY)

***NN108 Sub Award – Topiramate as a Disease Altering Therapy for CSPN***  
**[U01 NS095388]**  
**07/01/2017 – 12/31/2023 [Role: Subcontract PI; PI: G. Smith (VCU)]**

***NN109 Sub Award – A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects with GNE Myopathy***

[U01 AR070498]

09/01/2017 – 04/30/2024 [Role: Subcontract PI; PI: A. Amato (Massachusetts General Hospital)]

***NN110 Sub Award – A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson's Disease***

[U01 NS114001]

09/15/2019-06/30/2024 [Role: Subcontract PI; PI: A. Videnovic (Massachusetts General Hospital)]

***NN111 Sub Award – A Phase 2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis and Assess Markers of Disease***

[U01 NS120901]

09/15/2021-08/31/2026 [Role: Subcontract PI; PI: S. Clardy (Utah)]

**PREVIOUS**

**University of Iowa**

*A Randomized, Double-Blind, Placebo Controlled, Phase IIa, Parallel Group, Two-Cohort Study to Determine the Safety, Tolerability, Clinical, and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Patients with Parkinson's Disease – Biostatistics Coordinating Center*

The Michael J. Fox Foundation for Parkinson's Research

03/01/2017 – 05/31/2020 [Role: PI, Biostatistics Coordinating Center; PI: T. Simuni (Northwestern)]

*MEDication Focused Outpatient Care for Underutilization of Secondary Prevention*

NIH R18 HL116259

04/01/2014 – 03/31/2020 [Role: PI, Data Coordinating Center; PI: BL Carter (U. Iowa)]

*Enhancing Scientific Inquiry in Clinical Neurosciences Through Methodology Training*

NIH U34 DK099845

04/01/2014 – 03/31/2020 [Role: Subcontract PI, Course Co-Director; PI: W. Meurer (U. Michigan)]

*Systemic Synuclein Sampling Study (S4) – Clinical, Data Management & Statistical Core*

The Michael J. Fox Foundation for Parkinson's Research

03/01/2015 – 12/31/2019 [Role: PI, Statistics Core]

*Amyloid Imaging – PPMI Substudy*

The Michael J. Fox Foundation for Parkinson's Research

03/01/2014-02/28/2019 [Role: PI, Statistics Core]

*Three Site Assessment of the Potential for Home Dexterity Monitoring in a PD Biomarker Study (TAP-PD) – PPMI Sub Study*

The Michael J. Fox Foundation for Parkinson's Research

03/01/2014-02/28/2019 [Role: PI, Statistics Core]

*Amitriptyline and Topiramate in the Prevention of Childhood Migraine: DCC*

NIH U01 NS077108

09/30/2011-08/31/2017 [Role: PI, Data Coordinating Center]

*LRRK2 Cohort Consortium – Statistics*

The Michael J. Fox Foundation for Parkinson's Research

06/02/2011-11/30/2017 [Role: PI, Statistics Core]

*A Collaborative Model to Improve BP Control and Minimize Racial Disparities – DCC*

NIH R01 HL0918434

08/01/09 – 02/28/15 [Role: PI, Data Coordinating Center]

*Secondary Prevention of Small Subcortical Strokes SPS3*

NIH U01 NS038529

12/01/09 – 12/31/03 [Role: Subcontract PI; PI: OR Benavente (U. British Columbia)]

*Adaptive Comparative Effectiveness Trials for Comparing Two Treatments*

UF11128

05/23/11 – 03/31/12 [Role: Subcontract PI; PI: DR Nelson (U. Florida)]

*Clinical Islet Transplantation: Data Coordinating Center (CIT: DCC)*  
NIH U01 DK070431  
08/01/09 – 10/01/11 [Role: Co-Investigator; PI: WR Clarke (U. Iowa)]  
Role: Co-Investigator

*Carotid Occlusion Surgery Study (COSS): Data Management Center*  
NIH U01 NS041985  
08/01/09 – 12/01/10 [Role: Co-Investigator; PI: WR Clarke (U. Iowa)]

**NEURONEXT SUBCONTRACTS (NO FUNDED EFFORT – CTSDMC SUPPORT ONLY)**

*NN101 Sub award – SMA Biomarkers in the Immediate Post-Natal Period of Development*  
[U01 NS079163]  
08/15/2012 – 07/31/2016 [Role: Subcontract PI; PI: S. Kolb (The Ohio State University)]

*NN102 Sub award – Ibudilast in Phase II Trial in Progressive MS*  
[U01 NS082329]  
07/15/2013 – 06/30/2020 [Role: Subcontract PI; PI: R Fox (Cleveland Clinic)]

*NN103 Sub award – A Phase II Trial of Rituximab in Myasthenia Gravis*  
[U01 NS084495]  
09/15/2013 – 07/31/2019 [Role: Subcontract PI; PI: R Nowak (Yale)]

*NN104 Sub award – ZZ3K3A-201: Safety Evaluation of 3K3A-APC in Ischemic Stroke*  
[U01 NS088312]  
07/01/2014 – 06/30/2018 (Role: Subcontract PI; PI: P Lyden (Cedars Sinai)]

*NN105 Sub award – Tolerability of SRX246 in Huntington's Disease Patients*  
[U44 NS090616]  
09/01/2015 – 08/31/2018 [Role: Subcontract PI; PI: M Brownstein (Azevan)]

*NN106 Sub award – Cytochrome C Oxidase: Biomarker in Newly Diagnosed Glioblastoma Multiforme*  
[U01 NS093663]  
09/30/2016 – 06/30/2022 [Role: Subcontract PI; PI: C Griguer (U Iowa)]

*NN107 Sub Award – Effects of AFQ056 on Language Learning in Young Children with Fragile X Syndrome (FXS)*  
[U01 NS096767]  
09/30/2016 – 06/30/2023 [Role: Subcontract PI; PI: E. Berry-Kravis (Rush)]

**University of Alabama at Birmingham**

*Merck Quantitative Science Fellowship Program*  
Merck  
08/22/07 – 07/31/09 [Role: PI]

*Pharmacogenomics in Pulmonary Arterial Hypertension*  
NIH RO1 HL078946  
09/01/05 – 07/31/09 [Role: Statistician; PI: RL Benza (UAB)]

*Levels of Inflammatory Markers in the Treatment of Stroke*  
NIH RO1 NS050724  
05/25/05 – 04/30/09 [Role: Subcontract PI; PI: MSV Elkind (Columbia)]

*Effects of Intentional Weight Loss on Mortality Rate*  
NIH RO1 DK067487  
01/01/05 – 12/31/08 [Role: Co-Investigator; PI: DB Allison (UAB)]

*Secondary Prevention of Small Subcortical Strokes*  
NIH UO1 NS038529  
03/01/03 – 01/31/08 [Role: Subcontract PI; PI: OR Benavente (UT Health Sciences Center at San Antonio)]

*Design and Analysis of Microarray Gene Expression Studies in Plants: Towards Sound Statistical Principles*

NSF-01-158

01/01/03 – 12/31/07 [Role: Co-Investigator; PI: G Page (UAB)]

*Internal Pilots for Repeated Measures ANOVA*

NIH RO1 CA095749

01/15/03 – 12/31/07 [Role: Subcontract PI; PI: KE Muller (U. North Carolina)]

*Genetic Variants and Thrombosis: Renin Angiotensin.*

NIH RO1 HL99015

04/01/01 – 07/31/07 [Role: Subcontract PI; PI: PR Hebert (Yale)]

*Modulation of Innate Immunity in Lung Transplantation*

NIH RO1 HL72871

09/30/02 – 07/31/06 [Role: Statistician; PI: S Matalon (UAB)]

*UT-15 Open Grant in Pulmonary Hypertension*

United Therapeutics

10/01/01 – 04/01/05 [Role: Statistician]

## STUDENTS MENTORED

### UNIVERSITY OF IOWA

Chair (Doctoral Level):

**2024 (Expected):** Megan McCabe (Co-Chair w/ E. Bayman).

**2022:** Daniel Kang (Co-Chair w/ V. Yin), “Efficient Bayesian Adaptive Designs for Oncology Clinical Trials with Multiple Biomarker Subgroups”.

**2019:** Anne Wellhaven. “Pacing Modification by Incorporation of Lag in Early Phase Designs”

**2015:** Mitchell Thomann. “The Flexible Bivariate Continual Reassessment Method”

Committee Member (Doctoral Level):

**2021:** Alex Curtis. “Subgroup-Specific Dose Finding Using Bayesian Clustering in Phase I-II Clinical Trials”

**2017:** Janel Barnes. “Regression and Boosting Methods to Inform Precisionized Treatment Rules Using Data from Crossover Studies”

Advisor (Preceptorship – Master’s Level):

**2019:** Elliot Burghardt. “Reproducibility of Living Data: Validation of Published Research Using the Parkinson’s Progression Marker Initiative Living Database”

**2013:** J. Tucker Krone. “Simulation Study Addressing Common Phase II Endpoint Selection Issues”

**2012:** Elizabeth Zahn. “A Survey on the Perception and Use of Adaptive Designs in Clinical Trials”

**2011:** Emily Lundt. “Prediction of the Implementation of the Physician-Pharmacist Collaborative Model Using the Theory of Planned Behavior”

**2011:** Chelsea Caspell. “Analysis of Parkinson’s Biomarker Candidates”

### UNIVERSITY OF ALABAMA AT BIRMINGHAM

Chair (Doctoral Level):

**2008:** William Prucka. “Wavelet-Based Regression and Classification for Longitudinal Diffusion Tensor Imaging Data”

**2008:** Nitin Nair. “Adaptive Procedures to Detect Treatment Effect Under Suspected Treatment-Covariate Interactions”

**2007:** David Sawrie. “Preemptive Power for the Consulting Statistician: Novel Applications of Internal Pilot Design and Information Based Monitoring Systems”

Advisor (Master’s Level):

**2010:** Jiatao Ye (Co-Chair with Inmaculada Aban). “Power and Sample Size Estimation for a Three-Level Hierarchical Cluster Randomized Trial”

**2009:** Kerri Howard. “Ambulatory Blood Pressure as Related to White Matter Hyperintensity: A Preemptive Power Approach”

- 2008:** John Bentley. “Cardiovascular Risk Associated with Polymorphisms in Genes from the Renin-Angiotensin, Bradykinin, and Fibrinolytic Systems”
- 2005:** Qing Li. “The Association of the Metabolic Syndrome with PAI-1 and t-PA Antigen Levels”
- 2002:** Lili Wang. “An Evaluation of a Two-Stage Procedure to Address Interactions in Two-Stage Designs”

Committee Member (Doctoral Level):

- 2008:** Samprit Banerjee. “Bayesian Genome-Wide QTL Mapping for Multiple Traits”
- 2008:** Qing Li. “Interim Monitoring Efficacy, Safety, and Futility in Phase III Clinical Trials”
- 2007:** Tamekia Jones. “A Statistical Approach Identifying and Limiting the Effect of Influential Observations in Linear Regression”
- 2007:** Ayanbola Ayanlowo. “Examination of Novel Statistical Designs for Phase II and Phase III Clinical Trials”

Committee Member (Master’s Level):

- 2009:** Leigh Morton. “Comparison of Simon’s Two-Stage Design, Sequential Probability Ratio Test, and Triangular Test in Phase II Clinical Trials”
- 2006:** Scott Marshall. “A Comparison of Procedures to Control Type I Error in Multiple Testing Situations: False Positive Report Probability (FPRP) vs. False Discovery Rate (FDR)”
- 2004:** Lang Chen. “Model Selection in Microarrays”
- 2002:** Dongyan Yang. “The Confounding of Race and Geography: How Much of the Excess Mortality among African Americans is Explained by Geography”

Committee Member (Other):

- 2009:** Christopher Snyder, MSPH. (Epidemiology) “The Relationship of Blood Product Ratio to Mortality: Survival Benefit or Survival Bias?”
- 2009:** Robert B. Hines, PhD. (Epidemiology) “Comorbidity and Body Mass Index (BMI) as Predictors of Survival for African-Americans and Caucasians Following Surgery for Adenocarcinoma of the Colon”
- 2007:** Madhav Bhatta, PhD. (Epidemiology) “Impact of Immunosuppression on the Incidence and Clearance of Human Pappillomavirus (HPV) in HIV-Infected Women in Alabama”
- 2005:** Hanzhu Qian, PhD. (Epidemiology) “Association of Plasma Donation with Human Immunodeficiency Virus and Hepatitis C Virus Infections in Rural Shanxi Province, China”
- 2005:** Christopher Krawczyk, PhD. (Epidemiology) “Factors Associated with Delayed Initiation of HIV Medical Care Among Infected Persons Attending an Urban HIV/AIDS Clinic”
- 2004:** Jonathon Bender, PhD. (Epidemiology) “Cancer Incidence Among Employees at Semiconductor and Storage Device Manufacturing Facilities”
- 2004:** Dominik Alexander, PhD. (Epidemiology) “Post-Surgical Disparity in Survival Between African-Americans and Caucasians with Colorectal Adenocarcinomas”
- 2003:** Akanid Wapeewutikorn, MS. (Epidemiology) “Use of Complementary and Alternative Medicine Among Cancer Patients and Menopausal Women in the U.S. General Population”

**UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL**

Chair (Doctoral Level):

- 2007:** John Kairalla (Co-Chair with Keith Muller). “An Internal Pilot Study with Interim Analysis for Gaussian Linear Models”

Committee Member (Doctoral Level):

- 2007:** Sola Park. “Accounting for Bias and Uncertainty in Power for Multivariate Gaussian Linear Models”
- 2002:** Michael Jiroutek (Dr. Ph). “Choosing a Sample Size for Estimating a Confidence Interval to Insure Good Properties”

**HONORS AND AWARDS**

- 2022:** University of Rochester Michael P. McDermott Endowed Lectureship in Experimental Therapeutics
- 2020:** Named a Fellow of the American Academy of Neurology
- 2018:** University of Iowa College of Public Health Distinguished Faculty Lecture



**2016:** University of Iowa College of Public Health Faculty Service Award  
**2016:** Named a Fellow of the American Statistical Association  
**2015:** Named a Fellow of the Society for Clinical Trials  
**2013:** University of Iowa College of Public Health Faculty Research Award  
**2008:** Science Unbound Foundation Award, Best Paper by a UAB Based Investigator in General Statistics  
**2005:** Grizzle Distinguished Alumni Award, UNC Department of Biostatistics  
**2004:** Science Unbound Foundation Award, Best Paper by a UAB Based Investigator in General Statistics  
**2004:** UAB President's Award for Excellence in Teaching - School of Public Health  
**2003:** Nomination for the Charles C. Shepard Science Award for most outstanding peer-reviewed paper published by CDC/ATSDR scientists during the preceding year (Prevention and Control Category)  
**1999:** Barry H. Margolin Dissertation Award, UNC Department of Biostatistics  
**1995-1999:** National Institute for Environmental Health Sciences Training Grant  
**1997:** Special Commendation, Theory Doctoral Exam, UNC Department of Biostatistics  
**1997:** Special Commendation, Applied Doctoral Exam, UNC Department of Biostatistics  
**1997:** Delta Omega Book Award, UNC School of Public Health  
**1997:** UNC School of Public Health Student Award  
**1996:** Inducted into Delta Omega Public Health Honor Society  
**1993:** Chancellor's Citation for Academic Excellence, University of Tennessee-Knoxville  
**1992:** Named "Top Graduate" in University of Tennessee College of Business Administration  
**1992:** Epsilon Eta Chapter of Sigma Nu Fraternity Scholar of the Year

## OTHER PROFESSIONAL POSITIONS HELD

### UNIVERSITY OF NORTH CAROLINA DEPARTMENT OF BIostatISTICS (Chapel Hill, NC)

1995-1999 Graduate Research Assistant

### RHO, Inc. (Chapel Hill, NC)

1998 Statistician II

### COLLABORATIVE STUDIES COORDINATING CENTER (Chapel Hill, NC)

1995 SAS Programmer

### SCHLEGEL TENNESSEE, INC. (Maryville, TN)

1993-1994 Advanced Quality Planning Engineer

### SCHLEGEL, IOWA DIVISION (Keokuk, IA)

1993 SPC Statistician

## PROFESSIONAL SERVICE

### PROFESSIONAL ORGANIZATIONS

Society of Clinical Trials

**2023-Present:** Treasurer

**2023-Present:** Chair, Fellows Committee

**2022-2023:** Co-Chair, Fellows Committee

**2020-Present:** Member, Fellows Committee

**2016-2020:** Member, Communications Committee (Social Media Chair)

**2012-2017:** Board Member

**2012-2015:** Member, Program Committee

**2013-2014:** Program Chair

**2009-2012:** Chair, Education Committee

**2007-2012:** Member, Education Committee

**2009-2011:** Member, Education Outreach Committee

**2008-2009:** Co-Chair, Education Committee

American Statistical Association

**2011-2013:** Member, Biopharmaceutical Section Executive Committee

**2002-2009:** Chapter Representative for Alabama Chapter

**1999-2000:** Secretary for Middle Tennessee Chapter

Eastern North American Region (ENAR) of the International Biometric Society

**2007-2009:** Regional Advisory Board

**2007:** ENAR Program Chair for the Joint Statistical Meetings

Drug Information Association

American Academy of Neurology

## **JOURNAL EDITOR**

**2020-Present:** Statistical Editor – *Stroke*

**2019-Present:** Associate Editor – *Trials*

**2016-Present:** Associate Editor – *Clinical Trials*

**2011-2020:** Consulting Biostatistician – *Stroke*

**2011-2017:** Associate Editor – *Movement Disorders*

## **STUDY SECTIONS / GRANT REVIEWS**

National Institute of Neurological Disorders and Stroke (NINDS)

**August 2019-Present:** Reviewer, ZNS1 SRBA (EPPIC-NET Clinical Trials Review – 15 Total: 2019 – 2; 2020 – 6; 2021 – 7))

**December 2023:** Reviewer, ZNS1 SRBA (Clinical Trial Readiness for Rare Neurological & Neuromuscular Diseases)

**June 2023:** Reviewer (NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention)

**August 2022:** Reviewer [Network For Emergency Clinical Trials: Strategies to Innovate EmergEncy Care Clinical Trials Network (SIREN) – Data Coordinating Center (DCC)]

**August 2021:** Reviewer, ZNS1 SRBG (Clinical Trials and Comparative Effectiveness Studies)

**March 2021:** HEAL Initiative ZNS1 SRB G (37) (Non-Addictive Analgesic Therapeutics Development to Treat Pain)

**December 2018:** Reviewer, ZNS1 SRBA (Clinical Trial Readiness for Rare Neurological & Neuromuscular Diseases)

**June 2018:** Ad-Hoc Reviewer, NSD-K Study Section

**December 2017:** Reviewer, ZNS-SRBA (Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases) Special Emphasis Panel

**July 2017:** Acting Chair, Reviewer, ZNS-1SRBA (Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases) Special Emphasis Panel

**December 2016:** Reviewer, ZNS1-SRBC (SIREN CCC) Special Emphasis Panel

**December 2016:** Reviewer, ZNS1-SRBC (SIREN DCC) Special Emphasis Panel

**March 2015:** Ad-Hoc Reviewer, ZNS1-SRBB Special Emphasis Panel

**August 2012:** Ad-Hoc Reviewer, ZNS1-SRBB Special Emphasis Panel

**March 2012:** Ad-Hoc Reviewer, NSD-K Study Section

**October 2011:** Ad-Hoc Reviewer, ZNS1-SRBS Special Emphasis Panel

**August 2011:** Ad-Hoc Reviewer, ZNS1-SRBS Special Emphasis Panel

**November 2010:** Ad-Hoc Reviewer, ZNS1-SRBB Special Emphasis Panel

**October 2010:** Ad-Hoc Reviewer, NSD-K Study Section

**June 2006-June 2010:** Member, NSD-K Study Section

**January 2010:** Ad-Hoc Reviewer, ZNS1-SRBG Special Emphasis Panel

**December 2009:** Ad-Hoc Reviewer, ZNS1-SRBB Special Emphasis Panel

**December 2008:** Ad-Hoc Reviewer, ZNS1-SRBG Special Emphasis Panel

**October 2005:** Ad-Hoc Reviewer, NSD-K Study Section

**June 2005:** Ad-Hoc Reviewer, NSD-A Study Section

**November 2004:** Ad-Hoc Reviewer, NSD-A Study Section

**February 2004:** Ad-Hoc Reviewer, NSD-A Study Section

**June 2003:** Ad-Hoc Reviewer, NSD-K Study Section

National Institute for Allergy and Infectious Diseases (NIAID)

**February 2023:** Ad-Hoc Reviewer – Allergy and Asthma Statistical and Clinical Coordinating Center (AA-SCCC)

National Center for Advancing Translational Sciences (NCATS)

**October 2022:** Reviewer, CTSA Resource Center U24 Review

**February 2013:** Ad-Hoc Reviewer, Limited Competition – Clinical and Translational Science Awards (CTSA) Consortium Wide Centers: Resources for Rapid Demonstration and Dissemination

National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)

**July 2022:** Reviewer, ZDK1 GRB-6 (Understanding and Targeting the Pathophysiology of Youth-Onset Type 2 Diabetes – Biostatistics Research Center)

**December 2021:** Reviewer, ZDK1 GRB-9 (NIDDK Clinical Trials)

**February 2021:** Reviewer, ZDK1 GRB-9 (NIDDK Clinical Trials)

**July 2020:** Reviewer, ZDK1 GRB-6 (A Trial of Transplanting Hepatitis C-Viremic Kidneys into Hepatitis C-Negative Kidney Recipients)

**May 2020:** Reviewer, ZDK1 GRB-N (Multi-Center Clinical Study Implementation Planning Cooperative Agreements)

**July 2019:** Reviewer, ZDK1 GRB-9 (Clinical Centers)

**May 2019:** Reviewer, ZDK1 GRB-9 (Biostatistics Research Centers)

**March 2019:** Reviewer (Data Coordinating Center for Diabetic Foot Consortium)

NIH Post-Acute Sequelae of SARS-COV-2 Infection (PASC) Initiative

**April 2021:** Reviewer

Center for Scientific Review

**June 2019:** Reviewer, Acute Neural Injury & Epilepsy (ANIE) Study Section

Cure Parkinson's Trust

**May 2019:** Grant Reviewer

The Michael J. Fox Foundation for Parkinson's Research

**March 2019:** Reviewer for Biomarkers Across Neurodegenerative Diseases (BAND) Program

**October 2016:** Chair, PPMI Data Challenge Review

**October 2016:** Reviewer for Improved Biomarkers & Clinical Outcome Measures Program – Data Science Review

**August 2015:** Reviewer for Biomarkers across Neurodegenerative Diseases (BAND) Program

**August 2014:** Reviewer for Biomarkers across Neurodegenerative Diseases (BAND) Program

**January 2014:** Reviewer for Biomarker/Data Use Applications

**October 2011:** Reviewer for LRRK2 RFA Applications

National Institute on Deafness and Other Communication Disorders (NIDCD)

**January 2019:** Reviewer, ZDC1 SRB-Y 54 (Clinical Trial Review)

**May 2018:** Reviewer, ZDC1 SRB-X 63 (NIDCD Aphasia Treatment Clinical Trial Review)

National Institute of Dental & Craniofacial Research (NIDCR)

**November 2018:** Chair, ZDE1 GZ08 (DPBRN Coordinating Center)

ALS Association

**March 2018:** Reviewer for Phase II Applications

**March 2016:** Reviewer for Phase II Applications

**December 2015:** Reviewer for Phase II Applications

**May 2015:** Reviewer for Phase II Applications

**February 2014:** Reviewer for Phase II Applications

**October 2013:** Reviewer for Phase II Applications

The Pacific Symposium on Biocomputing

**2004:** Reviewer

The Austrian Science Foundation Schroedinger Fellowship

**2002:** Reviewer

**2001:** Reviewer

## **DATA AND SAFETY MONITORING BOARDS**

**2022-Present:** Member, NIA Sponsored – “SHARE Pilot: Sharing Health Care Wishes in Primary Care”

**2021-Present:** Member, NIDDK Sponsored – “Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial (HBOT-UC)”

**2020-Present:** Member, NIDDK Sponsored – “Glycemic Observation and Metabolic Outcomes in Mothers and Offspring (GO MOMS)”

**2018-2023:** Member, VA-Sponsored – “Microbiota or Placebo After Antimicrobial Therapy for Recurrent *C. Difficile* at Home (MATCH)” (CSP #2004)

**2017-2020:** Chair, NIH-Sponsored – Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): A Pilot and Feasibility Study

**2012-2019:** Member, NINDS-Sponsored – “Rapid Administration of Carnitine in Sepsis (RACE)” Trial

**2012-2019:** Member, NIA Sponsored – “Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA<sup>3</sup>CT)”

**2015-2018:** Member, DOD Sponsored – Chronic Effects of Neurotrauma Consortium (CENC)

**2005-2012:** Member, NINDS Sponsored - “Interventional Management of Stroke Study (IMS III) Trial”

**2005-2012:** Member, NINDS Sponsored - “Albumin in Acute Stroke (ALIAS)” Trial

**2009-2011:** Member, Medivation, Inc. Sponsored - “A Phase III, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild to Moderate Huntington’s Disease (HORIZON)”

**2008-2010:** Chair, NINDS Sponsored – “Chronic Migraine Treatment Trial”

**2008-2009:** Member, NINDS Sponsored - “Lithium in ALS (LALS) Trial”

**2008:** Member, NCCAM Sponsored - “Creatine Safety Tolerability & Efficacy in Huntington’s Disease (CREST-E) Trial”

**2004-2008:** Member, NINDS Sponsored – “Clinical Trial of High Dose coQ10 in ALS (QALS) Trial”

**2003-2004:** Member, NINDS Sponsored - “Ankle Strengthening to Improve Gait and Function in CP Trial”

#### **FDA ADVISORY PANELS**

**2018-Present:** Member, FDA Gastrointestinal Drugs Advisory Committee

**June 2023:** Ad-Hoc Member, FDA Endocrinologic and Metabolic Drugs Advisory Committee

**April 2022:** Ad-Hoc Member, FDA Oncologic Drugs Advisory Committee

#### **REFEREE MANUSCRIPTS**

Statistical Reviewer for:

*Stroke* (42 Total: 2003 - 4; 2004 - 2; 2005 - 5; 2006 – 2; 2007 – 3; 2008 – 1; 2009 – 1; 2010 – 3; 2011 – 5; 2012 – 6; 2013 – 1; 2014 – 3; 2017 – 1; 2018 – 1; 2019 – 1; 2020 – 1; 2021 – 1; 2022 – 1)

*Movement Disorders* (35 Total: 2010 – 4; 2011 – 11; 2012 – 4; 2013 – 6; 2014 – 3; 2015 – 4; 2016 – 3)

*Circulation* (6 Total: 2005 – 1; 2006 – 2; 2008 – 1; 2009 – 1; 2010 – 1)

Ad-Hoc Reviewer for Many Journals:

*Statistics in Medicine* (11 Total: 2000 - 1; 2003 - 1; 2004 - 1; 2005 – 1; 2006 – 3; 2011 – 1; 2012 - 1; 2013 – 1; 2014 – 1)

*Clinical Trials* (9 Total: 2008 -2; 2012 – 1; 2014 – 1; 2016 – 1; 2018 – 4)

*Neurology* (7 Total: 2008 – 2; 2017 – 2; 2018 – 1; 2020 – 1; 2022 – 1)

*The Journal of the American Medical Association* (6 Total: 2004 - 1; 2005 – 1; 2007 - 1; 2013 - 3)

*Journal of Neurotrauma* (5 Total: 2004 – 3; 2005 – 2)

*Obesity* (3 Total: 2010 – 1; 2011 – 1; 2017 – 1)

*Journal of Biopharmaceutical Statistics* (2 Total: 2019 – 1; 2021 – 1)

*Trials* (2 Total: 2014 – 1; 2015 – 1)

*Journal of Statistical Computation and Simulation* (2 Total: 2008 – 1; 2010 – 1)

*Epidemiology* (2 Total: 2007 – 1; 2008 - 1)

*The American Statistician* (2 Total: 2000 – 1; 2008 - 1)

*Hypertension* (2 Total: 2004 - 1; 2005 - 1)

*Biometrical Journal* (2 Total: 2009 – 1; 2012 - 1)

*Brain* (1: 2022)

*Journal of the Royal Statistical Society – Series A* (1: 2017)

*The American Journal of Clinical Nutrition* (1: 2017)  
*Biometrics* (1: 2014)  
*International Journal of Biostatistics* (1: 2013)  
*Parkinsonism & Related Disorders* (1: 2012)  
*Pharmaceutical Statistics* (1: 2012)  
*Computer Methods and Programs in Biomedicine* (1: 2007)  
*Computational Statistics and Data Analysis* (1: 2005)  
*Behavior Research Methods, Instruments, & Computers* (1: 2004)  
*Applied Bioinformatics* (1: 2004)  
*Genetic Epidemiology* (1: 2004)  
*Neuroepidemiology* (1: 2004)  
*The American Journal of Human Genetics* (1: 2003)  
*Diabetes* (1: 2003)  
*Diabetologia* (1: 2003)  
*Obesity Reviews* (1: 2003)  
*Bioinformatics* (1: 2002)  
*Human Heredity* (1: 2002)  
*The Journal of the American Statistical Association* (1: 2002)

## **GENERAL**

**2023:** External Reviewer, University of Rochester Experimental Therapeutics Fellows Program  
**2007-2022:** Member, Drug Information Association (DIA - previously sponsored by PhRMA) Adaptive Designs Working Group  
**2020:** Participant, “*Enabling Efficient Paths to Early Intervention in Parkinson’s Disease*”, Joint Meeting of Critical Path for Parkinson’s Disease, Michael J. Fox Foundation for Parkinson’s Research, and FDA (Virtual Due to COVID-19)  
**2011-2017:** Member, DIA Adaptive Designs Working Group Case Studies Subteam  
**2017:** External Reviewer, University of Rochester Experimental Therapeutics Fellows Program  
**2017:** Participant, The Michael J. Fox Foundation for Parkinson’s Research Exenatide Trial Assessment Meeting  
**2017:** Participant, The Michael J. Fox Foundation for Parkinson’s Research Regulatory Workshop Planning Meeting – “Patient Selection & Stratification Biomarkers in Disease-Modifying Trials for Early-Stage PD”  
**2016:** Member, ALS FDA Clinical Trials Guidelines Committee  
**2007-2009:** Member, PhrMA Adaptive Designs Working Group Communications Workstream

## **UNIVERSITY SERVICE**

### **UNIVERSITY OF IOWA**

**2016-Present:** University Conflict of Interest Review Committee  
**2018:** Member, Search Committee for Stroke Division Director

### **UNIVERSITY OF ALABAMA AT BIRMINGHAM**

**2006-2009:** UAB Graduate Council  
**2004-2008:** UAB Alternate Faculty Senator for School of Public Health  
**2004-2008:** UAB Faculty Senate Curriculum and Research Committee  
**2007:** Member, Committee to Select Recipient of the Ellen Gregg Ingalls/UAB National Alumni Society Award for Lifetime Achievement in Teaching

## **SCHOOL / COLLEGE OF PUBLIC HEALTH SERVICE**

### **UNIVERSITY OF IOWA**

**2023:** Member, Department of Epidemiology Faculty Search Committee  
**2020:** Member, Associate Dean for Academic Affairs Search Committee  
**2011-2014:** College of Public Health Research Council  
**2011:** College of Public Health Associate Dean Search Committee  
**2009-2010:** Member, CEPH Accreditation Workshop 2.0 Committee

### **UNIVERSITY OF ALABAMA AT BIRMINGHAM**

**2008-2009:** Chair of the Faculty, UAB School of Public Health  
**2008-2009:** School of Public Health Finance Committee  
**2002-2009:** Contributor and Grader for Department of Epidemiology Written Examination  
**2006-2007:** Member, Committee to Select Recipient of SoPH President's Excellence in Teaching Award  
**2006-2007:** Member, School of Public Health Associate Dean Search Committee  
**2005:** Biostatistics representative to Department of Epidemiology PhD Review Committee  
**2003-2005:** Chair, SoPH Admissions and Graduation Committee  
**2002-2005:** SoPH Editorial Review Board  
**2001-2005:** Dept. representative to SoPH Admissions and Graduation Committee

## **DEPARTMENT SERVICE**

### **UNIVERSITY OF IOWA**

**2021:** Co-Chair, Faculty Search Committee  
**2020-Present:** Chair, MS & PhD Curriculum Review Committee  
**2014-Present:** Chair, Woolson Award Selection Committee  
**2016-2020:** Member, PhD Curriculum Review Committee  
**2018:** Co-Chair, Tenure Track Faculty Search Committee  
**2017:** Member, Tenure Track Faculty Search Committee  
**2015-2016:** Chair, Curriculum Committee  
**2015:** Member, Department of Biostatistics DEO Search Committee  
**2013:** Member, Doctoral Exam Restructuring Committee  
**2012:** Chair, Clinical Track Faculty Search Committee  
**2011:** Chair, Tenure Track Faculty Search Committee  
**2009-2011:** MS Examinaton Committee  
**2009-2011:** Admissions Committee

### **UNIVERSITY OF ALABAMA AT BIRMINGHAM**

**2006-2009:** Director of Graduate Studies  
**2002-2009:** Graduate Program Committee  
**2003-2006:** Dept. alternate representative to SPH Educational Policy Committee  
**2005:** Interim Chair, Graduate Program Committee  
**2001-2002:** Teaching Evaluation Committee

Member of several faculty search committees